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Cover illustration: Terminally differentiated NT2N neurons by treatment with AraC 
during 6 days. Cells were doubly immunolabeled for NeuN/Fox-3 (red) and β-III-
tubulin (green), combined with Hoechst 33342 nuclear staining (blue). 
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1. PHOSPHOLIPASE Cβ1 
1.1. Phosphatidylinositol-specific phospholipase C 
Transduction of extracellular signals into intracellular responses mediated by G 
protein-coupled membrane receptors requires amplification systems, which are usually 
based on the ability of transmembrane receptors to regulate the activity of membrane-
associated and/or cytosolic enzymes. Upon activation, these enzymes promote a rapid 
increase in the intracellular concentration of reaction products (known as second 
messengers), which transduce extracellular signals into intracellular signaling cascades, 
thus promoting specific physiological responses relevant for survival, proliferation, 
differentiation, and intercellular communication. 
Among plasma membrane-associated enzymes, two major families emerge as the 
most important players in signal amplification: the so-called effector proteins adenylate 
cyclase and phosphatidylinositol-specific phospholipase C (also known as PtdIns-PLC 
or PI-PLC, but hereafter referred to as PLC). Because there is a wide variety of G 
protein-coupled receptors, each responding to specific agonists (such as hormones and 
neurotransmitters), different extracellular signals converge to affect the catalytic activity 
of these effector enzymes. 
 
1.1.1. Catalytic activity of PLC isozymes 
Phosphatidylinositol-specific phospholipase C is the target of several transducer 
mechanisms in response to a plethora of physiological stimuli, such as agonist 
(hormones, neurotransmitters, growth factors, chemokines…) activation of G-protein 
coupled receptors, or elevation of intracellular calcium levels. In this way, 
phosphoinositide hydrolysis in response to one or more extracellular signal type has 
been detected in all mammal tissues studied.  
The major substrate of PLC phosphatidylinositol is the minor plasma membrane 
phosphoinositide inositol 4,5-bisphosphate (PtdIns 4,5-P2. Hereinafter, we refer to this 
phosphoinositide as PIP2; and positions of phosphate groups in the inositol ring will be 
mentioned only if necessary for disambiguation). By catalyzing the hydrolysis of the 
phosphodiester bond on the third position (sn-3) of the glycerol backbone, PLC 
generates the second messengers cyclic inositol 1,4,5-triphosphate (Ins 1,4,5-P3 or IP3) 
and diacylglycerol (DAG). Water-soluble IP3 diffuses to the cytosol and bind its 
receptor on the ER, causing Ca2+ release from intracellular stores, whereas hydrophobic 
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DAG remains bound to inner layer of the plasma membrane, where it can activate 
different isoenzymes belonging to the family of protein kinase C (PKC) (Berridge, 
1983; Nishizuka, 1984). The substrates used by the enzymatic activity of PLC are still 
under study and discussion. Clearly, the discussion is not sterile and should be 
maintained the importance of this question, given that the substrate used determines the 
percentage that IP3 represents over other inositol phosphates (see Figure 1B), with only 
IP3 having a well defined intracellular function. Considering the increasing number of 
functions assigned to PIP2, the regulation of its plasma membrane concentration may 
have important functional consequences, as it will be described later. Focusing on the 
central nervous system, it can be concluded that the matter is not fully resolved. 
Specifically, the use of intact cells or membrane preparations, the presence or absence 
of detergents or divalent ions (like Ca2+ and Mg2+), or the presence of exogenous or 
endogenous substrates appear to be determinant factors to direct the findings in either 
direction. Simultaneously, the first studies performed in platelets and proposing PIP2 as 
the main substrate (Berridge, 1983; Downes and Wusterman, 1983), demonstrated that 
the partially purified PLC enzymatic activity was able to hydrolyze not only exogenous 
PIP2, but also (PI) PtdIns and PtdIns 4-P (PIP), but not non-phosphorylated inositides. A 
few years later, it was described that stimulation of PLC enzymatic activity with the 
muscarinic acetylcholine receptor agonist carbachol, promoted hydrolysis of exogenous 
PI, PIP and PIP2 in membrane preparations of rat cerebral cortex (Claro et al., 1989). All 
the three substrates required the Ca2+ ion, within the range of physiological 
concentrations, and the ionic detergent deoxycholate, although PI hydrolysis required 
slightly higher Ca2+ concentration than PIP and PIP2 (Claro et al., 1989). The 
importance of deoxycholate in vitro has been linked to facilitation of PLC access to 
endogenous polyphosphates (Chung et al., 1985; Plantavid et al., 1986). However, PLCs 
appear to act primarily on PIP2 in their native cellular environment, although few 
studies addressed this question rigorously (Fisher et al., 1990; Batty and Nahorski, 
1992; for review, Balla T, 2013). 
Finally, the work of several independent laboratories has consistently demonstrated 
that the phosphoinositide cycle (biosynthetic and hydrolytic machinery) is present in the 
cell nucleus, and may be important for various nuclear events such as mRNA export, 
DNA repair, and gene transcription (Irvine, 2003). The presence of phosphoinositide 
metabolism in the nuclear envelope was first reported by Smith and Wells (1983) using 
nuclear preparations from rat liver. Later, Cocco et al. (1987) demonstrated for the first 
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time that envelope-depleted nuclei were able to synthesize PIP and PIP2 in vitro, 
showing that phosphoinositide cycle also occurred at internal nuclear domains (see also, 
Payrastre et al., 1992; Garcia-Bustos et al., 1994). At present, it is widely accepted the 
existence of phosphoinositide signaling within the nucleus, where the major PLC 
substrate PIP2 and its products IP3 and DAG are involved in a variety of nuclear events 
(mRNA export, DNA repair, gene transcription, splicing pre-mRNA transcripts…) and 
cellular responses, including differentiation, proliferation and neoplastic transformation 
(Neri et al., 1999; D'Santos et al., 2000; Irvine, 2003). 
 
Figure 1. A. Schematic representation of phosphoinositide phosphorylation and PIP2 hydrolysis 
to generate the second messengers DAG and IP3. B. Possible metabolic routes of 
phosphoinositides involve 3-phosphatase, PI-3 kinase, PI-4 kinase and PLC enzymatic activity. 
Modified from Lodish et al. (2000). 
 
1.1.2. Structural and functional domains of PLC isozymes 
PLC activity comprises a large and diverse group of enzymes that differ in structure 
and cellular distribution. Until the XX century, there were identified 10 PLC isozymes 
in mammalians, which were classified into three different families; four PLCβ (1, 2, 3, 
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4), two PLCγ (1, 2) and three PLCδ (1, 3, 4), excluding from this later group an 
isozyme, originally called PLCα, that corresponds to a proteolytic fragment of PLCδ1 
(Rhee et al., 1989; Bae and Rhee, 1997). Later three new PLC families were discovered: 
PLCη, PLCζ and PLCε (Lopez et al., 2001; Song et al., 2001; Kelley et al., 2001; for 
review Suh et al., 2008 and Balla, 2013), making up a total of 13 isolated PLC isoforms 
in mammals, excluding splicing variants (Fig. 2). The PLC isozyme families differ in 
size, although the amino acid sequences are relatively conserved among the different 
families. The catalytic domains, termed X-Y, share at more than 60% sequence 
homology among the isoforms of the same PLC family (Rhee et al., 1989; Rhee and 
Bae, 1997). The linker amino acid sequence between the X and Y regions of the 
catalytic domain varies considerably when the different families are compared. For 
example, it is composed of 40, 110 and 190 aminoacids in PLCβ, PLCδ and PLCε 
isoforms, respectively, whereas the X-Y linker of PLCγ contains 400 residues and 
includes two Src homology domain 2 (SH2) and one Src homology domain 3 (SH3). 
SH2 domains bind phosphotyrosine containing peptide sequences, whereas SH3 binds 
proline-rich sequences. In general, these SH domains are involved in the negative 
regulation of the PLCγ kinase activity, since they confer a conformation to the protein 
that somehow prevents the access of the substrate to the catalytic domains of the 
enzyme, and only upon phophsorilation a suitable conformation for catalytic activity is 
adopted (Carpenter and Ji, 1999). In its turn, SH3 domain confers mitogenic properties 
to PLCγ by allowing it to interact with several Ras/p21 protein activators. 
The catalytic activity of all PLC isozymes strictly depends on the presence of Ca2+ 
ions, with PLCδ being the more sensitive to this ion. Different structural and mutational 
studies with the PLCδ have managed to identify those residues of the catalytic domains 
that contribute to the recognition of the substrate, Ca2+ ion binding, and catalytic 
activity. In this way, it has been determined that Lys-438, Ser-522 and Arg-549 are 
critical for the preferential hydrolysis of polyphosphoinositides against 
monophosphoinositides, while the substitution of the Lys-440 affects selectively the 
hydrolysis of PIP2, indicating that Lys-438, Ser-522 and Arg-549 would be involved in 
the interaction with the 4-phosphate group, whereas Lys-440 would be related to the 
interaction of 5-phosphate groups. It should be noted that these residues are conserved 
in both PLCβ and γ isozymes (Ellis et al., 1998). Finally, recent structural studies of 
PLCβ2 isozyme have led to the characterization of a sequence (residues 516-535), 
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located between the X and Y catalytic domains, which exert an inhibitory function on 
the catalytic activity of the enzyme. This sequence is preserved in PLCβ1 and PLCβ3, 
and will confer an autoinhibitory function to these isoforms (Hicks et al., 2008). 
 
 
Figure 2. Organization of the structural and functional domains of the different PLC isozime 
families. All share in common X-Y catalytic, PH, EF-hand and C2 domains. Comments of other 
family-specific domains are incorporated in the introduction text. Taken from Balla, 2013. 
 
Similarly to many different proteins involved in intracellular signaling mechanisms, 
the PLCβ, PLCγ and PLCδ isozymes share in common a pleckstrin homology (PH) 
domain, consisting of 100 residues within the amino-terminal region, critical for binding 
of some PLC isozymes to polyphosphoinositides and IP3 (Rameh et al., 1999; Harlan et 
al., 1994). PLCγ isozyme contains a second split PH domain flanking the SH2-SH2-
SH3 tandem repeat. This additional PH domain has no affinity for phospholipids and 
has been implicated to interact directly with the TRPC3 calcium channel, suggesting a 
role in direct coupling between PLCγ and agonist-induced calcium entry (Wen et al., 
2006).	   The well-characterized PH domain of PLCδ1 binds stereospecifically and with 
high affinity to the head group PIP2, IP3, and has become a valuable tool for studying 
cellular PIP2 functions. The amino acid sequences of the PLCδ1 PH domain responsible 
for the interaction with PIP2 have been elucidated, showing that they are necessary for 
plasma membrane targeting of and catalytic activity of PLCδ1. Thus, PIP2 binding 
facilitates plasma membrane anchoring required for catalysis of phosphoinositides, 
whereas IP3 production leads to sequestration and translocation of PLCδ1 to the 
cytoplasm. In this way, changes in PIP2 and IP3 levels due to activation of other PLC 
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isozymes could modulate the catalytic activity of PLCδ1 (Essen et al., 1996; Ferguson 
et al., 1995). The dissimilarity in the amino acid sequences of the PH domain among 
PLC isozymes accounts for differences in phoshpoinositide binding affinity and for the 
diverse mode of membrane interaction. For example, various studies reported that the 
PH domain of PLCγ has a high affinity for PtdIns 3,4,5-P3 but not for PIP2, suggesting a 
role for PtdIns 3,4,5-P3 polyphosphoinositide in activation of PLCγ by its translocation 
to the plasma membrane (Razzini et al., 2000). On the other hand, the plasma 
membrane anchoring of PLCβs is not altered by PIP2 levels, suggesting that the PH 
domain is not directly involved in targeting of PLCβs isozymes to the plasma membrane 
(Wang et al., 1999). By contrast, the PH domain of PLCβ1 shows affinity for PtdIns 3-
P, suggesting that this phophoinositide would play an important role in the recruitment 
and activation of PLCβ isozymes in systems activated by PtdIns 3-kinases (Razzini et 
al., 2000) (Fig. 1). In addition, the PH domain of PLCβs seems to contain a binding 
sequence for βγ subunits of G proteins. Therefore, we could conclude that the PH 
domain facilitates plasma membrane anchoring of the different PLC isozymes but with 
different modes of interactions with phoshpoinositides and even βγ subunits of G 
heterotrimeric proteins in the case of PLCβ isozymes. 
The analysis of the three-dimensional structure of PLCδ1 revealed the presence of 
two additional domains: the EF-hand located between the PH and the X catalytic 
domains, and the C2 domain, which is usually represented as an extension of the Y 
catalytic domain. As shown in figure 2, both the EF-hand and the C2 domain are present 
in all PLC isozymes (Essen et al., 1996; Lopez et al., 2001; Suh et al., 2008; Balla et al., 
2013). The EF-hand domain consists of a duplication of two EF-hand units, each 
composed of	   two alpha helices linked by a short loop region of about 12 amino acids. 
The EF-hand domain of PLCδ1 is able to bind Ca2+, as it has been observed in calcium 
binding proteins (Maki et al., 2002), and this binding appears to be required for the 
correct interaction between the PH domain and PIP2 (Yamamoto et al., 1999; Rhee, 
2001). However, the role of the EF-hand domain in other PLC families is unclear. As 
described below, a loop between the third and fourth EF-hands of PLCβs interacts with 
GTP-activated Gαq and is involved in regulating GTPase activating protein (GAP) 
activity of PLCβ (Waldo et al., 2010). The C2 domain of PLCs is composed of 
approximately 120 residues and is also present in many membrane-associated proteins.  
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Figure 3. Structure of Gαq•PLCβ3. A. Domain architecture of PLCβ3 drawn to scale and 
consisting of a N-terminal PH domain, a series of four EF hands, a catalytic TIM barrel, a C2 
domain, and a carboxy-terminal (CT) domain. The CT domain is not necessary for Gαq binding, 
and, therefore, PLCβ3 truncated at residue 886 was used to facilitate crystallization. Three 
distinct regions of PLCβ3 that interact with Gαq are indicated by red numerals. B. Overall 
structure of the AlF4--dependent complex of Gαq•PLCβ3 as viewed from the plane of the 
membrane. PLCβ3 is depicted as a ribbon cartoon with domains coloured as in (A). Activated 
Gαq is depicted as a green surface with nucleotide-dependent switches (Sw1 to Sw3) in shades 
of red. Hα1/Hα2 (red 3) at the end of the C2 domain of PLC-b3 lies within the canonical 
effector-binding region of Gαq formed by α3 starting at M248, the subsequent loop containing 
W263, and switch 2 containing Q209. The X/Y linker (orange) connects the two halves of the 
catalytic TIM barrel, and an ordered portion of the linker occludes the active site of the lipase 
highlighted by the Ca2+ (yellow ball) cofactor. Adapted from Waldo et al. (2010). 
The C2 domain of PLCδ1 contains up to four Ca2+-binding sites that modulate the 
Ca2+-dependent membrane anchoring, thus facilitating the interaction of the enzyme 
with the phosphoinositides (Essen et al., 1996; Grobler and Hurley, 1998). In contrast, 
the C2 domain of PLCβ1 and PLCβ2 does not participate in Ca2+-dependent interaction 
with the plasma membrane, but it associates with high affinity and specificity to 
activated Gαq (Gαq-GTP) subunits (Wang et al., 1999). Recently, the crystal structure 
of the activated Gαq-GTP/PLCβ interface has been resolved (Waldo et al., 2010), 
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showing the presence of two Gαq-GTP-interaction sites C2 domain flanking amino acid 
sequences highly conserved among the four PLCβ isoforms. 
All the PLCβ isoforms, except one of the PLCβ4 splice variants, contain a long 
carboxy-terminal sequence downstream the Y domain of approximately 450 residues, 
whereas this region is very short or almost absent in PLCγ or PLCδ isozymes. This 
region has been shown to contain many of the determinants for interaction with Gαq as 
well as for other functions such as membrane binding and nuclear localization 
(Rebecchi and Pentyala, 2000; Rhee, 2001; Drin and Scarlata, 2007; Faenza et al., 2008; 
for review, Suh et al., 2008). Thus, C-terminal truncation of PLCβ2 generated enzymes 
that were activated by Gβγ but not by Gαq (Lee et al., 1993). Similarly, Wu et al. (1993) 
demonstrated that truncation of the long carboxy-terminal coil of PLCβ1 impaired Gαq. 
However, a recent high-resolution structural study of the interaction between the active-
state Gαq and PLCβ3 revealed that the absence of the long C-terminal extension of 
PLCβ3 did not affect high affinity binding of PLCβ3 to Gαq (Waldo et al., 2010). In 
contrast, this study demonstrates that three distinct regions of PLCβ3, highly conserved 
among PLCβ isozymes, are involved in active-state Gαq-PLCβ interaction: [i] a loop 
between the third and fourth EF hands, [ii] a region of that connects the catalytic Y and 
the C2 domais, and [iii] a segment composed of a helix-turn-helix at the C terminus of 
the C2 domain. Of these three regions, the former and the later also contain critical 
residues for GAP activity (Fig. 3, 5). Of note, none of the three sites are located within 
the regions previously thought to be essential for interaction for Gαq. As discussed by 
these authors the C-terminal domain is important for membrane association, but 
whether it has additional function(s) in the signaling complex remains unclear. The 
model proposed by Waldo et al. (2010) considers that the carboxy-terminal domain of 
PLCβs basally associates with membranes, whereas the X/Y linker blocks the lipase 
active site. Upon activation of heterotrimeric Gq, Gαq-PLCβ complex formation 
anchors and orients the lipase active site at membranes, leading to repulsion of the X/Y 
linker and freeing the active site for PIP2 hydrolysis (Reviewed from Waldo et al., 2010; 
Fig. 4). Indeed, in a recent report, the same group has demonstrated that neither Gαq nor 
Gβ1γ2 are able, by themselves, to activate PLCβ3-mediated hydrolysis of a PIP2 analog 
in the absence of membranes or detergents, despite both Gαq and Gβ1γ2 robustly 
activated PIP2 hydrolysis at membranes (Charpentier et al., 2014). Moreover, deletion 
of the autoinhibitory X-Y linker (Figs. 4, 5) drastically sped up PLCβ3 activation 
kinetics of PIP2 in membranes, but not of the soluble analog in membrane free 
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preparations. Additionally, a short helix-turn-helix region downstream the C2 domain 
(Lyon et al., 2011; Charpentier et al., 2014; Figs. 3, 5) cooperates with the X-Y linker to 
prevent the productive association of PLCβ isozymes with membranes. In this way, 
membranes would act as a channel between Gαq and Gβγ on the one side and these 
autoinhibitory elements on the other side. 
Apart from the different identified structural and functional domains described for 
the different PLC isoforms, it has been determined for PLCε the existence of an amino-
terminal domain similar to the GEF protein, a nucleotide exchange factor of guanine 
specific for Ras, and at least one carboxy-terminal domain for Ras binding (Fig. 2), 
which probably would replace the function of the PH domain in the other PLC families 
(Kelley et al., 2001; López et al., 2001; Song et al., 2001). 
 
 
Figure 4. Model for activation of PLCβ3 by GTP-activated Gαq. Gαq (green) bound to GDP 
is sequestered by Gβγ (red and yellow) and does not interact with PLCβ, depicted as a gold 
toroid except for its CT domain (light pink) and X/Y linker (orange cylinder and dotted lines). 
The CT domain basally associates with membranes, whereas the X/Y linker blocks the lipase 
active site. Upon activation of heterotrimeric Gq, Gαq-GTP dissociates from Gβγ and interacts 
with the main portion of PLCβ. Complex formation anchors and orients the lipase active site at 
membranes, leading to repulsion of the X/Y linker and freeing the active site for hydrolysis of 
PIP2 into IP3 and DAG. Adapted from Waldo et al. (2010). 
 
Of particular interest, PLC isozymes are subjected to alternative splicing, resulting 
in different expression variants. For example, this phenomenon affects the carboxy-
terminal region of PLCβ1 and PLCβ4 transcripts, leading to the expression of different 
splice variants (Bahk et al., 1994; Kim et al., 1998). To date, three PLCδ4 splice 
variants have been described (ALTI, II, and III), of which ALTI and II contain 
additional amino acids between the X and Y domains, while ALTIII variant undergoes a 
change in the X domain becoming catalytically inactive. Curiously, the PH domain of 
this variant displays high affinity for PIP2 and it has been proposed to negatively 
regulate the activity of other PLCs by competing with their PH domains for PIP2 
binding (Lee and Rhee, 1996). Indeed, overexpression of the PH domain of PLCδ4-
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ALTIII was sufficient to decrease basal resting levels of IP3, and suppress its elevation 
despite treatment with agonists known to stimulate IP3 production (Nagano et al., 1999). 
Another PLC-related catalytically inactive protein known as p130, originally identified 
as an IP3-binding protein similar to PLCδ, lacks a number of amino acids in the X 
catalytic domain. This catalytically inactive PLCδ-like protein inhibits Ca2+ 
mobilization from intracellular stores by sequestering IP3. In this way, p130 counteracts 
PLC-IP3 signalling (Takeuchi, 2000). 
 
1.2. The PLCβ1 isoform 
The detailed analysis of the human gene PLCβ1 gene hosted on chromosome 20 by 
fluorescence in situ hybridization (FISH) and PCR screening enabled to determine the 
entire structure of exons and introns (Caricasole et al., 2000; Peruzzi et al., 2000, 2002). 
Moreover, in rodent and human tissues (Bahk et al., 1994; Caricasole et al., 2000; 
Peruzzi et al., 2002), PLCβ1 exists as two alternatively splice variants, the 138 kDa 
PLCβ1a (1216 aa) and the 134 kDa PLCβ1b (1141 aa), derived from alternative splicing 
at the 3’ end of the gene (Caricasole et al., 2000; Peruzzi et al., 2002). The PLCβ1b 
variant replaces the 75 C-terminal residue of PLCβ1a with 32 residues unique to 
PLCβ1b (Fig. 5). The importance of the PLCβ1 C-terminal domain may rely in two 
aspects. First of all, C-terminal region contains determinants for Gαq and phosphatidic 
acid stimulation (but not Gαq interaction, see above), electrostatic dependent 
association with membrane lipids, nuclear localization, and phosphorylation/regulation 
by protein kinase Cα and MA Pkinase (Bahk et al., 1994; Litosch, 2000; Martelli et al., 
2000; Xu et al., 2001a,b; Fig. 5).  
The classical role of PLCβ1 in phosphoinositide metabolism at the plasma 
membrane and cytoplasm in response to many extracellular stimuli is well established 
and, since more than two decades, it is known that this signal transduction mechanism 
also exists in the nucleus. In various cell types, PLCβ1 seems to be the predominant 
isoform in the nucleus, and its activation is independent of the plasma membrane 
PLCβ1. Even though PLCβ1 expression increases during cell growth and differentiation 
in various cell types, the activation mechanism of this isozyme has not been fully 
elucidated. Before a detailed description of the available experimental evidences, it 
must be noted that a systematic analysis of signal transduction mechanisms, enzymatic 
activity and protein expression in the nucleus of neural cells has not been addressed for 
the different PLC families and isoforms. 
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Martelli et al. (1992) demonstrated for the first time the presence of PLCβ1 in the 
nucleus of quiescent Swiss 3T3 fibroblasts, whereas PLCγ1 was exclusively 
cytoplasmic. In addition, this group demonstrated that PLCβ1 activity was increased by 
2-3 fold in the nucleus, in response to mitogenic stimulation by insulin-like growth 
factor-1 (IGF-1) (Martelli et al., 1992). Thereafter, the presence of PLCβ1 in the nuclear 
matrix has been confirmed by various research groups in different cell lines and tissues 
(Divecha et al., 1993; Marmiroli et al., 1994; Fee et al., 1994; Liu et al. 1996). Of note, 
it has been shown that PLCβ1 is the most abundant PLC isozyme in the nucleus of 
several cell types (Martelli et al., 1992; Divecha et al, 1995) and, moreover, the amount 
of hydrolyzed PIP2 correlates well with PLCβ1 abundance (Divecha and Irvine, 1995). 
Currently, a consensus exists that PLC-β1 is the major PLC isozyme in the nucleus of 
various cells, even though also PLCβ2, PLCβ3 and PLCβ4 have been shown to be in 
this organelle (Bertagnolo et al., 1997; Cocco et al., 1999)  
 
Figure 5. Schematic representation of the domains of the different domains and residues critical 
of PLCβ1a and PLCβ1b splice variants critical for catalytic activity, Gαq interaction, GAP 
activity and subcellular localization. 
 
The molecular determinant for nuclear localization of PLCβ1 was identified as a 
consensus domain known as bipartite nuclear localization signal (NLS) (Kim et al., 
1996). The bipartite NLS is defined as (K/R)(K/R)X10–12(K/R)3/5, where (K/R)3/5 
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represents at least three of either lysine or arginine of five consecutive amino acids, in 
which the linker region has been found to be tolerant to amino acid conversion (Robbins 
et al., 1991). Notably, substitution of the cluster of basic lysine residues 1056, 1063, and 
1070 (called a mutant cDNA M2b) with isoleucine, prevents nuclear localization of 
PLCβ1. Nevertheless, the relative distribution of this isoenzyme between the nuclear 
fraction and other cellular compartments is highly variable depending on the cell type 
analyzed, suggesting the presence of other molecular determinants for subcellular 
localization of PLCβ1. For example, Martelli et al. (1992) and Marmiroli et al. (1994) 
found PLCβ1 to be exclusively expressed in the nucleus of osteosarcoma SaOS-2 cells 
and Swiss 3T3 cells, respectively, whereas Divecha et al. (1993) observed that only 
about 2% of the total PLCβ1 was localized in nuclei of rat liver cells. This apparent 
inconsistency may be due to differences between nuclear isolation methods and/or cell 
types. Also to the existence of PLCβ1a and PLCβ1b splice variants, which could be 
expressed at different relative levels in different cell types could account for the 
discrepancy. Indeed, although a bipartite NLS has been mapped to a cluster of basic 
residues common to both variants (Kim et al., 1996), PLCβ1a has in its unique carboxy-
terminal tail a typical nuclear export signal (Fig. 5), which may result in this variant 
being less concentrated in the nucleus (Bahk et al., 1994). This could explain, at least in 
part, why PLCβ1a is usually equally distributed in the plasma membrane, cytoplasm 
and nucleus, whereas PLCβ1b is almost completely nuclear in several cell lines (C6Bu-
1 glioma and Friend murine erythroleukaemia cells -MEL- cells). In this regard, at 
difference with the absence of nuclear PLCβ1 protein in rat liver tissue reported by 
Divecha et al. (1993), later studies demonstrated that PLCβ1b variant is almost 
exclusively nuclear in rat liver tissue (Bahk et al., 1998; Faenza et al., 2000; Crljen et 
al., 2004; Fiume et al., 2005), suggesting that the antibody used in the study by Divecha 
et al. (1993) only recognized the PLCβ1a isoform. 
In the last years, a critical role for the PLCβ1b-specific C-terminal tail in targeting 
this variant to the sarcolemma of cardiomyocytes has been demonstrated (Grubb et al., 
2008, 2011). Thus, PLCβ1b contains a proline-rich domain near the extreme carboxyl-
terminus that interacts with the SH3 motifs of the scaffold protein Shank3 in 
cardiomyocytes, whereas the three carboxy-terminal amino acids of PLCβ1a constitute 
a PDZ-interacting domain. As shown by Grubb et al. (2008), the proline-rich domain of 
PLCβ1b is responsible for the selective targeting of this splice variant to the 
sarcolemma via interaction with Shank3 (Grubb et al., 2011), whereas PLCβ1a remains 
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cytosolic. Moreover, the integrity of a PLCβ1b-Shank3-Homer 1c protein complex is 
required for Gq-mediated signaling at the sarcolemma (Grubb et al., 2011, 2012). 
Interestingly, Shank3 belongs to a family of scaffold proteins of the postsynaptic 
density, where it provides multiple connections between glutamate receptor complexes 
and cytoskeleton (Böckers et al., 2001), such as coupling of mGluR5-Homer with PSD-
95 (Tu et al., 1999). This makes plausible that the splice variant-specific carboxy-
terminal tail is a key determinant of PLCβ1a and PLCβ1b subcellular localization in 
neurons. 
In summary, although the two splice variants of PLCβ1 have identical Gαq-
interacting domains and are comparably stimulated by Gαq, a myriad of evidence 
supports that the variant-specific extremes carboxy-termini of PLCβ1a and PLCβ1b 
contain molecular determinants for subcellular distribution. However, a deep analysis of 
the expression of PLCβ1a and PLCβ1b splice variants in nervous tissue or mammalian 
cell lines is still to be made. 
 
1.3. Nuclear phosphoinositides and PLCβ1 activity 
There is now abundant and solid evidence that phosphoinositides constitute a true 
component of the nuclear envelope and matrix. Smith and Wells (1983) carried out the 
first study reporting that phosphoinositide metabolism is also present in the nuclear 
membrane. Later, Cocco et al. (1987) demonstrated for the first time that envelope-
depleted nuclei from MEL cells were able to synthesize PIP and PIP2 in vitro, showing 
that the phosphoinositide metabolism also exists within internal nuclear domains (see 
also, Payrastre et al., 1992; Garcia-Bustos et al., 1994). Moreover, about 50% of nuclear 
PIP2 remains in envelope-depleted nuclei, along with more than 80% of the enzymes 
involved in phosphoinositide metabolism, such as DAG kinase and PtdIns(4)P-5-kinase 
and PtdIns(5)P-4-kinase activities. During the last two decades, much experimental data 
about the involvement of phosphoinositide cycle in a variety of cellular responses, such 
as, differentiation, proliferation, neoplasic transformation and DNA repair have been 
accumulated (Neri et al., 1999; D'Santos et al., 2000). Kuriki et al. (1992), using a rat 
model of hepatocyte regeneration, detected increased levels of PLC activity and inositol 
phosphate accumulation in isolated nuclei 20-22 h after partial hepatectomy. The 
identification of sequences which are essential for nuclear localization and the 
possibility to express mutated recombinant proteins that have lost their capacity to 
localize in the nucleus have unequivocally demonstrated intranuclear localization of 
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phosphoinositide metabolism-related enzymes, such as type II PtdIns(5)P-4-kinase 
PIPKIIβ, diacylglycerol kinase-zeta (DGKζ), and PLCβ1 (Topham et al., 1998; Ciruela 
et al., 2000; Faenza et al., 2003). 
 
1.3.1. Nuclear speckles as nuclear subdomains for phosphoinositide signaling 
The experimental data showing that both polyphosphoinositides and their 
metabolizing enzymes are localized within internal nuclear domains arose the question 
of which would be their precise distribution. Data accumulated in recent years, identify 
“nuclear speckles” (Fig. 6) as major candidates (For review, Cocco et al., 2006; 
Schramp et al., 2012). Several approaches, combining subcellular fractionation 
techniques, western blot analysis and colocalization with pre-mRNA probes (Osborne et 
al., 2001) concluded that these domains organize in "clusters" formed by chromatin 
granules, which would be wrapped by newly transcribed mRNA. It is thought that these 
regions are nuclear storage sites of transcription factors, small nuclear 
ribonucleoproteins (snRNPs) and hyperphosphorylated forms of RNA polymerase II 
(Mortillaro et al., 1996; Spector et al., 1991, 1993; Lamond and Spector, 2003). The 
presence of many enzymes involved in the phosphoinositide cycle such as kinases 
necessary for the synthesis of PIP2, various PLC isoforms, and DGKs has been 
demonstrated in these domains. Therefore, "nuclear speckles" emerge as important 
subnuclear domains for the phosphoinositide signaling, strengthening the idea of the 
role of nuclear phosphoinositides in mRNA processing. 
 
Figure 6. Schematic diagram illustrating the nuclear localization of the most 
representative elements of the PtdIns nuclear cycle. The picture on the left shows the 
"nuclear speckles" within the core using a specific marker. On the right, the elements forming 
the "speckles" and known relationships with transcription factors are observed. Modified from 
L. Cocco et al. (2006). 
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1.3.2. Role and synthesis of PIP2 in nuclear speckles 
The nuclear phosphoinositide cycle can be distinguished from that present at the 
plasma membrane at different levels. For instance, several agonists exclusively 
stimulate the membrane or nuclear cycles, whereas others stimulate both but with 
different kinetics (Martelli et al., 1999; Cocco et al., 2001; Irvine, 2003; Cocco et al., 
2009), and the regulation mechanisms of nuclear phosphoinositide metabolism differs 
from that operating at the plasma membrane. Nuclear phospholipid signaling requires 
an array of coordinated of lipid kinases, phosphatases, and effectors. Of these elements, 
phosphatidylinositol phosphate kinases (PIPKs) tightly regulate the spatial and temporal 
generation of PIP2. Using laser scanning confocal microscopy and immunofluorescence 
staining, intranuclear phosphoinositides (PIP, PIP2, and PtdIns 3,4-P2), and type I (also 
known as PIPKI or PIP5K) and type II PIP (known as PIPKII PIP4K) kinases have been 
identified (Boronenkov et al., 1998). Specifically type I kinases PIPKIα and PIPKIβ and 
type II, PIPKIIα and PIPKIIβ were identified at nuclear speckles (Boronenkov et al., 
1998). Although the amount of PtdIns 4-P (the substrate of type I PIP kinases) is about 
20-fold higher than that of PtdIns 5-P (the substrate of type II PIP kinases) in the 
nucleus, the relative generation of PtdIns 4,5-P2 at the 5 vs. 4 OH position has been 
shown to be only ∼1.8, suggesting that both substrates and enzyme types are relevant 
for PIP2 synthesis (Vann et al., 1997; Keune et al., 2011). However, using an elegant 
biochemical approach to discard that radiolabeling of the 4-position is due to new 
synthesis of PtdIns 4-P by PI phosphorylation rather than to the synthesis of PtdIns 4,5-
P2 (PIP2) from PtdIns 5-P2 by type I PIP kinases, Vann et al. (1997) showed that at least 
90% of nuclear PIP2 is derived from type I PIP kinases, suggesting a role for type II PIP 
kinases in regulating PtdIns 5-P levels rather than in generating PIP2. Coming back to 
type I PIP kinases, it has been demonstrated that the carboxy-terminus of PIPKIα 
interacts with Star-PAP (nuclear speckle targeted PIPKIα regulated-poly(A) 
polymerase), a novel nuclear poly(A) polymerase that couples with the transcriptional 
machinery. In response to oxidative stress, PIPKIα-generated PIP2 specifically 
modulates Star-PAP at the 3’-end of pre-mRNAs to control the expression of select 
group of genes, including the ones involved in stress responses (For review, Li et al., 
2013). However, the upstream regulators of nuclear speckle-associated PIPKIα has not 
yet been identified. One proposed major candidate is the tumor suppressor 
retinoblastoma protein RB (pRB), which interacts with and stimulates PIPKIα in the 
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nucleus but not the plasma membrane (Divecha et al., 2002), indicating a role for pRB 
in regulating the levels of nuclear PIP2. It has been suggested that transcriptional 
regulators and/or chromatin remodelling complexes may interact with and recruit type I 
PIP kinases to control local synthesis of PIP2 (Jones and Divecha, 2004). 
Although nuclear phosphoinositides are known to change in response to external 
stimuli, how these changes are transduced is poorly understood. Early studies using 
purified nuclei showed that exogenous phospholipids could affect transcription and 
replication of DNA in vitro (Capitani et al., 1986), with negatively charged lipids 
leading to chromatin decondensation, whereas positively charged ones have the 
opposite effect (Kuvichkin, 2002). Interestingly, binding of PIP2 to the carboxy-terminal 
tail of histones H1 and H3 reverses histone H1-mediated inhibition of basal RNA 
transcription (Yu et al., 1998). Additionally, PIP2 has been shown to regulate the 
chromatin structure of T cells by interaction with the chromatin-remodelling complex 
BAF (Zhao et al., 1998). Thus, exogenously added PIP2 leads to translocation of BAF 
complex from a nuclear soluble fraction to an insoluble fraction, mimicking the effects 
of T-cell stimulation with anti-T-cell receptor/CD3 complex antibodies or with phorbol 
12-myristate 13-acetate (PMA)/ionomycin. Although there is no experimental evidence 
showing that nuclear PIP2 levels are increased upon T-cell activation, the data are 
consistent with a role for PIP2 in regulating BAF complex localization. One central 
component of the BAF chromatin-remodeling complex is BRG-1, an ATPase subunit 
homologous to the yeast SWI/SNF2 protein, a member of the DEAD/H superfamily of 
DNA and RNA helicases (Eisen et al., 1995) that are critical for remodeling activities 
such as nucleosomal assembly, sliding and positioning. Among components of 
mammalian chromatin-remodeling complexes there are actin or actin-related proteins, 
which modulate remodeling activity both in vitro and in vivo (Shen et al., 2003). BRG-1 
has two domains that can interact with actin, one of which contains a lysine-rich patch 
that can interact also with PIP2. It has been suggested that PIP2 disrupts actin-BRG-1 
interaction, thus allowing binding of actin to nuclear matrix components (Rando et al., 
2002), a phenomenon analogous to PIP2-mediated uncapping of actin, which stimulates 
actin polymerisation (Yin and Janmey, 2003). Additionally, upon transcriptional 
activation, BRG-1 is the first component of the BAF complex recruited to the active 
promoter (Memedula and Belmont, 2003). It has been proposed that locally synthesized 
or H1/H3-bound PIP2 may allosterically stimulate BRG-1 to interact and recruit other 
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components of the BAF complex and/or increase its interaction with the nuclear matrix 
leading to its stabilization at the promoter (Jones and Divecha, 2004). 
Apart from its specific roles, intranuclear PIP2 is the source of downstream second 
messengers including PtdIns 3,4,5-P3 (PIP3), which can be generated from PIP2 by class 
I and class II PI3Ks. These enzymes have been found in nucleus, with class IA PI3Ks 
being the major responsible for synthesis of nuclear PIP3 (D’Santos et al. 1998; 
Gonzales and Anderson, 2006). Additionally, the presence of nuclear PTEN and SHIP-2 
phosphatases acting on PIP3 has been reported. PTEN and SHIP-2 preferentially 
dephosphorylate the 3- and 4-positions of PIP3, thus generating two different di-
phoinositide species, PtdIns 4,5-P2 and PtdIns 3,4-P2 (Cocco et al., 2006). Therefore, 
PI3Ks and PTEN activities likely impact on PLC-hydrolysable PIP2 levels, whereas 
PtdIns 3,4-P2 generated by SHIP-1 might constitute an additional second messenger 
with proper functions, as it could be the case for PIP3. 
Despite the wealth of knowledge accumulated during the last years about nuclear 
PI3K activity, the important physiological roles assigned to it and the potential 
physiological relevance of the products of PI3K-mediated PIP2 hydrolysis, of more 
importance to the present work are the role of nuclear PLCβ1 and its catalytic activity in 
nuclear signaling cascades. 
 
1.3.3. Regulation of nuclear PLCβ1 enzyme activity 
The above-mentioned experimental data reveal a key role of PIP2 in regulating 
chromatin remodeling and transcription. Being the most abundant PLC isozyme in the 
nucleus (Martelli et al., 1992; Divecha et al., 1995), PLCβ1 emerges as a major player 
in regulating PIP2 levels and, consequently, nuclear PIP2-mediated signaling. Moreover, 
DAG and IP3, generated by the hydrolysis of PIP2 by PLCβ1, are known regulators of 
gene transcription, DNA synthesis, stress response, mitosis and cell cycle progression 
(D’Santos et al., 1998), as it will be described below. 
One interesting question regarding activation of nuclear PLCβ1 isoform is whether 
the mechanisms described in the plasma membrane also take place in the nucleus. 
Activation of PLCβs by G-protein coupled receptors at the plasma membrane and the 
participation of α subunits (αq, α11, α14, and α16) belonging to the Gq family and βγ 
dimers belonging to other families of G proteins is well known (Rhee and Bae, 1997). 
By contrast, there are few studies reporting the existence of such signal transduction 
mechanism for nuclear PLCβs. Of the few ones dealing with this topic, two reports by 
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O'Malley and colleagues stand out. Thus, O'Malley et al. (2003) demonstrated that the 
metabotropic glutamate receptor mGluR5 is localized in nuclear membranes of 
mGlurR5-overexpressing HEK cells, and of midbrain and cortical neurons. Moreover, 
nuclei isolated from mGluR5-expressing HEK cells and brain neurons responded to the 
addition of glutamate, but not carbachol, with Ca2+ oscillatory responses that were 
blocked by the mGluR5-selective antagonist 2-methyl-6-(phenylethynyl)-pyridine 
(MPEP) or EGTA. Five years later, the same group (Kumar et al., 2008) demonstrated 
that these responses were dependent on PtdIns-PLC activity. Thus, nuclear Ca2+ 
oscillations elicited by mGluR activation were abrogated in nuclei pretreated with either 
the general PLC inhibitor U73122 or the PtdIns-PLC inhibitor 1-O-octadecyl-2-O-
methyl-sn-glycero-3-phosphorylcholine (ET-18-OCH3). Of note, Ca2+ oscillations were 
also abrogated in nuclei isolated from cells transfected with small interfering RNA 
(siRNA) targeted to PLCβ1 mRNA. Because blockade of ryanodine and IP3 receptors 
prevented Ca2+ oscillations, it was concluded that the second messenger IP3 generated 
by hydrolysis of PIP2 by PLCβ1 mediated this response. Indeed, Kumar et al. (2008) 
elegantly demonstrated that IP3 is generated in the nucleus following activation of 
nuclear mGluR5 receptors. To this end, HEK cells were transfected with a PIP2/IP3 
“biosensor”, consisting of a construct containing the PH domain of PLCδ1 fused to 
enhanced green fluorescent protein (pEGFP-C1-PLCδ1-PH). Because the PH domain of 
PLCδ1 binds with 20-fold higher affinity to IP3 than to PIP2, it could be possible to 
demonstrate translocation IP3 from the nuclear envelope to the nucleoplasm upon 
glutamate treatment. Collectively, these results showed that nuclear PLCβ1 can be 
activated in a similar way to membrane PLCβ1 but independently from signal 
transduction mechanisms linked to plasma membrane receptors. 
However, within the nucleus, the above-mentioned metabotropic receptor-mediated 
signal transduction mechanisms is circumscribed to the nuclear envelope, whereas most 
studies have described the bulk of nuclear PLCβ1 protein to be localized in discrete foci 
within the nuclear matrix (Avazeri et al., 2000; Tabellini et al., 2003; Martelli et al., 
2005; Bavelloni et al., 2006; Miyara et al., 2008; Fiume et al., 2009). Currently, a 
consensus exists that activation of intranuclear PLCβ1 is dependent on mitogen-
activated protein kinases (MAPKs). Early studies demonstrated the existence of a 
polyphosphoinositide cycle under the control of IGF-1 in nuclei isolated from Swiss 
3T3 cells (Divecha et al., 1991), and showed that IGF-1 stimulation promoted nuclear 
DAG synthesis and translocation of protein kinase C-α (PKCα) to the nucleus (Neri et 
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al., 1998). One year later, Martelli et al. (1999) reported that impairment of extracellular 
signal-regulated kinase (ERK) translocation to the nucleus by pretreatment of Swiss 
3T3 cells with the microtubule-depolymerizing compound colchicine prevented 
activation of nuclear PLCβ1 by IGF-1. Thereafter, Xu et al. (2001a) demonstrated ERK-
PLCβ1 interaction and mapped the ERK phosphorylation target on PLCβ1 at serine 982 
(Fig. 7). This residue is located within a Pro-Ser-Ser-Pro motif, common to PLCβ1a and 
 
 
Figure 7. Schematic diagram depicts regulation mechanisms of PLCβ1 enzymatic activity 
in the nucleus of IGF-1-stimulated mouse fibroblasts. Activation and termination of PLCβ1 
activation depends on phosphorylation at serine residues 982 and 887, respectively. Illustration 
from Cocco et al. (2006). 
 
PLCβ1b splice variants (Fig. 5). Further evidence of the key role of serine 982 
came from the analysis of the effect of glycine substitution of this residue (S982G). In 
fact, overexpression of the PLCβ1-S982G mutant prevented initiation of the 
phosphoinositide cycle and DAG production stimulated by IGF-1 (Xu et al., 2001a). 
The same group demonstrated that DAG production by transient activation of nuclear 
PLCβ1 results in nuclear translocation of PKCα, leading to phosphorylation of Serine 
887 (Xu et al., 2001b; Figs. 5,7). Moreover, alanine substitution of this residue (S887A) 
and negative dominants of PKCα leads to a sustained activation of nuclear PLC activity 
following IGF-1 stimulation (Xu et al., 2001b). Their results, showing that DAG 
production drives nuclear translocation of PKCα for termination of the IGF-1-dependent 
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PLCβ1 activation, are the first evidence of a specific role for downstream PLCβ1 
second messengers in the nucleus. These mutants have proved to be invaluable tools in 
the elucidation of the role of nuclear PLCβ1 in cell cycle control and differentiation (see 
next sections). 
 
1.4. Role of PLCβ1 enzyme activity in cell physiology 
Early studies aimed at determining the role of nuclear phosphoinositide metabolism 
in proliferative responses provided some insight into the importance that 
phosphoinositide hydrolysis might have in cell cycle control. York and Majerus (1994) 
monitored the levels of PI, PIP and PIP2 during the cell cycle of HeLa cells after release 
from block at G1/S boundary by thymidine/aphidicolin. Nuclear levels of PI, PIP and 
PIP2 decreased by about 50-70% during S phase, with plasmatic phosphoinositide levels 
remaining unchanged. Also, nuclear levels of phosphoinositides inversely correlated 
with nuclear PLC activity and DNA synthesis in response to growth factors and cell 
differentiation. Cocco et al. (1987), found very low levels of PIP2 levels in envelope 
depleted nuclei isolated from growing MEL cells, whereas nuclei cells induced to 
differentiate with dimethyl sulphoxide (DMSO) displayed high levels in nuclear 
concentrations of phosphoinositides in parallel with the cessation of DNA synthesis. 
The fact that no differences were observed between growing and differentiating MEL in 
the amount of kinases responsible for PIP and PIP2 synthesis suggested that 
phosphoinositide-hydrolizing activity accounted for cell cycle-dependent changes in 
phosphoinositide mass. 
 
1.4.1. Role of PLCβ1 in the control of cell proliferation and cell differentiation 
The first studies assigning a role to PLCβ1 in proliferation and differentiation were 
published in the mid 90s of last century. In cultured MEL cells, Divecha et al. (1995) 
showed that PLC activity, DAG production and PLCβ1 expression correlate directly 
positively with cell proliferation and negatively with cell differentiation. DMSO-
induced differentiation of MEL cells is paralleled with a corresponding decrease in 
PLCβ1 expression, whereas transfection of cells with wild-type PLCβ1 attenuates 
DMSO-induced differentiation (Matteucci et al., 1998). In contrast, transfection with a 
construct encoding for PLCβ1 lacking the bipartite NLS had no effect, showing that 
nuclear but not cytoplasmic PLCβ1 is responsible for the maintenance of the 
undifferentiated state of MEL cells. Some observations suggest that PLCβ1 is also 
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involved in DNA replication during rat liver regeneration. After partial hepatectomy, 
nuclear PLC activity increases transiently in the S phase (Kuriki et al., 1992). A later 
study (Albi et al., 2003) demonstrated that increased activity of nuclear PLC in 
regenerating rat liver occurs before the peak of DNA replication and involves the 
enzyme activity associated to the chromatin but not to the nuclear membrane. 
Furthermore, Albi et al. (2003) reported that PLCβ1 co-localizes at DNA replication 
sites much more than PLCγ, which was also detected at the nuclear envelope. These 
authors suggested that increased activity of PLCβ1 could trigger DNA replication, PLCγ 
be involved in G2/M phase transition through lamin phosphorylation. 
One piece of evidence that implicates PLCβ1 in the control of cell proliferation 
comes from two studies in two isolated Swiss 3T3 cell clones. Both clones express IGF-
1 receptor that binds IGF-1 peptide but only one of them is mitogenically-responsive 
and shows a very high rate of DNA synthesis under IGF-1 stimulation. Indeed, nuclei 
isolated from responsive cells showed a marked decrease in PIP and PIP2 levels upon 
IGF-1 stimulation, whereas irresponsive cells did not (Martelli et al., 1991). 
Additionally, PKC was seen to be activated only in responsive cells, suggesting a direct 
link between polyphosphoinositide metabolism, PKC activation and early events 
leading to cell division. The same authors pointed to PLCβ1 as the nuclear enzyme 
responsible for hydrolysis of phosphoinositides in response to IGF-1 (Martelli et al., 
1992). A later report from the same group, using antisense RNA and overexpression 
based approaches, showed that PLCβ1 isoform is required in these cells for initiation of 
DNA synthesis in in response to IGF-1 (Manzoli et al., 1997). Using an inducible 
construct in which recombinant PLCβ1 transcription was under the control of the Lac 
repressor, Billi et al. (1997) were able to analyze the subcellular localization and 
partitioning of PLCβ1 after IGF-1 stimulation of 3T3 cells, showing that PLCβ1 levels 
increased in the nucleus in coincidence with DNA synthesis during the S phase of the 
cell cycle. 
Several studies carried out by the group of Lefevre and colleagues have highlighted 
the importance of nuclear PLCβ1 activity in the control of mouse oocyte meiosis 
(Avazeri et al., 2000, 2003). In mammals, oogonia proliferate mitotically in ovaries 
during fetal life and then become primary oocytes that enter the meiotic cell cycle 
before they arrest at prophase I until puberty. At this time a few oocytes enter a growth 
phase (folliculogenesis), with the rest remaining quiescent. During folliculogenesis 
oocytes remain arrested in prophase I but enlarge about 100-fold and display a large 
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nucleus known as germinal vesicle (GV). Acquisition of meiotic competence by oocytes 
requires germinal vesicle breakdown (GVBD) before successful fertilization can take 
place. This process is preceded by Ca2+ oscillations in the region close to the nucleus. 
PLCβ1 is translocated to the GV within the hour preceding GVBD (Avazeri et al., 
2000), this process is Ca2+ dependent as the Ca2+ chelator BAPTA prevents 
translocation (Avazeri et al., 2003). More recently, Igarashi et al. (2007) have shown 
that the amplitude of Ca2+ oscillations that follow PLCζ-dependent initial transient 
elevation of intracellular Ca2+ at early stages of mammalian egg fertilization (Saunders 
et al., 2002) is PLCβ1-dependent. Taken together these results show that PLCβ1 plays a 
key role in oocyte maturation in egg activation, in concert with sperm-derived PLCζ. 
As described in the previous section, there is evidence that mitogens such as IGF-1 
are able to activate PLCβ1 via MAPK/ERK pathway. Translocation of ERK to the 
nucleus phosphorylates PLCβ1 at serine 982 leading to increased catalytic activity and 
production of nuclear DAG, which in turn recruits PKCα to the nucleus for termination 
of mitogen-activation of PLCβ1 via phosphorylation at residue serine 887 (Xu et al., 
2001a,b; Lukinovic-Skudar et al., 2005). Several lines of evidence have demonstrated 
that catalytic activity, phopsphorylation at serine 982 and nuclear localization of PLCβ1 
are necessary for cell differentiation. However, the cellular responses demonstrated to 
be PLCβ1-dependent are distant from the initiation point of the signaling cascade, and 
intermediate molecular events are far from being totally understood. Among data 
linking PLCβ1 activity and cell cycle control, considerable experimental evidence has 
been accumulated on the involvement of PLCβ1 in the regulation of cyclins and cyclin-
dependent kinases (cdks) and cell cycle progression. In this regard, Faenza et al. (2000) 
demonstrated that MEL cells transfected with either PLCβ1a or PLCβ1b splice variants 
overexpressed cyclin D3 and its kinase (cdk4) even though cells were serum-starved 
(which induces arrest in the G0/G1 phase). As a result of PLCβ1 overexpression, these 
authors observed that a significant increase of pRb phosphorylation on serines 795, 780, 
and 807/811 and activation of the E2F1 transcription factor. It is known that 
phosphorylation of pRb by cyclin/CDK complexes releases E2F1 to enable transcription 
of genes necessary for G1/S and cell cycle progression (Mittnacht, 1998) (Fig. 8). Of 
note, these effects were not observed when cells were transfected with the M2b mutant 
that prevents nuclear localization of PLCβ1 (PLCβ1M2b). In conclusion, nuclear 
PLCβ1-dependent signaling triggers cyclin D3/cdk4 activation and cell cycle 
progression. 
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In contrast with results reported in MEL cells, PLCβ1 expression increases during 
withdrawal of C2C12 myoblasts from the cell cycle, leading to differentiation into 
multinucleated myotubes (Faenza et al., 2003). By combining microarray mRNA, 
phenotypic analysis and siRNA, the same group demonstrated that overexpression of 
PLCβ1 but not PLCβ1M2b in MEL cells results in upregulation of the CD24 antigen, 
which is involved in differentiation and hematopoiesis (Fiume et al., 2005). Moreover, 
overexpression of the PLCβ1M2b mutant prevented formation of mature multinucleated 
myotube, strongly suggesting that PLCβ1 plays a key role in myoblast differentiation.
 
Figure 8. Schematic diagram showing the role PLCβ1 in cell cycle progression and 
differentiation. 
 
More recently, a role for PLCβ1 in concert with PLCγ1 in the activation of the 
cyclin D3 promoter has been demonstrated during differentiation of C2C12 myoblasts 
(Faenza et al., 2007). The question of whether not only nuclear localization of PLCβ1 
but also its catalytic activity is necessary for activation of the cyclin D3/cdk4 pathway 
and differentiation of C2C12 myoblasts was resolved by Ramazzotti et al. (2008) using 
a catalytically inactive PLCβ1 by mutation of histidines 331 and 378 located at the X 
domain (Fig. 5). Thus, overexpression of the catalytically inactive PLCβ1 results in 
lower levels of cyclin D3 mRNA after insulin treatment. Additionally, this study 
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provided interesting data, showing that PLCβ1 signaling activity results in upregulation 
of c-jun (a member of AP-1 transcription complex) and its binding to the cyclin D3 
promoter during myoblast differentiation. 
Studies in the adipocyte differentiation model of 3T3-L1 fibroblasts have provided 
further evidence of the role of nuclear PLCβ1 and its catalytic activity in cell 
differentiation (O'Carroll et al., 2009). Similar to that observed in C2C12 myoblasts, 
PLCβ1 activity is upregulated in two phases during differentiation. The first one takes 
place within 5 min after induction of differentiation, is regulated by pERK and PKCα, 
and is not dependent on nuclear translocation of PLCβ1. The second one begins after 48 
h, is independent of pERK and PKCα, and requires both upregulation and nuclear 
translocation of PLCβ1 protein. Overexpression of PLCβ1M2b and PLCβ1-S982G, 
which impair nuclear translocation and phosphorylation by ERK, respectively (see 
section 1.2.3. and Fig. 5) revealed that both phases of PLCβ1 activity are required for 
3T3-L1 fibroblasts to differentiate into adipocytes (O'Carroll et al., 2009). 
Collectively, these data highlight the key role of nuclear PLCβ1 and its catalytic 
activity in cell cycle control and differentiation. 
 
1.4.2. Role of PLCβ1 in neuronal differentiation 
PLCβ1 is strongly regulated during development of human cortex, being almost 
absent in fetal cerebral cortex and highly expressed in adults, as demonstrated at both 
gene transcript and protein levels (Caricasole et al., 2000; Peruzzi et al., 2002; Ruiz de 
Azua et al., 2006; Montaña et al., 2012). Moreover, functional activity difference 
increases drastically postnatally as demonstrated by measurement of IP3 production 
after stimulation of membranes with guanosine-5'-o-3 thiotriphosphate (GTPγS) or 
carbachol (in the presence of GTPγS). The involvement of PLCβ1, activated by the type 
I metabotropic receptor mGluR5, in cerebral cortex development has been analyzed in 
Plcb1- and mGluR5-knockout mice (Hannan et al., 2001; Böhm et al., 2002; Spires et 
al., 2005). The fact that both Plcb1-/- and mGluR5-/- mice exhibit alterations in the 
formation of the so-called "barrels" of the somatosensory cortex emphasizes the 
importance of this signal transduction for correct cortical development. It has been 
suggested that morphological reorganization of cortical neurons to form "barrels" 
depends on the transmitted signals during a critical period of postnatal development 
(Fox et al., 1996; O'Leary et al., 1994).  Therefore, the primary somatosensory cortex of 
rodents provides an excellent model for the study of activity-dependent cortical 
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development. In this context, Spires et al. (2005) analyzed the neuronal ultrastructure, 
synapse formation and morphology of dendritic spines in "barrels" of Plcb1-/- mice. This 
study revealed a decrease in the proportion of symmetrical synapses in the postnatal day 
5 and their disappearance on day 19, suggesting a transient imbalance in excitatory and 
inhibitory circuits (Spires et al., 2005). These observations indicate that PLCβ1 
signaling pathway play a key role in the coordinated development of the cerebral cortex. 
In line with this idea, Plcb1-/- mice generated by Kim et al. (1997) died suddenly at 
early postnatal stages and death was preceded by status epilepticus or recurrent seizures 
characterized by tonic–clonic or tonic extension of the whole body. These seizures were 
similar to those induced by the GABAA-receptor antagonist pentamethylenetetrazole 
(metrazol), Also, Plcb1-/- mice have been shown to develop aberrant mossy fiber 
projections and hippocampal degeneration, which correlates with spontaneous seizures 
during early postnatal development (Böhm et al., 2002). Moreover, the murine model 
recapitulates the human phenotype described by Kurian et al. (2010), which described 
that an homozygous deletion, involving the promoter element and exons 1, 2 and 3 of 
human PLCB1 gene led to tonic seizures in early infancy, subsequently infantile spasms 
and death. Other Plcb1-/- mice display schizophrenia-related behaviors but a less severe 
phenotype with no spontaneous seizures (Koh et al., 2008; McOmish et al., 2008a,b; 
Koh, 2013). Interestingly, deficits of PLCβ1 expression in prefrontal cortex (Udawela et 
al., 2011) or deletion in the PLCB1 gene (LoVasco et al., 2012) have been observed in 
human schizophrenic patients. Also, missense mutations in the SH3 domain of the 
human SHANK3 gene (an interaction site for PLCβ1b, see section 1.1.4. and Fig. 5), 
lead to a schizoaffective phenotype and epileptic seizures (Gauthier et al., 2010). 
The above described evidences in animal models and humans point to a role of 
PLCβ1 in postnatal development of cortical neurons. The fact that functional and 
morphological deficits appear during postnatal life and mutations of the scaffold protein 
of the postsynaptic density Shank3 mimic PLCβ1 deficits suggests that PLCβ1 
signaling, rather than necessary for neuronal differentiation of cortical neurons, is 
required for synaptic activity-dependent neuronal maturation. This assumption would 
imply that membrane but not nuclear PLCβ1 is involved in maturation of cortical 
neurons. However, it must be noted that all isoforms of the PLCβ family are expressed 
in brain cortex (Ruiz de Azúa et al., 2006), contain a nuclear localization signal 
(Rebecchi and Pentylana, 2000) and are expressed in neuronal nuclei (García del Caño 
et al., 2015). Consequently, redundant PLCβs could compensate for the loss of PLCβ1 
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during early neuronal differentiation. Therefore, cell models are necessary to ascertain 
whether PLCβ1 is required for differentiation of neurons as it has been observed for 
several cell types. In this regard, the pluripotent NTERA2/D1 (NT2) cell line, which 
can be induced to differentiate in vitro into postmitotic NT2N neurons (Andrews, 1984), 
represents a valuable model to study molecular mechanisms underlying neuronal 
differentiation, including the role of PLCβ1 enzyme. Interestingly, it has been shown 
that differentiation of NT2 progenitors into NT2N mature neurons is associated with 
increased expression levels of the Gαq/11, PLCβ1 isoform and PLC activity (Novak et 
al., 2000). These data on the expression of elements leading to PLCβ1-induced 
signaling during NT2 cell differentiation are still very scarce, but provide an 
encouraging start point to address one the major issues in the present study. 
 
1.5. Translin-Associated Factor X: a novel binding partner of PLCβ1 involved in 
RNA silencing 
Recently, using the carboxy-terminal coil of PLCβ1 as bait in a yeast two-hybrid 
approach, Aisiku et al. (2010) have identified the protein translin-associated factor X 
(TRAX) a new binding partner of PLCβ1. TRAX is a 33 kDa protein that forms a DNA 
and RNA binding complex with translin (26 kDa), the only known binding partner of 
TRAX before the discovery of TRAX-PLCβ1 association (Jaendling and McFarlane, 
2010). Translin is a single-stranded DNA and RNA-binding protein with proposed 
functions in chromosomal translocations in lymphoid cells and mRNA transport and 
storage in brain and testis (Wang et al., 2004), and both TRAX and translin have been 
found to be essential for normal cell proliferation (Hecht et al., 2004; Wang et al., 2004; 
Yang et al., 2004; Jaendling, 2010).  
 
Figure 9. Linear representation of TRAX and Translin protein depicting the location of several 
domains. Nb and Cb, refer to basic domains located closer to the N-terminus and C-terminus, 
respectively, that mediate nucleic acid binding activity; NES, nuclear export signal, LZ, putative 
leucine zipper domain; NLS, nuclear localization signal. Modified from Li et al. (2008). 
  INTRODUCTION 
	  
	  
29 
As seen in figure 9, TRAX contains a nuclear localization signal (NLS) and 
Translin is thought to possess a nuclear export signal (NES), and it has been suggested 
that TRAX-Translin complex mediates dynamic changes in the subcellular localization 
of the complex, allowing for shuttling between nuclear and cytoplasmic compartments. 
Under conditions where the level of TRAX is higher than translin, the NLS of TRAX 
would be exposed, leading to nuclear localization of the complex. In contrast, when 
translin is in excess the complex would move to the cytosol (Aoki et al., 1997; Cho et 
al., 2004). 
 
Figure 10. A. Ribbon 
representation of C3PO 
complex, in which the two 
TRAX subunits are colored 
in yellow and orange, and the 
six Translin subunits are 
colored in cyan or light cyan. 
B. Orthogonal view of A 
from the top of C3PO of the 
complex. Modified from Ye 
et al. (2011).  
The conserved Translin-TRAX complex, also known as Component 3 Promoter of 
RISC (C3PO), is a complex formed by six Translin and two TRAX subunits that form 
an asymmetric octamer with the RNase catalytic residues located on the TRAX subunits 
(Fig. 10). C3PO helps guiding double stranded RNA into the silencing machinery as 
part of the RNA-induced complex (RISC) (Liu et al., 2009), whose other two major 
components are Argonaute-2 (Ago2) and Dicer-2 (Dcr-2). It has been demonstrated 
TRAX-Translin complex is necessary for efficient RNA interference (RNAi) mediated 
by small interfering RNAs (siRNAs) (Liu et al., 2009; Ye et al., 2011). RNA 
interference regulates gene expression by the slicer activity of Ago2, which degrades 
target mRNA with the aid of siRNA (Hammond et al., 2001). In this pathway, double 
strand RNA is transferred to the RLC (consisting of Dcr-2 and R2D2) and processed 
into 21-25 bp duplex RNA. The TRAX-Translin complex binds to the RLC and RISC 
(consisting of Ago2, Dcr-1, Tudor staphylococcal nuclease -TSN-, vasa intronic gene -
VIG- and Drosophila FMR -dFMR-), thus forming the holo-RISC through an 
interaction between Drc-2 and Ago2. This allows the passenger strand to be 
endonucleolytically cleaved from the duplex RNA to form the single-stranded siRNA, 
this process being enhanced by C3PO (TRAX-Translin) activity. Then, the guide strand 
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targets the holo-RISC complex to the complementary mRNA for degradation (Fig. 11; 
Jaendling and McFarlane, 2011) 
 
Figure 11. Schematic drawing showing the siRNA mediated RNA interference pathway and the 
proposed role of C3PO. Illustration taken from Jaendling and McFarlane (2011). 
 
Noticeably, Aisiku et al. (2010) demonstrated that TRAX competes with activated 
Gαq (Gαq-GTPγS) but not unactivated Gαq (Gαq-GDP) for binding to PLCβ1 without 
affecting its affinity for membrane association. Because, the carboxy-terminal sequence 
used for yeast two-hybrid screening of PLCβ1-interacting partners encompassed the 
Gαq-interacting sequences flanking the C2 domain of PLCβ1 (Wang et al., 1999; Waldo 
et al., 2010; Lyon et al., 2011; Figs. 3, 5), it is very likely that TRAX interacts in at least 
one of these two regions, although the interaction sequence in PLCβ1 has not been 
mapped. 
Recently, the same research group (Philip et al., 2012) has demonstrated a crosstalk 
between metabotropic receptor-mediated Gαq activation, subcellular localization of 
TRAX and the machinery involved in RNA interference. Thus, consistent with the 
ability of TRAX to disrupt the association between PLCβ1 and Gαq-GTPγS, Ca2+ 
signals observed after carbachol stimulation of PLCβ1- and Gαq-overexpressing HEK 
cells are abrogated upon co-transfection with TRAX. Conversely, carbachol stimulation 
of HEK cells overexpressing PLCβ1 (but having normal endogenous levels of Gαq and 
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TRAX) promotes translocation of a population of TRAX to the nucleus, indicating that 
TRAX localization is responsive to Gαq activation. But the most interesting finding by 
Philip et al. (2012) was that association between TRAX and PLCβ1 regulates the 
activity of the RISC complex affecting siRNA regulation of specific genes. They 
observed that overexpression of PLCβ1 reversed the activity of glyceraldehyde 3-
phosphate dehydrogenase (GADPH) and lactate dehydrogenase (LDH) siRNAs, but did 
not affect siRNA silencing of other genes such as cyclophilin, Hsp90, translin. 
Moreover, overexpression of PLCβ1 rescued cells from cell death caused by 
transfection with GADPH and LDH siRNAs. This effect was independent of PLCβ1 
catalytic activity and could be reversed by overexpression of a constitutively active 
form of Gαq, which very likely results from displacement of TRAX from its association 
with PLCβ1. In addition, they observed that GADPH siRNA, but not Hsp90 siRNA, 
increased co-localization of PLCβ1 with Ago2 and Dcr-2, indicating that only specific 
siRNA sequences trigger association of PLCβ1 to the RISC complex to reverse 
endonucleolytical cleavage of the duplex siRNAs, which impairs efficient degradation 
of specific target mRNAs (for review, Philip et al., 2013). 
Interestingly, endogenously encoded, short (21–25 nt), single-stranded microRNAs 
(miRNAs) that posttranscriptionally regulate gene expression are temporally and 
spatially expressed during neuronal differentiation, acting as switches for neuronal stem 
cell differentiation (Shi et al., 2010; Coolen et al., 2012; Palm et al., 2013). This 
function requires incorporation of miRNAs to the RISC silencing machinery to target 
mRNAs for mRNA degradation and translational repression. In mammalian brain, many 
miRNAs are particularly enriched, where they participate in neuronal differentiation and 
even act locally controlling growth cone and synapse formation (Sun et al., 2013). 
Moreover, altered miRNA function or expression in neural stem cells has been shown to 
be associated with neurological disorders, such as Parkinson´s and Alzheimer’s diseases 
(Palm et al., 2012; Maffioletti et al., 2014). Additionaly, TRAX- and translin-knockout 
mice display a wide spectrum of neurological deficits (Chennathukuzhi et al., 2003; 
Stein et al., 2006; Li et al., 2008). Therefore, it is conceivable that PLCβ1 could play a 
key role in neuronal differentiation by regulating endogenous miRNA activity thanks to 
its ability to associate to the RISC complex via TRAX.  As a first step in testing this 
hypothesis, it is required an initial characterization of TRAX expression, subcellular 
localization and of PLCβ1-TRAX interaction during neuronal differentiation. 
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2. NT2-DERIVED POSTMITOTIC NEURONS: A MODEL	   OF TERMINALLY 
DIFFERENTIATED ADULT HUMAN NEURONS 
Neuronal differentiation is a complex, developmentally regulated neurobiological 
phenomenon that involves proliferation arrest of neural progenitors and expression of 
neuron-specific genes, followed by neurite extension and morphological and functional 
polarization. In the vertebrate nervous system, the two broad types o neural progenitors 
(neural crest-derived cells and multipotent cells of the ventricular zone) have the ability 
to differentiate into neurons, astrocytes or oligodendrocytes. Neuronal differentiation 
appears to follow a common pattern in which proneural genes (members of the basic 
helix-loop-helix (bHLH) family of transcription factors) select progenitor cells 
previously specified to a neuronal fate. Subsequent phases involve the activity of 
proneural genes, which either alone or in coordination with other genes, activate Notch 
signaling, cell cycle withdrawal, and pan-neuronal and neuron phenotype-specific gene 
expression (for review, Jessell, 2000; Bertrand et al., 2002, Briscoe and Ericson, 2001). 
However, a still major challenge in developmental neurobiology is to elucidate the 
factors that govern the progression of the cascade of morphological and biochemical 
events that encompass the process of neuronal differentiation from neural progenitors. 
For these studies, human neuronal cells can be obtained from three different sources: 
embryonic stem cells (ESCs) derived from inner cell mass of the preimplanted human 
embryo, embryonic germ cells (EGCs) derived from primodal germ cells isolated from 
embryonic gonads and embryonic carcinoma cells (ECCs) derived from tumors in adult 
humans (Fig. 12). 
Of these possibilities mentioned above, continuously dividing ECCs with neuronal 
characteristics has proven to be a very potent tool for biochemical and molecular 
biological studies. On one hand, biochemical studies usually require a large amount of 
homogenous cells. On the other hand, at difference with primary neurons, most cell 
lines are easy to transfect with non-viral vectors, which enables inexpensive, easy, safe 
and quick gen transfer to dissect molecular mechanisms underlying neuronal 
differentiation or to generate novel cell lines stably expressing the desired foreign gene 
product. In this regard, the pluripotent NTERA2/D1 (NT2) cell line, derived from 
human testicular embryonic carcinoma cells (Andrews, 1984), represents a committed 
neuronal precursor cell that can be induced to differentiate in vitro into postmitotic 
cells, known as NT2N (or hNT) neurons. Moreover, NT2N cells have the ability to 
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establish functional synapses and to develop neuronal electrophysiological properties, 
including generation of action potentials and the presence of spontaneous excitatory and 
inhibitory postsynaptic currents (Hartley et al., 1999a; Podrygajlo et al., 2010; Öz et al., 
2013). Consequently, the NT2N cell type is now widely accepted as a suitable model 
for the study of neuronal networks, and differentiation and synaptogenesis processes. 
 
Figure 12. Sources of human neuronal cells. Modified from Donovan and Gearhart (2001). 
 
In addition, the NT2 clonal line represents a promising cell source for neuronal 
replacement therapy applicable to the treatment of some neurological conditions, 
including neurodegenerative disorders such as Parkinson’s, Huntington’s and 
Alzheimer’s diseases, and acute brain injury such as stroke and head trauma. To this 
end, grafts or cells in suspension from embryonic ventral mesencephalic tissue, adrenal 
medullary cells, other neuronal and non-neuronal cells, and even genetically modified 
cells have produced encouraging results, but none of them are fully satisfactory 
(Martínez-Morales et al., 2013). As a consequence, researchers have focused their 
efforts on either trying to increase the efficacy of existing tissue and cell candidates or 
searching for alternative sources of donor cells. In this sense, NT2N neurons maintain 
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their neuronal phenotype after transplantation into the rodent brain (Trojanowski et al., 
1993; Kleppner et al., 1995; Baker and Mendez, 2005) and spinal cord (Hartley et al., 
1999b; Lee et al., 2000). Furthermore, NT2N grafts have been shown to improve motor 
deficits in animal models of stroke (Borlongan et al., 1998a,b; Saporta et al., 1999) and 
Huntington’s disease (Hurlbert et al., 1999), making NT2N neurons excellent 
candidates for cell replacement therapy in neurological disorders (Trojanowski et al., 
1997; Lee et al., 2000; Nelson et al., 2002; Borlongan et al., 2006; Hara et al., 2008). 
Indeed, in a phase I clinical trial on 12 patients with basal ganglia stroke and stable 
motor deficits, NT2N cells were seen to integrate with the host brain tissue for long 
periods and with no detectable tumor formation (Kondziolka et al., 2000; Meltzer et al., 
2001; Nelson et al., 2002), leading to a Phase II study in 18 patients with basal ganglia 
infarct (Kondziolka et al., 2005). Although statistical significance could not be reached 
due to the small population size analyzed, both studies showed an apparent trend 
towards functional improvement (Banerjee et al., 2010, for review). 
Progress in the field of neuronal replacement using NT2 committed to differentiate 
with retinoic acid (RA) is limited by the long time frame necessary to generate 
postmitotic NT2N neurons and also by the low proportion of terminally differentiated 
neurons. Thus, neuronal differentiation of NT2 progenitors, first described by Andrews 
(1984) and later on improved by Pleasure et al. (1992), involves treatment of NT2 
progenitors with RA during 4 weeks followed by mitotic inhibitors for 7-10 days, with 
only about 5% of the initial population of NT2 cells becoming differentiated. Recently, 
using nucleoside analogues, Musch et al. (2010) achieved successful differentiation of 
NT2 cells in less than one week, thus offering a rapid protocol to obtain postmitotic 
neurons, which could be potentially useful for neuronal replacement therapy. However, 
whereas NT2N neurons obtained by treatment with RA have been shown to express a 
variety of classical neurotransmitters, neurotransmitter-related enzymes and 
transporters, including γ-aminobutyric acid (GABA), tyrosine hydroxylase (TH), 
choline acetyltransferase (ChAT) and glutamate transporters (Podrygajlo et al., 2009; 
Coyle et al., 2011), there are no published data about neuronal phenotypes resulting 
from nucleoside-induced differentiation of NT2 cells. Therefore, one major objective of 
the present study will be to establish a quick and efficient method for neuronal 
differentiation of NT2 progenitors and to characterize the resulting neuronal 
phenotypes. 
 II. OBJECTIVES 
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As mentioned in the introduction, the involvement of PLCβ1 in cell differentiation 
has been extensively reported in a variety of cell lines (Cocco et al., 2009), and there is 
suggestive evidence that PLCβ1 plays a key role in neuronal differentiation. This later 
idea derives from observations that Plcb1-/- mice (Kim et al., 1997; McOmish et al., 
2008a,b; Koh, 2013) and humans with deletions of the PLCB1  (Udawela et al., 2010; 
LoVasco et al., 2012) display functional and morphological deficits that become evident 
during postnatal life. 
To address the issue of whether PLCβ1 plays an important role in neuronal 
differentiation, cell models suitable for gene and siRNA transfer to either force or 
knockdown the expression of the desired protein are necessary. In relation to the present 
project, these approaches will enable to ascertain whether PLCβ1 is necessary and/or 
sufficient for neuronal differentiation, and whether PLCβ1a and PLCβ1b splice variants 
play a specific role in this process. Among the cell lines available, the pluripotent NT2 
embryonic carcinoma cells line is widely accepted as an excellent model for the study 
human neuronal differentiation. Currently, there is a wealth experimental evidence 
documenting that treatment with retinoic acid (RA) promotes differentiation of NT2 
progenitors into postmitotic NT2N neurons (Andrews, 1984; Pleasure et al., 1992). 
Apart from being phenotypically characterized with regard to the expression of 
neurotransmitter-related enzymes and transporters, it has been shown that NT2N 
neurons are able to functionally integrate into the rodent and human brain and even to 
promote functional recovery in animal models of various neurological diseases 
(Banerjee et al., 2010). 
However, the use of RA-differentiated NT2 progenitors is limited by the long time 
frame necessary to generate postmitotic NT2N cells and also by the low proportion of 
terminally differentiated neurons, making this procedure useless for transient 
transfection-based approaches. On the basis of a recent report showing that nucleoside 
analogues promote neuronal differentiation of NT2 cell in less than one week, the first 
objective of the present study will be to establish an alternative NT2 differentiation 
procedure that overcomes these drawbacks mentioned above. 
The neurochemical characterization of a rapid and efficient method for neuronal 
differentiation of NT2 cells using nucleotide analogues will provide the basis for 
biochemical and molecular biological approaches aimed at determining the role of 
PLCβ1 in neuronal differentiation. 
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With these challenges in mind, the major objectives of this thesis are: 
1. To establish and characterize an experimental model for human neuronal 
differentiation by short exposure of NT2 progenitors to nucleoside analogues. 
2. To analyze the expression of PLCβ1a and PLCβ1b splice variants in subcellular 
fractions of the adult rat cerebral cortex and of NT2 cells. 
3. To analyze the time-course expression of PLCβ1a and PLCβ1b variants during 
neuronal differentiation of NT2 cells. 
4. To study the role of PLCβ1 in neuronal differentiation of PC12 and NT2 cells. 
5. To analyze the expression and subcellular localization of TRAX during neuronal 
differentiation of NT2 cells. 
6.  To analyze the PLCβ1-TRAX interaction in differentiating NT2 cells and the effect 
of TRAX silencing on neuronal differentiation of PC12 and NT2 cells. 
 III. MATERIALS 
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1. GENERAL MATERIALS, CHEMICAL AND REAGENTS 
- Acetone (Panreac, 211007). 
- Chloral hydrate (Panreac, 141975). 
- DL-Dithiothreitol (DTT) (Sigma-Aldrich, 43815). 
- Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA, Sigma-
Aldrich, E4378). 
- Ethylenediaminetetraacetic acid (EDTA, Panreac, ED). 
- Filter paper (Bio-Rad, 165-0962). 
- Gelatin (Panreac, 142060). 
- Glycerol (Sigma-Aldrich, G8773). 
- Glycine (Bio-Rad, 161-0724). 
- Hydrochloric acid 37% (Panreac, 141020). 
- Magnessium Chloride Hexahydrate (Panreac, 131396). 
- Methanol (Sigma-Aldrich, 32213). 
- Mowiol (Calbiochem, 17951). 
- P-phenylenediamine, 1,4-Benzenediamine hydrochloride (PPD, Sigma-Aldrich, 
P1519). 
- Paraformaldehyde (PFA, Panreac, 141451). 
- Potassium chloride (Sigma-Aldrich, P5405). 
- Saponin (Sigma-Aldrich, 84510). 
- Sodium azide (Panreac, 122712). 
- Sodium chloride (Sigma-Aldrich, S7653). 
- Sodium Hydroxide (Probus, 131687). 
- Sodium phosphate dibasic (PO4Na2H, Sigma-Aldrich, S0876). 
- Sodium phosphate monobasic (PO4NaH2, Sigma-Aldrich, S0751). 
- Sucrose (Sigma-Aldrich, S0389). 
- Tris(hydroxymethyl)aminomethane (Trizma® Base, Sigma-Aldrich, T1503). 
- Tritón X-100 (Sigma-Aldrich, T8787). 
- Tween-20 (Bio-Rad, 170-6531). 
- Urea (Sigma-Aldrich, U5378). 
- β-mercaptoethanol (Sigma-Aldrich, M7522). 
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2. SPECIFIC MATERIALS, CHEMICALS AND REAGENTS 
2.1. Cell culture and transfection 
2.1.1. Disposables 
- 0.22-µm-pore-size syringe filters (Millipore, SLGP05010). 
- 15 and 50 mL centrifuge tubes (Corning, 430791 and 430291). 
- 25, 75 and 150 cm2 cell culture flasks (Corning, 3055, 430725 and 430824). 
- 5, 10 and 25 mL pipettes (Corning, 4487, 4487 and 4489 ). 
- 6-, 12- and 24-well culture dishes (Corning, 3516, 3513 and 3526). 
- 96-well EIA/RIA plates (Corning, 3590). 
- Cell scrapers (Corning, 3011). 
- Gene Pulser/MicroPulser Electroporation Cuvettes (Biorad, 165-2088). 
2.1.2. Transfection media 
- DharmaFECT 1 Transfection Reagent (Dharmacon, T-2001-02). 
- Lipofectamine® 2000 (Invitrogen, 11668027). 
2.1.3. Culture media, supplements, inductors and substrates 
- BD Matrigel™ Basement Membrane Matrix (GIBCO, 354234). 
- Dulbecco’s Modified Eagle’s Medium (DMEM, ATCC, 30-2002™). 
- Dulbecco’s Phosphate Buffered Saline (DPBS) (1X) (GIBCO, 14190-094). 
- Fetal bovine serum (FBS, Sigma-Aldrich, F6178). 
- Fetal horse serum (FHS, Sigma-Aldrich, H1270). 
- Lithium chloride (Panreac, 141392). 
- Nerve Growth Factor (NGF, Sigma-Aldrich, N0513). 
- OptiMEM™ (Life Technologies, 51985-034). 
- Poly-D-lysine hydrobromide (Sigma-Aldrich, P6407). 
- Penicillin 10.000 U/mL, Streptomycin 10.000 µg/mL (Lonza, 17-602E). 
- Trans retinoic acid (Sigma-Aldrich, R2625). 
2.1.4. Antimitotics 
- 2’-deoxy-5-azacytidine (DAC, Sigma-Aldrich, A1287). 
- 5-Fluoro-2’-deoxiuridine (FUdR, Sigma-Aldrich, F8791). 
- Citosine β-D-arabinofuranoside (AraC, Sigma-Aldrich, C1768). 
- Uridine (Sigma-Aldrich, U3750). 
  
 MATERIALS 
 
 
43 
2.1.5. Other products 
- Cell culture grade dimethylsulfoxide (DMSO, ATCC, 4-X). 
- Cell culture grade water (Sigma-Aldrich, W3500). 
- Trypsin-EDTA (0,05%), phenol red (GIBCO, 25300-054). 
 
2.2. Western blot 
- Acrylamide/Bis-acrylamide, 40% solution (Bio-Rad, 161-0148). 
- Ammonium persulfate (Bio-Rad, 161-0700). 
- BCA Protein Quantification Kit (Abcam, ab102536). 
- Blotting Grade Blocker Non-Fat Dry Milk (Bio-Rad, 170-6404). 
- Bovine Serum Albumine (Sigma-Aldrich, A3608). 
- Bio-Rad DC Protein Assay Kit I (Bio-Rad, 500-0111). 
- Bromophenol blue (Sigma-Aldrich, 11439). 
- CL-XPosure film (Thermo Scientific, 34089). 
- Clarity Western ECL substrate (Bio-Rad, 170-5060). 
- Coomassie brilliant blue dye (Bio-Rad, 161-0400). 
- Developer (Sigma-Aldrich, 7042) and fixative (Sigma-Aldrich, P7167) for CL-
XPosure films. 
- IGEPAL (Sigma-Aldrich, 18896). 
- Immun-Blot® PVDF Membrane (Bio-Rad, 162-0177). 
- Iodoacetamide (Sigma-Aldrich, I1149). 
- Laemmli Buffer (Bio-Rad, 161-0737). 
- Phenylmethanesulfonyl fluoride (PMSF, Sigma-Aldrich, P7626). 
- Precision Plus Protein™ Dual Color Standards (Bio-Rad, 161-0374). 
- RNase-free recombinant DNase I (TaKaRa, TB 2270A). 
- Sodium dodecyl sulfate (SDS, Amersham, L3771). 
- TEMED (Bio-Rad, 161-0800). 
- γ-Globulin (Bio-Rad, 500-0208). 
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2.3. Antibodies and sera for immunofluorescence and Western blot 
2.3.1. Primary antibodies 
Table 1. Primary antibodies used 
Antibody Dilution Species & clonality Isotype Immunizing antigen Source, Cat. No. IF WB 
BiP - 1:500 
Rabbit 
polyclonal 
IgG 
Synthetic peptide corresponding to amino acids 
within the last 660 residues of the C terminus of 
mouse GRP78/BiP. 
Abcam, ab21685 
ChAT 1:100 1:1000 
Goat 
polyclonal 
Serum Human placental enzyme. Millipore, AB144P 
CyPA - 1:500 
Mouse 
monoclonal 
IgG2a Recombinant CyPA protein of human origin. 
Sta Cruz Biotech. 
Inc., sc-134310 
clone 6-YD13 
DCX 1:200 1:500 
Goat 
polyclonal 
IgG 
Synthetic peptide mapping at the C-terminus of 
human doublecortin. 
Sta Cruz Biotech. 
Inc., sc-8066 
GAD67 1:100 1:1000 
Mouse 
monoclonal 
IgG2a Recombinant GAD67 protein. 
Millipore, 
MAB5406, 
clone 1G10.2 
GFP - 1:2500 
Rabbit 
polyclonal 
IgG GFP isolated from Aequorea victoria. Invitrogen, A11122 
Golgi - 1:2000 
Rabbit 
polyclonal 
Serum 
Synthetic peptide encompassing residues 200-
300 of human 58K Golgi protein. 
Abcam, ab5820 
Gαq/11 1:200 1:1000 Rabbit 
polyclonal 
IgG 
Peptide mapping within a domain common to Gα 
11 of mouse origin. 
Sta Cruz Biotech. 
Inc., sc-392 
HA 1:500 1:1000 
Mouse 
monoclonal 
IgG1 
Synthetic peptide corresponding to the 
hemagglutinin sequence CYPYDVPDYASL. 
Covance, MMS-
101P, 
clone 16B12 
Histone H1 - 1:200 
Mouse 
monoclonal 
IgG2a Biopsy cells from human leukaemia. 
Sta Cruz Biotech. 
Inc., sc-8030 
Lamin B1 1:100 - 
Mouse 
monoclonal 
IgG1 
Purified cell nuclei from human epithelioid 
carcinoma. 
Sta Cruz Biotech. 
Inc., sc-56144 
MAP2 1:200 - 
Mouse 
monoclonal 
IgG1 Bovine MAP2. 
Sigma-Aldrich, 
M2320 
Na+/K+ 
ATPase 
- 1:450 
Mouse 
monoclonal 
IgG1 
α1 subunit of Na+/K+ ATPase purified from lamb 
kidney. The epitope maps at residues 496-506. 
Sigma-Aldrich, 
A277, 
clone M8-P1-A3 
Nav1.6 Na+ 
channel 
1:200 - 
Mouse 
monoclonal 
IgG1 
Synthetic peptide corresponding to amino acids 
459-476 within the cytoplasmic loop I-II of rat 
Nav1.6. 
NeuroMab, 75-026 
NeuN 1:200 1:1000 
Mouse 
monoclonal 
IgG1 Purified cell nuclei from mouse brain. 
Millipore, MAB377 
clone A60 
NF200 1:400 1:10000 
Rabbit 
polyclonal 
IgG NF200 protein purified from bovine spinal cord. 
Sigma-Aldrich, 
N4142 
NR1 - 1:1500 
Rabbit 
polyclonal 
Serum 
Synthetic non-phosphopeptide around the 
phosphorylation site of human NMDAR1 at 
serine 897 (RSSKD). 
Abcam, ab52177 
Nuclear 
Pore 
Complex 
- 1:1000 
Mouse 
monoclonal 
IgG1 Nuclear pore complex mixture Abcam, ab24609 
PIP2 1:100 - 
Mouse 
monoclonal 
IgM 
Liposomes containing synthetic di-palmitoyl 
PtdIns (4,5)P2. 
Tocris, 2368, 
clone 2C11 
PLCβ1 
(D-8) 
1:125 - 
Mouse 
monoclonal 
IgG2b 
Synthetic peptide mapping within amino acids 
831-1063 of rat PLCβ1. 
Sta Cruz Biotech. 
Inc., sc-5291 
PLCβ1 
(N-ter) 
- 1:750 
Mouse 
monoclonal 
IgG1 
Synthetic peptide corresponding to amino acids 
4–159 of the rat PLCβ1. 
BD Transduction 
Laboratories, 
610924 
PLCβ1 
(R-233) 
1:500 - 
Rabbit 
polyclonal 
IgG 
Synthetic peptide mapping within amino acids 
831-1063 of rat PLCβ1. 
Sta Cruz Biotech. 
Inc., sc-9050 
PLCβ1a 
(G-12) 
1:250 1:500 
Rabbit 
polyclonal 
IgG 
Synthetic peptide corresponding to a unique C-
terminal region of PLCβ1a splice variant. 
Sta Cruz Biotech. 
Inc., sc-205 
PLCβ4 - 1:500 Rabbit 
polyclonal 
IgG 
Synthetic peptide mapping at the C-terminus of 
rat PLCβ4. 
Sta Cruz Biotech. 
Inc., sc-404 
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Antibody Dilution Species & clonality Isotype Immunizing antigen Source, Cat. No. 
SC-35 1:500 - 
Mouse 
monoclonal 
IgG 
Synthetic peptide sequence corresponding to 
SC-35 splicing factor. 
Abcam, ab11826 
SNAP-25  1:4000 
Mouse 
monoclonal 
IgG1 
Tissue cell preparation: this antibody was raised 
against a crude synaptic preparation from the 
post mortem human brain. 
Abcam, ab24732 
TH 1:100 1:1000 
Rabbit 
polyclonal 
Rabbit 
SDS-denatured tyrosine hydroxylase from rat 
pheochromocytoma. 
Millipore, AB152 
TRAX 
(56) 
- 1:2000 
Mouse 
monoclonal 
IgG1 Amino acids 1-207 of TRAX of human origin. 
Sta Cruz Biotech. 
Inc., sc-136108 
TRAX 
(FL-290) 
1:125 - 
Rabbit 
polyclonal 
IgG Full length TRAX of human origin. 
Sta Cruz Biotech. 
Inc., sc-98554 
VGluT1 1:200 1:1500 
Rabbit 
polyclonal 
IgG 
Synthetic peptide from a cytoplasmic loop of rat 
(C-terminal) VGluT1. 
Abcam, ab72311 
β-Actin - 1:40000 Mouse 
monoclonal 
IgG1 
An epitope mapping at the N-terminal end of β-
actin. 
Sigma-Aldrich, 
A5441 
β-Tubulin - 1:500 Mouse 
monoclonal 
IgG1 
An epitope in the carboxy-terminal part of all five 
isoforms of β-tubulin (between amino acids 281-
446). 
Sigma-Aldrich,  
T-4026 
β-Tubulin-III 1:1000 1:1000 Chicken 
polyclonal 
Chicken 
serum 
Synthetic peptides corresponding to different 
regions shared by human and rat β-tubulin III. Abcam, ab41489 
 
2.3.2. Secondary antibodies for Immunofluorescence and fluorescent dyes 
- Alexa Fluor 568 Goat anti-Rabbit (Invitrogen, A11036). 
- Alexa Fluor 568 Goat anti-Mouse (Invitrogen, A11031). 
- Alexa Fluor 488 Goat anti-Rabbit (Invitrogen, A11034). 
- Alexa Fluor 488 Goat anti-Mouse (Invitrogen, A11029). 
- Alexa Fluor 488 Donkey anti-Goat (Invitrogen, A11055). 
- DyLight 549 Donkey anti-Rabbit (Jackson Immuno Research, 711-506-152). 
- DyLight 549 Donkey anti-Mouse (Jackson Immuno Research, 715-506-151). 
- DyLight 649 Donkey anti-Mouse (Jackson Immuno Research, 715-496-151). 
- DyLight 649 Goat anti-Chicken (Jackson Immuno Research, 103-495-155). 
- Cy 5 Donkey anti-Rabbit (Jackson Immuno Research, 711-176-152). 
- DyLight 488 Donkey anti-Chicken (Jackson Immuno Research, 703-486-155). 
- Hoescht 33342 (Sigma-Aldrich). 
2.3.3. Secondary antibodies for Western blot 
- Anti-rabbit IgG HRP conjugate (Amersham, NA934). 
- Anti-mouse IgG HRP conjugate (Amersham, NXA931). 
- Anti-Goat IgG HRP conjugate (Sigma-Aldrich, A5420). 
- Rabbit anti-Chicken IgY HRP conjugate (Sigma-Aldrich, A9046). 
2.3.4. Normal sera 
- Normal goat serum (NGS, Vector Laboratories, U0328). 
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- Normal rabbit serum (NRS, Vector Laboratories, T1127). 
- Normal donkey serum (NDS, Vector Laboratories, U0111). 
 
2.4. Molecular biology 
2.4.1. Agarose gel electrophoreis 
- Agarose D1 Low EEO (Conda, 8016). 
- 100 bp DNA ladder (Nippon Genetics, MWD100). 
- 1kb DNA ladder (Nippon Genetics MWD1). 
- 1kb DNA ladder (Thermo Scientific, SM1163). 
- Low range DNA ladder (Thermo Scientific, SM1203). 
- 50X TAE (Tris/AceticAcid/EDTA) buffer (Biorad, 161-0743). 
- GelRed Nucleic Acid Stain 10000X (Biotium, 41003). 
2.4.2. Bacterial culture 
- Ampicillin Sodium Salt (Sigma-Aldrich, A9518). 
- Kanamycin Sulphate Supplement (OXOID, SR0092). 
- Medium for bacterial culture on agar, LB Agar (Lennox) (Conda, 1083). 
- Medium for bacterial culture in suspension, LB Broth (Lennox) (Conda, 1231). 
- Sterile Petri dishes (Kord, 905). 
2.4.3. DNA purification 
- NucleoBond® Xtra Midi Plus (Machery Nagel, 740412.50). 
- Nucleospin® Gel and PCR Clean-Up (Machery Nagel, 740609.250). 
- NucleoSpin® Plasmid (Machery Nagel, 740588.250). 
2.4.4. PCR and cloning 
- KAPA HiFi PCR Kit, including high-fidelity Taq polymerase, buffers and dNTPs 
(KAPA Biosystems, KK2101). 
- PCR Tube Strips (Biorad, TCS0803). 
- ONE Shot TOP 10 Chemically Competent E. Coli (Invitrogen, C4040). 
- T4 DNA Ligase (Takara, 2011A). 
- 10X T4 DNA Ligase Buffer (Takara, 2011A). 
- Zero Blunt TOPO PCR Cloning Vector (Invitrogen, P/N 46-0757). 
- Restriction Enzymes 
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Table 2. Restriction enzymes used. All from New England Biolabs. 
Enzyme Cleavage site Ref. 
AgeI A^CCGGT R0552S 
BamHI G^GATCC R0136S 
BglII A^GATCT R0144S 
BsrGI T^GTACA R0575S 
EcoRI G^AATTC R0101S 
EcoRV GAT^ATC R0195S 
HindIII A^AGCTT R0104S 
KpnI GGTAC^C R0142S 
MluI A^CGCGT R0198S 
NheI-HF G^CTAGC R3131L 
NotI GC^GGCCGC R0189L 
PmlI CAC^GTG R0532S 
XbaI T^CTAGA R0145S 
XhoI C^TCGAG R0146S 
XmaI C^CCGGG R0180L 
- Buffers for restriction enzymes: 
• NE Buffer 1 (New England Biolabs, B7001S). 
• NE Buffer 2 (New England Biolabs, B7002S). 
• NE Buffer 3 (New England Biolabs, B7003S). 
• NE Buffer 4 (New England Biolabs, B7004S). 
• EcoRI Buffer (New England Biolabs, B0101S). 
• BSA 100X (New England Biolabs, B9001S). 
2.4.5. Plasmid constructions 
Table 3. Constructions used. 
Name Coding product Use Source Cloning vector 
PLCβ1a Human PLCβ1a 
Overexpression of the transgen in 
eukaryotic cells 1 
pcDNA 3.0 
PLCβ1b Human PLCβ1b 
HA-PLCβ1a N-terminal HA-tagged PLCβ1a 
HA-PLCβ1b HA-tagged PLCβ1b 
PLC-β1a-eYFP PLCβ1a-eYFP fusion protein Overexpression of the transgen in 
eukaryotic cells for analysis of 
PLCβ1a-TRAX interaction by FRET 
2 
TRAX-eCFP TRAX-eCFP fusion protein 
eYFP eYFP 
Negative control for FRET 
eCFP eCFP 
eCFP-eYFP eYFP-eCFP fusion protein Positive control for FRET 
shRNA-01 Scramble shRNA Overxpression of non-target shRNA  
1 
pSuperior.gfp/neo 
(Origene) 
Contains an EGFP 
reporter gene to 
monitor transfection 
rate 
shRNA-87 
PLCβ1-shRNA Overxpression of shRNA expression 
for PLCβ1 siRNA silencing 
shRNA-89 
shRNA-97 
shRNA-99 
1Own production by PCR and subcloning. 
2Laboratory of Dr. Suzanne Scarlatta; Dept. of Physiology & Biophysics, Stony Brook University. 
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2.4.6. Small interfering RNAs 
Table 4. ON-TARGET plus SMART pools from Dharmacon. 
Name Code Protein encoded by the mRNA target 
PLCB1 siRNA L-010280-00-0020 Human PLCβ1 
Plcb1 siRNA L-092936-02-0020 Rat PLCβ1 
Tsnax siRNA L-097955-02-0020 Rat TRAX 
Tsn siRNA L-099674-02-0020 Rat Translin 
Gna11 siRNA L-092615-02-0020 Rat Gαq/11 
Non-targeting Pool D-001810-10-20 Negative control 
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1. CELL CULTURE AND TRANSFECTION 
1.1. Culture of NT2 and PC12 cells 
Human teratocarcinoma NTERA2-D1 (hereafter referred to as NT2) cells from the 
American Type Culture Collection (ATCC®, CRL-1973™) were maintained in 
complete medium (DMEM®, supplemented with 10% FBS and antibiotics -100 U/mL 
penicillin and 100 µg/mL streptomycin) at 37ºC under a humidified atmosphere 
containing 5% CO2. PC12 cells were cultured in similar conditions except that DMEM 
was supplemented with 10% FHS and 5% FBS. 
 
1.2. Transfection 
1.2.1. Transfection of plasmidic DNA 
Cells were allowed to grow to ∼70-80% confluence and then transfected. NT2 cells 
were transfected with Lipofectamine® 2000 in antibiotic and serum-free medium 
according to the manufacturer’s instructions, using a ratio of 2 µL of Lipofectamine for 
1 µg DNA. The amount of DNA used was 0.5, 1 and 2.5 µg for 24-, 12- and 6-well 
plates, respectively. 
PC12 cells were grown in 25 cm2 culture flasks to ∼70-80% confluence, washed 
with sterile PBS, trypsinized, centrifuged for 5 min at 1500 x g and resuspended in 10 
mL of antibiotic and serum-free medium. 800 µL of the cell suspension were pipeted 
into a 4 mm BioRad cuvette and placed in an electroporator (BioRad Gene Pulser 
Xcell). Conditions for transfection were 10 µg DNA, 250 V, 500 µF, ∞ Ω. After a 10 
ms pulse, cells were allowed to rest for 1-2 min, and 1 mL of DMEM was added to each 
cuvette. Then, cells were plated onto LabTek chambers coated with Poly-D-Lysine 
(Sigma-Aldrich). Three to four hours post-transfection, the wells were washed with 1 
mL of PBS, and 1.5 mL of DMEM containing 100 ng/mL NGF. After 3 days, 
transfected cells were induced to differentiate (see below) and used for imaging. 
 
1.2.2. Transfection of siRNAs 
For small interfering (siRNA)-mediated gen knockdown in NT2 and PC12 cells, we 
used species-specific ON-TARGET plus SMART pool siRNAs (see Materials), which 
consist of four siRNAs to the same target gene mixed together. For control experiments, 
ON-TARGET plus Non-targeting Control siRNA Pool was used, which consists of four 
small RNAs designed for minimal targeting of human, mouse or rat genes and modified 
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to reduce potential off-targets. NT2 cells grown to ∼70-80% in 12-well plates were 
transfected with 5 nmol siRNA, using DharmaFECT 1 Transfection Reagent in 
antibiotic and serum-free medium. The transfection mix was prepared according to the 
manufacturer’s protocol, using a ratio using a ratio of 2.5 µL of DharmaFECT 1 
Reagent for 5 nmol siRNA. 
PC12 cells were transfected by electroporation as described above with 40 nmol 
siRNA (section 1.2.1.). 
 
2. NEURONAL DIFFERENTIATION OF NT2 AND PC12 CELLS 
2.1. Retinoic acid-induced differentiation of NT2 cells 
For differentiation of NT2 progenitors with all-trans retinoic acid (RA, Sigma-
Aldrich), cells were treated as previously described by Pleasure et al. (1992). NT2 cells 
at 80% confluence were treated during 4 weeks with 10 µM RA containing complete 
medium, which was replaced every 3 days. Cells were then treated briefly with 0.05% 
trypsin-EDTA (Sigma-Aldrich) and mechanically dislodged, that is, culture flasks were 
struck on each side 10 times. Floating cells were counted using the trypan-blue 
exclusion assay and replated at a density of 2.1 × 105 cells/cm2, in either 75 cm2 culture 
flasks or poly-D-lysine treated 12 mm glass coverslips, both pre-coated with 1:25 
diluted Matrigel™ (BD Biosciences, Madrid, Spain), and maintained in complete 
medium. Twenty-four hours later, the culture medium was replaced with fresh medium 
containing mitotic inhibitors (10 µM uridine -Sigma-Aldrich, 10 µM 5-Fluoro-2'-
deoxyuridine -Sigma-Aldrich, and 1 µM cytosine β-D-arabinofuranoside -AraC -Sigma-
Aldrich) and maintained under these conditions for 2 weeks, thus obtaining RA-
differentiated NT2N cells (hereafter referred to as RA/NT2N cells). Medium containing 
mitotic inhibitors was replaced every 3 days (Fig. 13, left panel). 
 
2.2. Nucleoside analogue induced differentiation of NT2 cells 
Induction of neuronal differentiation using 2'-deoxy-5-azacytidine (DAC) or 
Cytosine β-D-arabinofuranoside (AraC) was performed based on a previous report 
showing that exposure of NT2 cells for only 6 days leads to neuronal differentiation 
(Musch et al., 2010). For preliminary assays progenitor NT2 cells were exposed to 
equitoxic concentrations of DAC or AraC (Tan et al., 2007; Musch et al., 2010). 
Briefly, NT2 cells at 80-90% confluence were treated with 1 µM DAC or 20 µM AraC-
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containing medium for 24 h, 48 h, 72 h or 6 days. Medium from cultures treated for 
more than 48 h, was replaced with fresh complete medium supplemented with the 
corresponding nucleoside analogue every two days. Results of preliminary experiments 
led us to choose AraC to induce neuronal differentiation (see Results) and, therefore, 
this compound was used for subsequent experiments (Fig. 13, right panel). 
 
2.3. Modified AraC differentiation protocol 
Because low cell density can compromise neuronal survival and differentiation, we 
tested whether increased confluence improves the yield of terminally AraC-
differentiated neurons (hereafter referred to as AraC/NT2N cells). For this purpose, 
cells were trypsinized after 72 h of treatment (a time point at which most cell have 
acquired a neuron-like morphology, see results), counted and replated in complete 
medium on a 3-fold smaller growth surface area. Thus, cells from a 75 cm2 culture flask 
were passed to either a 25 cm2 flask (for Western blot analysis) or to 13 wells of a 24-
well plate (for immunofluorescence analysis). These conditions corresponded to a 
density of 1,75 to 2 x 105 viable cells/cm2. Next morning, culture medium was replaced 
with 20 µM AraC-containing complete medium (AraC-differentiation medium), and 
cells were maintained in this medium until day 6, starting from the initial culture of 
NT2 progenitors. Cells grown on 25 cm2 flasks were dissociated with trypsin and the 
amount of viable cells was calculated using the trypan-blue dye-exclusion method. The 
amount of cells in the initial cultures was calculated by counting viable NT2 cells 
recovered from untreated cultures at a time point corresponding initiation of treatment 
in cultures exposed to 20 µM AraC (Fig. 13, right panel). 
 
2.4. Differentiation of PC12 cells 
The PC12 cell line from the American Type Culture Collection (ATCC® 
CRL1721™), derive from a pheochromocytoma of the rat adrenal medulla composed of 
a mixture of neural crest-derived neuroblastic and eosinophilic cells. This cell line has 
been widely used as a model of sympathetic neuron differentiation. When exposed to 
NGF, PC12 cells undergo cell cycle arrest and acquire neuronal polarity with abundant 
branching varicose processes similar to those observed in primary cultures of 
sympathetic neurons. Neurochemically, differentiated PC12 cells synthesize and store 
the catecholamines dopamine and norepinephrine (Greene and Tischler, 1976) 
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To induce differentiation, PC12 cells at ∼50% density were treated with NFG at a 
final concentration of 100 ng/mL and the differentiation medium was renewed every 
two days. Cells were defined as differentiated when displayed neurites at least two cell 
body diameters (∼30 µm) long, with a well (Ignatius et al., 1985). 
 
 
 
Figure 13. Schematic diagrams of the protocols used to induce differentiation of NT2 
progenitors into postmitotic NT2N neurons. Left, RA-induced differentiation schedule. Right, 
AraC-induced differentiation following either a 6-day uninterrupted AraC treatment or a two-
step schedule that involves dissociation of cells at mid at mid-treatment to increase cell density. 
 
3. IMMUNOFLUORESCENCE 
3.1. Fixation 
For fixation, cells were washed twice with phosphate buffered saline 0.1 M, pH 7.4 
(PBS) at room temperature and incubated with paraformaldehyde 4% in phosphate 
buffer 0.1 M, pH 7.4 (PB) for 10 min at room temperature. Thereafter, cells were 
washed three times with PBS and stored at 4ºC for no more than 4 days before 
immunofluorescence. Because RA- and AraC-differentiation protocols could not be 
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carried out in parallel, for assays involving comparison between these two conditions 
PBS was replaced with a a cryoprotectant solution (consisting of glycerol 50% in PB) 
and cells were stored at -20ºC for periods no longer than two months before 
immunostaining. For all antigens analyzed, preliminary assays showed no changes in 
immunoreactivity or immunostaining profile in cells treated under these conditions. 
Isolated nuclei seeded on gelatin-coated slides were immersed in buffered 4% 
paraformaldehyde for 5 min at room temperature. 
 
3.2. Immunofluorescence 
NT2 cells were washed with 0.1 M PBS, pH 7.4 and fixed in buffered 4% 
paraformaldehyde for 4 min, both at 20°–25°C. Thereafter, cells were blocked for 1 h 
with gelatin-histology buffer (0.1 M PBS, pH 7.4, containing 0.22% gelatin, 0.05% 
saponin, 1% BSA, and 1% normal serum from the specie in which the secondary 
antibody was raised). Antibody dilutions and subsequent washes were also performed in 
this gelatin-histology buffer. Subsequently, cells were incubated overnight at 4ºC with 
the primary antibody at the appropriate dilution (see Table 1 in Materials for details), 
washed three times and incubated for 1 h at 20-25ºC in an adequate 1:400 diluted 
fluorescent dye-conjugated secondary antibody. All secondary antibodies were adsorbed 
against several species to prevent undesired cross-reactions (see Materials for details). 
Double-immunostaining was performed in the same way except that mixtures of 
primary antibodies from two different host species and species-specific secondary 
antibodies conjugated to different fluorophores were used. Nuclei were counterstained 
with Hoechst 33342 diluted to 0.1 µg/mL in gelatin histology buffer. Finally, cells were 
mounted onto glass slides using homemade Mowiol mounting medium containing anti-
fade reagent PPD. 
Immunofluorescence experiments in isolated nuclei from adult rat cortex were 
carried out identically, except that saponin was omitted in the first step. 
 
3.3. Microscope studies and imaging 
All microscope images were acquired with an epifluorescence microscope Carl 
Zeiss Axio Observer.Z1, equipped with a HXP120C metal halide lamp illumination 
source and a high-resolution monochromatic camera (AxioCam MRm, 1388 x 1040 
pixels), all from Carl Zeiss MicroImaging, Inc (Gottigen, Germany). Conventional 
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epifluorescence images were acquired using a 20 x Plan-Apochromat objective (NA 
0.8). Higher resolution images were acquired using a structured illumination module 
(ApoTome) and a XYZ motorized stage (Carl Zeiss MicroImaging, Inc), using a 63 x 
Plan-Apochromat objective (NA 1.4), and optical sections (0.24 µm intervals in the z-
axis) were obtained with the Zeiss ApoTome device, with camera settings adjusted to 
obtain images with a pixel size of 0.01 µm2. Bandpass filters used were 49 DAPI (Ex G 
365/Em 445/50) for Hoecsht’s staining, 38 HE eGFP (Ex 470/40, Em 525/50) for Alexa 
Fluor 488, and 43 HE Cy3 shift free (Ex 550/ 25, Em 605/70) for Alexa Fluor 568 and 
DyLight 549. Images were digitized using Zeiss Axio Vision 4.8 software (Carl Zeiss 
MicroImaging, Inc). A pseudocolor was assigned to each channel and minor 
despeckling was performed on ImageJ (NIH, Bethesda, MD, USA) software. For 
illustration, images were exported to TIFF format, and compiled and labeled using 
Adobe Photoshop CS3 (San Jose, CA, USA). 
 
4. MORPHOMETRIC ANALYSES 
4.1. AraC-induced differentiation: neuronal vs. non-neuronal phenotypes 
Available markers for morphometric analyses, microtubule-associated protein 2 
(MAP2), Tau, neurofilaments and β-III-tubulin differ somewhat to the degree that they 
are expressed in the cell body as opposed to neurites. Because β-III-tubulin was 
expressed in cell bodies and throughout all neurites of differentiated cells, delivering at 
the same time high contrast, we chose antibodies against β-III-tubulin as the primary 
marker for measurements of neurite length, area and arborization. In addition, cells 
classified as non-neuronal, on the basis of their low or no NeuN/Fox-3 expression and 
their polygonal morphology, were also immunopositive for β-III-tubulin (see Results). 
Thus, morphometric analysis of terminally differentiated AraC/NT2N neurons and non-
neuronal cells remaining after the 6-day period of treatment with AraC was performed 
on fluorescence microscope images of cells doubly stained for β-III-tubulin and 
NeuN/Fox-3, and counterstained with Hoechst 33342. For this purpose, conventional 
epifluorescence images were acquired using a 20 x Plan-Apochromat objective (NA 
0.8). Multiple images from cultures were taken using the Carl Zeiss Mosaic module 
with focus adjustment. Subsequent stitching and aligning individual images with an 
overlap of 10% resulted in 2.0 x 1.5 mm mosaic images. Measurements were performed 
on three mosaic images obtained from three independent experiments. A total of 33 
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neuronal and 33 non-neuronal cells per mosaic were analysed, starting from the centre 
of the image. Figures 35A-F correspond to a portion of a mosaic image used for 
morphometric analysis and depict the different steps of image processing to obtain 
values of the analysed parameters. 
To identify neuronal and non-neuronal cells, absence of or very weak 
immunolabelling for the neuronal marker NeuN/Fox-3 was used as the first cut-off 
criterion to classify cells as non-neuronal. Additionally, cells showing weak to moderate 
immunoreactivity for NeuN/Fox-3 but displaying flat polygonal morphologies and no 
neurites were also classified as non-neuronal (Figs. 35A-C, arrows). To measure the 
area of nuclei, binary images were obtained by thresholding the Hoechst channel to 
include only nuclei using ImageJ software (NIH, Bethesda, MD, USA). Grayscale-
converted images from the β-III-tubulin channel allowed for an easy visualization of the 
whole cell area, including lamellar extensions (Fig. 35D). The NeuN/Fox-3 channel, 
binary images corresponding to Hoechst staining and inverted grayscale images 
corresponding to the β-III-tubulin channel were loaded as separate image stacks in 
ImageJ software. Area of nucleus and total cell area were determined for each cell. In 
addition, area of cell body and length of neurites was determined for each AraC/NT2N 
neuron. The area of nuclei was selected on the corresponding stack with the wand 
(tracing) tool of ImageJ and then measured. Unhealthy or fragmented nuclei and false-
positive particles were excluded from the analysis. The total area of cells, including 
nuclei, was measured after manually tracing cell boundaries, using the polygon 
selection tool, on the grayscale-converted images corresponding to the β-III-tubulin 
channel (schematically illustrated in fig. 35E). Cell somata were manually outlined and 
their area measured. When the boundaries were not clearly defined due to the presence 
of flat lamellar extensions, β-III-tubulin staining accumulation was used to define the 
limits of neuronal bodies (Fig. 35F). Neurites were traced using the segmented line tool 
and their length measured (Fig. 35F). 
 
4.2. RA vs. AraC differentiated NT2N neurons 
Cell bodies of RA/NT2N neurons were organized into aggregates, making it 
impossible to discern cell boundaries using conventional fluorescence microscopy. On 
the other hand, neuronal nuclei of RA/NT2N neurons were considerably smaller than 
those of AraC/NT2N neurons and could not be accurately analysed under the 20 x 
	   METHODS 
	  
	  
	  
58 
objective. For these reasons, measurements of the area of somata and nuclei of 
RA/NT2N cells were performed on high-resolution images of virtual sections acquired 
under the 63 x Plan-Apochromat objective. Z-stacks were then loaded into NIH ImageJ 
and carefully examined to ensure that measurements were performed at the widest part 
of each cell soma and nucleus analysed. Measurements were performed using NIH 
ImageJ software, basically as described above. In our culture conditions, neurites of 
RA/NT2N cells were organized in bundles, which did not allow the assignment of 
neurites to individual neuronal bodies and prevented reliable length measurement their 
length. Hence, in the context of the present study, which focuses on the phenotypic 
characterization of neurons derived from NT2 progenitors upon AraC treatment, this 
was not assessed in our study (see also Discussion below). 
All data (sections 4.1. and 4.2) represent average values obtained from 99 cells in 
three independent experiments (33 cells/experiment). 
 
5. TISSUE SAMPLING AND PREPARATION OF SUBCELLULAR 
FRACTIONS 
5.1. Preparation of subcellular fractions from the adult rat cerebral cortex 
5.1.1. Animals 
Male albine Sprague-Dawley rats, weighing 200–250 g at the time of arrival were 
obtained from Harlan Iberica (Barcelona, Spain). Upon arrival, animals were 
randomized and housed three per cage and kept in a controlled environment (12 h light-
dark cycle, lights on at 08:00 h A.M., and 22 ± 2°C room temperature) with food and 
water provided ad libitum. The animals, received at 7-8 weeks of age (data provided by 
the manufacturer), were allowed to acclimate for 1 week prior to any experimentation. 
On the day of experiments, rats had a weight of at least 250 g. All experimental 
procedures were carried out during the morning (between 10:00 and 12:00 A.M.). Rats 
were carefully handled in accordance with the guidelines of the European Communities 
Council Directive of November 24, 1986 (86/609/EEC). 
 
5.1.2. Tissue preparation 
Rats were anesthetized with an overdose of choral hydrate (1 g/kg, i.p.) and then 
sacrificed by decapitation. For brain extraction, the skin that covers the skull is removed 
and the skull was opened by two posteroanterior cuts following the outer edge of the 
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temporal bones with the help of scissors that were introduced in the core hole. After 
separating these bones with the help of a gouge, the dura was cut and the piece was 
inverted and for sectioning of cranial nerves arising from the brainstem, optic tracts and 
olfactory bulbs, allowing the brain to be detached by gravity onto saline. Subsequently, 
it was placed on a metal plate located on a container with crushed ice to keep the tissue 
under refrigeration. Then, with the aid of scissors, forceps and filter paper, blood clots 
and the meninges were removed from the sample and the piece was dissected carefully 
to obtain different brain regions. Initially, a sagittal incision was made in the central part 
of the brain to allow the separation of the cerebral hemispheres. Once those are 
completely separated, the hippocampus was dissected and the cortex separated from 
diencephalon and basal ganglia. After removing white matter from the cortical sample 
as much as possible, tissue was stored at -80°C until use. 
 
5.1.3. Tissue fractionation 
Preparation of subcellular fractions from rat cerebral cortex, enriched in cytosolic 
(Cyt) and plasma membrane (P2) proteins, was performed essentially as previously 
described for rat and human brain tissues (Garro et al., 2001; Sallés et al., 2001). 
Cortical tissue, stored at -80°C, was cold thawed and transferred to a vessel containing 
homogenization buffer (20 mM Tris-HCl, 1 mM EGTA, 0.32 M sucrose and 0.01% v/v 
protease inhibitor cocktail for inhibition of aspartic, cysteine, serine and aminopeptidase 
peptidases, pH 7,4) in a 1:4 w/v proportion. The brain tissue was homogenized with a 
Potter-Elvejem glass with Teflon plunger (Braun biotech International), where the 
distance between the piston and the tubewall is from 0.15 to 0.20 mm.  The 
homogenization process consisted of apply the Teflon plunger to homogenize the 
sample for a few seconds (7-10 times) at maximum speed (1500 rpm) by an electric 
motor. During the homogenization process, the mixture was kept refrigerated at 4°C 
with a ice jacket around the Potter-Elvejem glass to maintain the cold chain and prevent 
the degradation of the sample. Once that a homogeneous suspension was obtained, more 
homogenization buffer was added to obtain a 1:10 w/v proportion, again it was mixed 
gently and the whole solution was divided into centrifuge tubes. These tubes were 
subjected to a centrifugation at 1100 x g for 10 min at 4°C in a high speed refrigerated 
centrifuge (centrikon T-42K, KONTRON).  The pellet (P1, containing unbroken cells, 
debris and nuclei) was discarded and the supernatant was centrifuged again at 4000 x g 
for 10 min, making a total of three cycles of resuspension-centrifugation with the 
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homogenization buffer keeping the proportion of 1:10 w/v with respect to the original 
tissue sample. The first of these supernatants constituted the cytosolic fraction (Cyt), 
which was divided in 1 mL aliquots and stored at -80°C until use. After the third 
centrifugation, the obtained pellet (P2) is enriched in plasmatic membrane (Fig. 14). 
 
 
Figure 14. Schematic diagram showing the procedure to obtain subcellular fractions enriched in 
cytosol (Cyt), crude membranes (P2) and “isolated nuclei” (N). 
 
To obtain highly purified intact nuclei, useful for both immunofluorescence and 
Western blot analyses, we used the procedure previously reported by Thompson (1973) 
and Dent et al. (2010) with slight modifications. Cerebral cortices dissected from four 
adult rats were placed in ice-cold 0.32 M sucrose containing 1 mM MgCl2 and protease 
inhibitors. The cortices were then chopped finely and homogenized to give a 20% (w/v) 
homogenate in 2 M sucrose containing 1 mM MgCl2 and protease inhibitors. The 
homogenate was then diluted with and equal volume of homogenizing medium, filtered 
through muslin and centrifuged at 4ºC for 60 min at 64000 x g in a SW40Ti rotor 
(Beckman, 331302) at 4ºC. The resulting pellet was washed with 0.32 M sucrose 
containing 1 mM MgCl2 and protease inhibitors, and centrifuged for 5 min at 1500 x g 
to obtain a final pellet of highly purified intact nuclei (N fraction). Finally, nuclei were 
resuspended in a volume of 10 mL of 1 mM MgCl2 (containing protease inhibitors) and 
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counted under a light-phase microscope. Nuclei set aside for Western blot analysis were 
divided into aliquots of 4 x 106 nuclei, pelleted by centrifugation at 1500 x g for 5 min, 
and stored at -80ºC until use. Nuclei used for immunofluorescence analysis were 
resuspended in TM2 buffer (10 mM Tris-HCl, pH 7.4, 2 mM MgCl2, 0.5 mM PMSF, 50 
µM iodoacetamide) at a dilution of 2 x 106 nuclei/mL. Finally, 25 µL drops were laid on 
gelatin-coated slides, allowed to dry at room temperature, and stored at -80ºC until use 
(Fig. 14). 
The total protein content determination of each subcellular fraction was performed 
by the Bradford method (Bradford, 1976) using bovine γ-globulin as protein standard. 
All samples were resuspended in homogenization buffer and brought to an estimated 
concentration of ∼1.0-2.0 µg/µL on the basis of our previous experience. Thereafter, the 
the γ-globulin stock (2.0 µg/µL) and the samples (∼1.0-2.0 µg/µL) were diluted 80-fold 
with distilled H2O, thus obtaining a 25 µg/µL γ-globulin solution (A solution) and a 80-
fold diluted experimental sample (B solution). Before measurement, four serial dilutions 
of standard A solution and from each sample were prepared in duplicate as follows: 
A solution: γ -globulin standard (25 µg/µL) B solution: experimental sample 
[γ -globulin] = µg/mL Volume A solution  (µL) H20 (µL) Volume B solution (µL) H20 (µL) 
0 0 1000   
2.5  100 900 100 900 
5.0 200 800 200 800 
7.5 300 700 300 700 
10.0 400 600 400 600 
Table 5. Serial dilutions of γ-globulin standards and experimental samples for 
estimation of total protein concentration using the Bradford method. 
 
Thereafter, a volume of 200 µL of Bradford dye reagent was added to each tube of 
the serial dilutions of γ-globulin standard and experimental samples. Tubes were then 
mixed by vigorous shaking or vortex for ∼5 sec, and Bradford dye was allowed to react 
for 10 min. Thereafter, the absorbance was measured at 595 nm using a 
spectrophotometer. Blank was subtracted from the absorbance values, and data of 
absorbance vs. concentration (γ-globulin or experimental samples) were fitted by linear 
regression analysis. Protein concentration present in the original experimental samples 
(before the 80-fold dilution) of Cyt, P2, and N samples was calculated as follows: 
[Protein]sample = m´/m x 80 x 25 µg/mL 
Where m´and m are the slopes corresponding to the linear fits of the γ-globulin and 
the experimental sample, respectively, 80 is the fold dilution of the 2 µg/µL γ-globulin 
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stock and of the original samples and 25 µg/mL is the concentration γ-globulin in A 
solution (achieved by 80-fold dilution of the γ-globulin stock at 2 µg/µL). 
 
5.2. Preparation of subcellular fractions from NT2 cultures 
Isolation of cell nuclei from cells in culture usually involves a first solubilization 
step using non-ionic detergents, resulting in cells being fractionated in two fractions. 
One of them consisting of a mixture of plasma membrane, cytosol and intracellular 
organelles, and another one consisting of highly purified nuclei (Fiume et al., 2010). 
Here we carried out a modification of this procedure to enable obtaining a fraction of 
highly purified nuclei (N), on the one hand, and separating the plasma membrane (P2) 
and the intracellular heavy membranes (S2) from the cytosol (Cyt), on the other hand. 
 
 
Figure 15. Schematic diagram showing processing of NT2 cells to obtain fractions enriched in 
cytosol (Cyt), plasma membrane (P2), heavy membranes (S2) and “isolated nuclei” (N) 
fractions. 
NT2 progenitors, either untreated or treated with AraC during 72 h or 6 days, were 
harvested from 150 cm2 flasks. Cells were released from the surface of the culture flasks 
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using a cell scraper, collected in cold PBS and spun down at 500 x g for 5 min at 4ºC. 
Cells harvested from each 150 cm2 culture flask were resuspended in 500 µL of 0.32 M 
TM2 buffer (10 mM Tris-HCl, pH 7.4, 2 mM MgCl2, 0.5 mM PMSF, 50 µM 
iodoacetamide) and homogenized by 20 strokes through a syringe with a 20-gauge 
needle. The homogenate was then subjected to a centrifugation at 1100 x g for 5 
minutes at 4°C in a high speed refrigerated centrifuge (centrikon T-42K, KONTRON). 
The resulting supernatant (S1) and pellet (P1) were further processed to obtain plasma 
membrane (P2), cytosolic (Cyt), heavy membranes (S2) and highly purified nuclei (N). 
Centrifugation of the first supernatant (S1) at 30000 x g for 10 min at 4°C allowed 
to obtain a plasma membrane pellet (P2) and cytosolic (Cyt supernatant) (Fig. 15). To 
separate nuclei (N) from heavy membranes (S2), the P1 pellet, resulting from the first 
low-speed centrifugation step, was resuspended in 500 µL of cold nuclear isolation 
buffer (TM2, 1% Igepal and 10 mM β-Mercaptoethanol) and then incubated for 8 min 
on ice. The presence of the non-ionic detergent Igepal in this solution leads to 
solubilization of membranes, thus allowing separation of nuclei from attached 
membranes. To remove the external nuclear membrane, 500 µL of pre-chilled distilled 
water was added to the 500 mL suspension. This suspension was then subjected to 20 
passages through a syringe with a 21-gauge needle and checked on a phase contrast 
microscope to make sure that nuclei had lost their outer envelope. Passages through the 
needle were repeated as many times as needed, until nuclei completely stripped of the 
envelope, but still intact. The nuclear fraction was recovered in a translucent, glassy, 
and semitransparent pellet by centrifuging the suspension 800 x g for 10 min at 4°C. 
The supernatant was kept for acetone precipitation of proteins, whereas the nuclear 
pellet was resuspended in TM2 buffer containing 0.32 M sucrose and centrifuged at 800 
x g to obtain a final white pellet of highly purified nuclei (N). The supernatant 
containing heavy membranes was mixed with 5 volumes of cold acetone (-20ºC) and 
incubated for 2 h at -20ºC. The protein precipitate (S2) was collected by centrifugation 
at 10000 x g for 45 min at 4°C. The supernatant was discarded and the pellet 
resuspended in distilled water. The suspensions were split into four aliquots at the final 
centrifugation steps. Aliquots of the N fraction were treated with 1 µL (10 IU) RNase-
free recombinant DNase I (Takara Bio Inc.) in nuclear isolation buffer for 20 min at 
37ºC to favor access of bicinchoninic acid (BCA) reagent, (used to determine protein 
concentration) to nuclear proteins. One of the DNAse I-treated aliquots was set aside for 
BCA assay and the rest were treated with 0.25 M (NH4)2SO4 to release chromatin-
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bound proteins. For this purpose, a volume of 2 M (NH4)2SO4 was added dropwise to 
the DNase I-treated nuclear suspension to achieve a final concentration of 0.25 M, 
followed by 15 min incubation on ice. In our hands, optimal migration of nuclear 
proteins was only achieved by sequential treatment with DNase I and high-salt (0.25 M 
(NH4)2SO4). 
For BCA assays, all samples were brought to an estimated concentration of ∼0.25-
0.5 µg/µL, on the basis of our previous experience and three two-fold serial dilutions of 
each sample were made. 50 mL of each sample were loaded in duplicate to 96-well 
EIA/RIA plates and mixed with BCA copper reagent (100 µL/well). Reference BSA 
standards were loaded in parallel at increasing protein concentration (0, 0.02, 0.04, 0.08, 
0.16, 0.32, 0.64 µg/µL). After a 1 h incubation at 37ºC, absorbance was measured at 562 
nm using a Sunrise (Tecan) plate reader. Blank was subtracted from the absorbance 
values, and data of absorbance vs. BSA concentration were fitted by linear regression 
analysis, allowing determination of the actual protein concentration in Cyt, P2, S2 and 
N samples. 
 
6. WESTERN BLOT ANALYSIS 
6.1. Western blot 
Western blot was performed as previously reported (Garro et al., 2001; López de 
Jesús et al., 2006; Ruiz de Azúa et al., 2006; Montaña et al., 2012) with minor 
modifications. Briefly, three volumes of sample were mixed with one volume of 4X 
urea denaturation buffer (300 mg urea, 50 mg SDS, 120 mg DTT, 500 µL 100 mM Tris-
HCl, pH 8.0, 6 µL bromophenol blue 1% -w/v-) and boiled for 5 min. Denatured 
proteins were resolved by electrophoresis on sodium dodecyl sulfate-polyacrylamide 
(SDS–PAGE) gradient gels (5 to 10%, depending on the molecular mass of proteins to 
be resolved) using the Mini Protean II gel apparatus (Bio-Rad, Hercules, CA, USA) for 
about 2 h at 100 V. Proteins were transferred to 100% methanol-activated 
polyvinylidene fluoride (PVDF) membranes using the Mini TransBlot transfer unit 
(Bio-Rad, Hercules, CA, USA) at 90 V constant voltage for 1 h at 4ºC. Thereafter, 
PVDF membranes were then briefly washed with distilled H2O and allowed to dry and 
re-activated in 100% methanol. After a washing step of 10 min in washing buffer 
(phosphate buffer 0.2 M, pH 7.5, Tween-20 0.1 %) at room temperature, membranes 
were incubated in blocking buffer (PB 0.2 M, pH 7.5, Tween-20 0.2 %, non-fat dry milk 
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5%, BSA 0.5%) for 1 h at room temperature, followed by overnight incubation at 4 ºC 
with the corresponding primary antibodies diluted in blocking buffer at the adequate 
concentrations (see Materials, Table 1). Blots were washed and incubated with specific 
HRP-conjugated secondary antibodies diluted to 1:10000 in blocking buffer for 2 h at 
room temperature. Immunoreactive bands were revealed with the Clarity Western ECL 
system from BioRad, according to the manufacturer instructions, and either developed 
on x-ray films or acquired using an ImageQuant 350 digital image system (GE 
Healthcare). 
 
6.2. Immunodetection and measurements 
Immunoreactive bands developed on X-ray films were digitized using a 
transmittance scanner. Digital images of immunoreactive bands, either digitized from 
X-ray films using a transmittance scanner or acquired using the ImageQuant 350 imager 
device, were quantified by densitometry using ImageJ image analysis software (ImageJ, 
NIH, Bethesda, MD, USA). For comparison of protein expression between samples, 
two types of semiquantitative analysis were performed depending on the amount of 
sample available. The most accurate determinations involved SDS-PAGE analysis of 
increasing concentrations of total protein from all samples to be compared, which were 
run in parallel. Integrated optical density (OD) values from bands were used for linear 
regression analysis, which enabled to obtain a linear regression equation for each 
sample. The fold-change was then obtained by calculating the ratio between the slope of 
the curve in a given experimental sample and the slope of the curve in the reference 
sample (control condition). When the amount of protein was limiting, the fold-change 
was determined by directly calculating the ratio between OD obtained from 
immunoreactive bands after resolving equal amounts of protein from all samples. When 
it was possible, data were normalized to β-Actin or CyPA. When these controls were 
useless because their expression was different among samples to be compared, 
Coomassie Brilliant Blue gel staining was used to check for equal protein loading. 
 
7. FÖRSTER/FLUORESCENCE RESONANCE ENERGY TRANSFER 
MICROSCOPY (FRET) 
Differentiating NT2 and PC12 living cells co-expressing TRAX-eCFP and PLCβ1-
eYFP were viewed under an Olympus Fluoview FV1000 laser confocal microscope. 
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Only cells with similar expression of both eCFP and eYPF, such that both channels 
could be set at the same voltage and gain for a specific series of studies, were analyzed. 
Using Olympus software, FRET efficiency in TRAX-eCFP and PLCβ1-eYFP 
expressing cells was determined by sensitized emission after correction for spectral 
bleed through by analyzing images of control cells expressing donor proteins alone or 
acceptor proteins alone with the same intensity distributions as the sample, as 
previously described (Guo et al., 2010). The FRET efficiency (E) is calculated as shown 
in Equation 1, 
       (Eq. 1) 
where ϵ is the fluorescence in the CFP channel, rΨ is the ratio of the detector response 
of the CFP and YFP channels, and rQ is the ratio of the quantum yields of the CFP and 
YFP. nFRET is equal to the image obtained in the FRET channel minus bleed through 
in CFP (a) and YFP (b) channels as shown in Equation 2, 
        (Eq. 2) 
 
 
Figure 16. Schematic illustration of FRET experiments design. Constructions used consisted 
of TRAX-eCFP and PLCβ1-eYFP fusion proteins. Förster resonance energy transfer (FRET) 
consists of energy transfer between two light-sensitive fluorescent dyes (fluorophores). 
Fluorophores are chosen so that the emission spectrum of one of them (donor) overlaps 
significantly with the excitation spectrum of the other one (acceptor). During FRET, the CFP 
donor excited by a light source, transfers its energy to the YFP acceptor only if it they are in 
close proximity. This causes the YFP to emit light at a longer wavelength than the light emitted 
by CFP. The efficiency of this energy transfer is inversely proportional to the sixth power of the 
distance between donor and acceptor, making FRET extremely sensitive to small changes in 
distance and one of the best tools for the analysis of protein-protein interaction. 
Using controls with the same intensity distributions as the samples, we found that 
FRET efficiency values did not change significantly over a 10-fold range of 
acceptor:donor intensity ratios. Background FRET values were obtained by imaging 
cells co-expressing eCFP and eYFP, resulting in an nFRET = 0.014 ± 0.001 for all 
negative controls, including free eCFP and free eYFP and free eCFP and eYFP-PLCβ1. 
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Positive control values were obtained using a dodecapeptide labeled with eCFP and 
eYFP on both ends (i.e. eCFP-X12-eYFP), resulting in an FRET = 0.26 ± 0.006. 
 
8. CLONING 
8.1. General procedures 
8.1.1. Agarose gel electrophoresis 
To prepare 0.8 or 1% agarose gels used here, 50X TAE buffer was diluted to 1X 
using double distilled H2O (final composition, 40 mM Tris-acetate, 1 mM EDTA). 
Thereafter, 1.2 g or 1.5 g of agarose were boiled in 150 mL TAE 1X under continuous 
stirring by a magnetic stirrer until the solution appeared homogeneous. Evaporated 
distilled H2O was replenished when necessary to maintain the initial volume. The 
agarose solution was allowed to coil to approximately 60ºC before preparing the gel. 
Five volumes of DNA were mixed with one volume of 5X loading dye before gel 
loading. 100 bp and/or 1 kb DNA ladders were prepared and run in parallel with the 
DNA samples. For preparative gel electrophoresis, DNA samples were run at 90 V for 
about 2 h in cold 1X TAE buffer using a horizontal gel electrophoresis device (BioRad, 
BioRad, Wide Mini-Sub Cell GT System). For screening by restriction mapping, 
electrophoresis was performed using a electrophoresis device specially designed for 
minigel electrophoresis (Mupid® One Electrophoresis System, Eurogentec) at 135 V for 
30 min. 100 bp and/or 1 kb DNA ladders were prepared and run in parallel to the 
samples. After electrophoresis, gels were stained with GelRed nucleic acid stain 
following the manufacturer’s instructions. Visualization of DNA band and image 
acquisition was performed by UV light transillumination using an ImageQuant 350 
digital image system (GE Healthcare) (see Materials section for details on reagents). 
 
8.1.2. Extraction of DNA after preparative agarose gel electrophoresis 
The DNA fragments were directly visualized on the UV light transilluminator and 
the DNA fragments were excised from the agarose gel with a clean scalpel. Extraction 
of the DNA fragments from the gel slice was performed using Nucleospin Gel and PCR 
Clean-Up following the manufacturer’s instructions. DNA fragments were eluted in 30-
50 µL ultrapure culture grade H2O. DNA concentrations were estimated using 
NanoDrop ND-1000 Spectrophotometer by measuring absorbance at 260 nm. Protein 
contamination was assessed by the ratio of 260/280 nm absorbance readings. Ratios in 
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the range of 1.7-1.9 were considered acceptable. Other contaminants were assessed by 
the ratio of 260/230 nm absorbance reading. Values in the range of 2.0-2.2 were 
considered acceptable. 
 
8.1.3. Transformation of chemically competent cells 
10 µL of One Shot® TOP10 chemically competent E. coli cells were thawed on ice 
and 1 µl plasmid (diluted to 0.1 µg/µL) was added to the cells and mixed by gently 
stirring the pipette tip in a 500 µL Eppendorf tube. After 30 min on ice, were given a 
heat shock at 42°C for 30 sec in a water bath, followed by incubation on ice for 2 min. 
Thereafter, cells were grown in 200 µL LB at 37°C for 1 h with agitation and under 
aerobic conditions. After the hour cells were grown on agar plates with appropriate 
antibiotics for selection. Plates were incubated upside-down at 37°C overnight. 
Transformation with ligation products was performed identically except that 50 µL of 
chemically competent E. coli cells and 5 µL of ligation product were used for 
transformation. 
 
8.1.4. Bacterial growth for amplification of plasmids 
One individual colony from those grown in agar plate was inoculated in either 6 
mL (for miniprep purification) or 45 mL (form midiprep purification) of LB containing 
the appropriate antibiotic for selection and grown overnight at 37°C with agitation and 
under aerobic conditions. Thereafter, bacteria were spun down by centrifugation at 5000 
x g for 15 min, and plasmid was purified using NucleoSpin® Plasmid or NucleoBond® 
Xtra Midi Plus kits following the manufacturer’s instructions (see Materials for further 
details). 
 
8.2. shRNA constructions 
8.2.1. Design 
Small hairpin (or short hairpin) RNAs (shRNAs) consists of an artificial tight 
hairpin turn used to silence target genes via the endogenous RNA interference 
machinery (see Introduction, Fig. 11). Expression of shRNA in eukaryotic cells is 
typically accomplished by delivery of complementary DNA (cDNA) encoding for 
shRNA through either viral or plasmidic vectors. shRNA is an advantageous mediator 
of RNAi in that it has a relatively low rate of degradation and turnover. The use of 
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shRNA technology instead of duplex short RNAs encoding for siRNAs has two major 
advantages. First, vectors can be designed such that an inducible promoter controls the 
shRNA expression. Second, degraded siRNA is continuously replaced by newly 
synthesized shRNA. These features, overcome two major limitations of duplex siRNAs, 
i.e., the lack spatial and temporal control. 
 
Figure 17. Schematic drawing summarizing the major steps for cloning of shRNAs into the 
eukaryotic expression vector pSuperior.gfp/neo and processing of shRNA to generate mature 
siRNA. 
 
Here we used the pSuperior.gfp/neo plasmid (see Materials, Table 3), in which a 
DNA duplex encoding for the desired shRNA sequence can be easily inserted 
downstream the polymerase-III H1-RNA gene promoter. In the pSuperior.gfp/neo the 
H1 promoter is modified in a sequence between the TATA box and the RNA hairpin 
transcription start site to contain the tetracycline operator 2 (TetO2) site that serves as 
the binding site for two molecules of the Tet repressor. Although we did not use this 
feature in the present study, in the absence of tetracycline, transcription of shRNA is 
repressed in cell lines stably expressing the Tet repressor (TetR), and shRNA expression 
	   METHODS 
	  
	  
	  
70 
can be induced by tetracycline. Additionally, the plasmid contains an EGFP reporter 
gene under the control of the PKG promoter to monitor transfection rate, and a	  
neomycin resistance gene under control of separate PGK promoter for antibiotic 
selection of stable shRNA transfectant. 
DNA duplexes encoding for shRNAs are obtained by annealing of synthetic 
oligonucleotide pairs containing the target sequence (21 nucleotides (nt)) in both sense 
and antisense orientation, separated by a 9-nucleotide spacer. DNA oligonucleotides are 
designed such that: [i] form BamHI and HindIII sticky ends upon annealing for 
insertion into the BglII/HindIII-digested vector, [ii] when inserted, DNA duplexes have 
a well-defined start of transcription and a termination signal consisting of five 
thymidines (T) in a row (T5) [iii] the cleavage of the transcript at the termination site is 
after the second uridine (U), yielding a transcript resembling the ends of synthetic 
siRNAs, which also contain two 3’ overhanging T or U (nt). Because the BamH1 and 
BglII overhangs are cohesive, the resulting double stranded sequence can be inserted in 
the BglII/HindIII-digested pSuperior.gfp/neo vector. This leads to destruction of the 
BglII site, which facilitates screening of positive clones by digestion with BglII 
combined with a second restriction enzyme followed by agarose gel electrophoresis 
(Fig. 17). 
8.2.2. Oligonucleotides 
Code Sequences 
shRNA-01 
Ss: 5' GATCCCCGCGCGCTTTGTAGGATTCGTTCAAGAGACGAATCCTACAAAGCGCGCTTTTTA 3' 
As: 5' AGCTTAAAAAGCGCGCTTTGTAGGATTCGTCTCTTGAACGAATCCTACAAAGCGCGCGGG 3' 
5' GATCCCCGCGCGCTTTGTAGGATTCGTTCAAGAGACGAATCCTACAAAGCGCGCTTTTTA 3' 
    3' GGGCGCGCGAAACATCCTAAGCAAGTTCTCTGCTTAGGATGTTTCGCGCGAAAAATTCGA 5' 
shRNA 87 
Ss: 5' GATCCCCGGAAAGTGACGACGACGATTTCAAGAGAATCGTCGTCGTCACTTTCCTTTTTA 3' 
As: 5' AGCTTAAAAAGGAAAGTGACGACGACGATTCTCTTGAAATCGTCGTCGTCACTTTCCGGG 3' 
5' GATCCCCGGAAAGTGACGACGACGATTTCAAGAGAATCGTCGTCGTCACTTTCCTTTTTA 3' 
    3' GGGCCTTTCACTGCTGCTGCTAAAGTTCTCTTAGCAGCAGCAGTGAAAGGAAAAATTCGA 5' 
shRNA-89 
Ss: 5' GATCCCCCGCAAAGTAAACGGCAAGATTCAAGAGATCTTGCCGTTTACTTTGCGTTTTTA 3' 
As: 5' AGCTTAAAAACGCAAAGTAAACGGCAAGATCTCTTGAATCTTGCCGTTTACTTTGCGGGG 3' 
5' GATCCCCCGCAAAGTAAACGGCAAGATTCAAGAGATCTTGCCGTTTACTTTGCGTTTTTA 3' 
    3' GGGGCGTTTCATTTGCCGTTCTAAGTTCTCTAGAACGGCAAATGAAACGCAAAAATTCGA 5' 
shRNA-97 
Ss: 5' GATCCCCGGACCCCAAATTACGTGAATTCAAGAGATTCACGTAATTTGGGGTCCTTTTTA 3' 
As: 5' AGCTTAAAAAGGACCCCAAATTACGTGAATCTCTTGAATTCACGTAATTTGGGGTCCGGG 3' 
5' GATCCCCGGACCCCAAATTACGTGAATTCAAGAGATTCACGTAATTTGGGGTCCTTTTTA 3' 
    3' GGGCCTGGGGTTTAATGCACTTAAGTTCTCTAAGTGCATTAAACCCCAGGAAAAATTCGA 5' 
shRNA-99 
Ss: 5' GATCCCCGATTTCACTCCAGAAGTGTTTCAAGAGAACACTTCTGGAGTGAAATCTTTTTA 3' 
As: 5' AGCTTAAAAAGATTTCACTCCAGAAGTGTTCTCTTGAAACACTTCTGGAGTGAAATCGGG 3' 
5' GATCCCCGATTTCACTCCAGAAGTGTTTCAAGAGAACACTTCTGGAGTGAAATCTTTTTA 3' 
    3' GGGCTAAAGTGAGGTCTTCACAAAGTTCTCTTGTGAAGACCTCACTTTAGAAAAATTCGA 5' 
Table 6. Sequences of sense (Ss) and antisense (As) oligonucleotide pairs used to generate 
duplex DNA with BamHI and HindIII sticky ends (blue dashed cells). 
 
Oligonucleotides for cloning of shRNAs targeting human PLCB1 mRNA (NCBI 
accession, NM_015192) into the pSuperior.gfp/neo were purchased from OligoEngine 
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(Seattle, WA, USA). Two of the four shRNAs (shRNA-97 and shRNA-99) were 
designed by Dr. Marion Benoist (Mediterranean Institute of Neurobiology -INMED-, 
Luminy, Marseille) and the other two (shRNA-97 and shRNA-99) were designed using 
Oligoengine software (www. oligoengine.com). The oligonucleotides to generate the 
negative control or scramble shRNA (Table 6, shRNA-01) were purchased from 
OligoEngine. 
 
8.2.3. BglII/HindIII digestion of pSuperior.gfp/neo plasmid 
Digestion of pSuperior.gfp/neo vector was performed sequentially. HindIII 
digestion was performed for 1 h at 37 ºC in the following reaction mixture: 
 - 67 µL ultrapure culture grade H2O (to achieve a final volume of 100 µL). 
 - 10 µL of plasmid (1 µg/µL). 
 - 10 µL NEB Buffer 2 10X. 
 - 3 µL HindIII enzyme. 
The digestion product was purified by Nucleospin Gel and PCR Clean-Up DNA 
purification kit using the manufacturer’s instructions, eluted in 50 µL and digested with 
BglII enzyme for 1 h at 37ºC in the following reaction mixture: 
 - 19 µL ultrapure culture grade H2O (to achieve a final volume of 80 µL). 
 - 50 µL of Hind III-digested plasmid. 
 - 8 µL NEB Buffer 3 10X. 
 - 3 µL BglII enzyme. 
After digestion, purification of the linearized plasmid was performed by extraction 
from a preparative 1% agarose gel after being resolved by electrophoresis (see sections 
8.1.1. and 8.1.2.). 
 
8.2.4. Oligonucleotide annealing 
Stock oligonucleotides 100 µM were ditulted at a working concentration of 0.2 µM 
(1:500 dilution) in annealing buffer (100 mM NaCl, 50 mM HEPES, pH 7.4). For 
annealing of oligonucleotide pairs (Table 6) 1 µL of each of the complementary 
oligonucleotides (0.2 µM) were mixed with 48 µl of annealing buffer. Finally, 
annealing was performed in a thermocycler (BioRad, MyCycler™ Thermal Cycler 
System) using the following program: 94ºC for 4 min, 80ºC for 4 min, 75ºC for 4 min, 
70ºC 4 min, 4ºC, with cooling rate of 2ºC/sec between annealing steps. 
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8.2.5. Ligation 
For ligation of DNA 2 µl of each 10-fold diluted annealed oligonucleotides and 1 µl 
BglII/HindIII digested pSuperior.gfp/neo were added to 9.5 µL culture grade ultrapure 
H2O. After adding 1.5 µl T4 DNA ligase buffer 10X and 1 µL T4 DNA ligase, the 
mixture was mixed by vigorous shaking or vortex for ∼5 sec and incubated overnight at 
16ºC. As a negative control ligation was performed in the absence of annealed 
oligonucleotides. 
To minimize the appearance of false positives, 1 µL BglII was added to each tube 
containing the different ligation products before transforming chemically competent E. 
coli cells. Because the BglII site is destroyed upon ligation, only recircularized vectors 
with no insert are cleaved, thus preventing their replication. Transformation of bacteria 
with the different ligation products was performed as described above (see section 
8.1.3.). 
 
8.2.6. Screening of positive clones 
For screening, three independent positive clones from each ligation were grown for 
miniprep plasmid purification as described above (see section 8.1.4.) and eluted in 50 
µL ultrapure culture grade H2O. Thereafter, purified plasmids were digested by HindIII 
and EcoRI restriction enzymes for 1 h at 37ºC in the following reaction mixture: 
 - 33 µL ultrapure culture grade H2O. 
 - 10 µL of the plasmid eluate. 
 - 5 µL NEB Buffer 2 10X. 
 - 1 µL HindIII enzyme.  
The digested DNA was resolved by agarose gel electrophoresis in a minigel system 
and DNA bands were visualized as described above (see section 8.1.1.). 
 
 
Figure 18. Example of a negative (lane 2) and a positive clone 
(lane 3) digested with EcoRI and HindIII restriction enzymes. The 
expected size of restriction fragments for the recircularized vector 
were 5020 and 228 bp, whereas those expected for shRNA insert-
containing plasmid were 5202 and 282 bp. As it can be observed, 
the lower band in lanes 2 and 3 are consistent with restriction 
maps expected for a recircularized and a shRNA insert-containing 
vector, respectively. 
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Finally, sequencing of positive shRNA clones was performed by STAB-Vida 
(Lisbon, Portugal) with M13-RV primer. Once the clones were checked for the correct 
sequence, DNA from one clone corresponding to each shRNA was amplified for 
midiprep purification as described in 8.1.4. These plasmids were ready for cell 
transfection. 
 
8.3. Generation of pCDNA3-N-PLCβ1a- and pCDNA3-N-PLCβ1b-cloning vectors 
8.3.1. Design 
We designed a cloning strategy to generate pCDNA3-N-PLCβ1a- and pCDNA3-N-
PLCβ1b N-terminal cloning vectors for easy insertion of short DNA duplexes at the 
beginning of the human PLCB1a and PLCB1b coding sequences. By this way N-
terminal cloning vectors can be easily engineered to encode native or N-terminal tagged 
human PLCβ1a and PLCβ1b proteins. At the same time, the cloning strategy served to 
remove large 5’- and 3’ untranslated regions (UTRs) from the original plasmids 
pCMV6-XL6-PLCB1a and pCMV6-XL6-PLCB1b (OriGene Technologies, Burlington, 
Ontario, Canada), that could contain elements for endogenous regulation of translation 
(Chatterjee and Pal, 2009). 
 
8.3.2. Generation of pCDNA3-N-PLCβ1a N-terminal cloning vector 
To generate pCDNA3-N-PLCβ1a N-terminal cloning vector, AgeI and NotI 
restriction sites were introduced at the beginning and end of the human PLCB1a and 
PLCB1b coding sequences by polymerase chain reaction (PCR), using pCMV6-XL6-
PLCB1a as matrix. AgeI restriction site was introduced downstream the ATG start 
codon of PLCB1a coding sequence and NotI restriction site was introduced a few bases 
downstream the TGA stop codon of PLCB1a. To this end, the following primer pairs 
were used: 
 
PLCb1_AgeI_Fw 
PLCb1a_NotI_Rv  
5' aCCGGtGTGCACGCCTTGCAAC 3' 
5' GcgGccGCCATGCAATTTCTG 3' 
The sequences in yellow correspond to AgeI and NotI restriction 
sites. Lowercase letters correspond to nucleotides non 
complementary to the DNA sequence to be amplified by PCR. 
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8.3.2.1. Polymerase chain reaction (PCR) 
The following master mixture was prepared by adding each component in the indicated 
order: 
     Volume Final concentration 
 H2O    130 µl   
 5 X PCR buffer   40 µl  1 x (contains 2 mM Mg++) 
 dNTPs mix 10 mM  6 µl  0.3 mM each 
 Primer Fw 10 µM  6 µl  0.3 µM 
 Primer Rv 10 µM  6 µl  0.3 µM 
 HiFi Taq Polymerase  6 µl  1.5 units / 50 µl 
 Total volume    194 µl 
 
Prepare four PCR tubes were prepared as follows: 
Tube 
number 
Master mixture Matrix (pCMV6-XL6-PLCb1a vector 1µg/µL) 
1 48.5 µL 1.5 µL H2O 
2 48.5 µL 1.5 µL matrix 1/10 
3 48.5 µL 1.5 µL matrix 1/100 
4 48.5 µL 1.5 µL matrix 1/1000 
 
Place tubes in the thermocycler and run the following PCR program: 
94°C 5 min 
94°C 1 min  
60°C 30 sec  27 times 
68°C 2 min 
72°C 5 min 
4°C Hold 
 
5 µL of each of the PCR products were analyzed by agarose gel electrophoresis in a 
minigel system and DNA bands were visualized as described above (see section 8.1.1.). 
As it can be observed in figure 19, the three dilutions of the matrix yielded a net band of 
the expected size (3669 bp). Of the three reaction products we chose the one obtained 
with the lowest amount of matrix for preparative agarose gel electrophoresis and 
purification of the A3669 bp AgeI_PLCb1a_NotI amplicon as described in sections 
8.1.1. and 8.1.2. 
 
Figure 19. Analysis of PCR products. No product was observed in the 
lane corresponding to the H2O negative control, whereas a net band of 
the expected size for the AgeI_PLCb1a_NotI amplicon was observed 
at the three dilutions of matrix. 
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8.3.2.2. Insertion of the amplicon in the pCR®-Blunt II-TOPO cloning vector 
The purified 3669 bp AgeI_PLCb1a_NotI amplicon was inserted in the pCR®-
Blunt II-TOPO cloning vector (hereinafter TOPO; Fig. 21) using two different amounts 
of insert. 
  Conditons 
PCR product 1 µL 4 µL 
H2O 3 µL - 
Salt 1 µL 1 µL 
pCR-Blunt-TOPO vector 1 µL 1 µL 
 
After incubation of the mixtures during 30 min at room temperature, One Shot 
Top10 competent cells were transformed (see section 8.1.3.) and cultured on LB agar 
plates containing 50 µg/mL kanamycin. Although TOPO vector allows direct selection 
of recombinants via disruption of the lethal E. coli gene upon insertion of the PCR 
product (cells that contain non-recombinant vector are killed upon plating), we have 
observed the presence of surviving clones with no insert. Therefore, we took advantage 
of the possibility for blue/white selection coated the agar plates with 50 µL X-gal 
solution. Because amplicon insertion disrupts the LacZ gene present in TOPO, only 
white colonies are expected to have insert (Fig. 21). 
 
Figure 20. pCR®-Blunt II-TOPO is supplied 
linearized with Vaccinia virus DNA 
topoisomerase I covalently bound to the 3´ end of 
each DNA strand. Topoisomerase I binds to 
duplex DNA at specific sites and cleaves the 
phosphodiester backbone after 5′-CCCTT in one 
strand (Shuman, 1991). The energy from the 
broken phosphodiester backbone is conserved by 
formation of a covalent bond between the 3′ 
phosphate of the cleaved strand and a tyrosyl 
residue (Tyr-274) of topoisomerase I. 
The phospho-tyrosyl bond between the DNA and enzyme can subsequently be attacked by the 
5′ hydroxyl of the original cleaved strand, reversing the reaction and releasing topoisomerase 
(Shuman, 1994), which is very useful to efficiently clone PCR products. 
 
Both conditions used for insertion of the AgeI_PLCb1a_NotI in TOPO yielded 
abundant colonies (Fig. 21). 
Five white colonies were grown for miniprep plasmid purification as described 
above (see section 8.1.4.) and screening was performed with EcoRV and BglII 
restriction enzymes and NEB buffer 3, basically as described in section 8.2.6. Because 
the amplicon can be inserted into the plasmid in either direction, there are two possible 
restriction maps for positive clones: 
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 SENSE INSERTION ANTISENSE INSERTION 
Size of fragments 4503 
2691 
6172 
1022 
 
Figure 21. Degradation of the lactose 
analogue X-gal produces a blue precipitate. 
Because successful insertion of the amplicon 
disrupts the LacZ gene encoding for β-
galactosidase, only white colonies are 
expected to be positive. 
The restriction map of nearly all of the clones analyzed was consistent with the 
insertion of the AgeI_PLCb1a_NotI amplicon. Of them, one of them with the PCR 
product inserted in reverse was completely sequenced by STAB-Vida (Lisbon, 
Portugal) with the following primers: 
M13_Fw 5' TGTAAAACGACGGCCAGT 3' 
PLCb1_Int_5_Fw_1 5' AGCGAGATCCTCGGCTTAATG 3' 
PLCb1_Int_5_Fw_2 5' ACTGCTGGAAGTGAGGCTATG 3' 
PLCb1_Int_5_Fw_3 5' AGTGAAAGACTATGTGCCAGAC 3' 
M13_Rv 5' CAGGAAACAGCTATGACC 3' 
 
8.3.2.3. Construction of the pCDNA3-N-PLCβ1a N-terminal cloning vector 
Once checked for the correct sequence, the TOPO clone containing the 
AgeI_PLCb1a_NotI amplicon was used to generate the pCDNA3-N-PLCβ1a N-
terminal cloning vector by a digestion of the sequenced TOPO clone and pCDNA3.0 
plasmid in EcoRV and NotI sites followed by ligation of the AgeI_PLCb1a_NotI insert 
into the linearized pCDNA3.0 plasmid. 
EcoRV/NotI digestion of the TOPO clone and pCDNA3.0 plasmid was performed 
by incubation at 37ºC for 2 h in the in the following reaction mixture: 
 pCR-TOPO clone pCDNA3.0 
H20 75 µL 71 µL 
Buffer 3 (10 X) 10 µL 10 µL 
BSA (100 X) 1 µL 1 µL 
Amount of vector 10 µg 10 µg 
NotI 2 µL 4 µL 
EcoRV 2 µL 4 µL 
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The digested DNA was resolved by preparative 0.8% agarose gel electrophoresis as 
described above (see section 8.1.1.). Then, two fragments of 3692 bp and 5430 bp, 
corresponding to the insert and the linearized pCDNA3.0 plasmid, purified by 
extraction from gel as described in section 8.1.2. 
pCDNA3-N-PLCβ1a N-terminal cloning vector was generated by ligation of the 
above mentioned fragments. For this purpose, the following mixtures were prepared on 
ice: 
 Ligation Control 
Ultrapure H2O 8 µL 11 µL 
Insert 3 µL - 
Linearized pCDNA vector 1.5 µL 1.5 µL 
T4 DNA ligase buffer 10X 1.5 µL 1.5 µL 
T4 DNA ligase 1 µL 1 µL 
 
The mixture was mixed by vigorous shaking or vortex for ∼5 sec and incubated 
overnight at 16ºC. The resulting ligation products were used to transform chemically 
competent E. coli cells. Bacteria were then cultured on LB agar plates containing 100 
µg/ml ampicillin (section 8.1.3). 
Five individual clones were chosen, inoculated in 6 mL of ampicillin-containing 
LB, grown in suspension and purified using NucleoSpin® Plasmid kit (see section 
8.1.4.) and eluted in 30 µL ultrapure H2O. For screening by restriction mapping BglII 
and AgeI enzymes were used. Double digestion was performed sequentially using NEB 
buffers 3 and 1 for BglII and AgeI, respectively. Digestion was performed as described 
in section 8.2.3., except that 5 µL of plasmid and only 1 µL of each enzyme was used in 
a final volume of 10 µL. The digested DNA was resolved by agarose gel electrophoresis 
in a minigel system and DNA bands were visualized as described above (see section 
8.1.1.). 
 
Figure 22. Screening of clones after ligation. The 
expected size of restriction fragments for the 
pCDNA3-N-PLCβ1a N-terminal cloning vector 
were 5492, 2669 and 958 bp. As it can be observed, 
restriction maps of clones 1, 2 and 5 were consistent 
with the theoretical one. 
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As seen in figure 22, three of the five clones had restriction maps coherent with the 
expected one. Therefore, one of them was chosen for sequencing (STAB-Vida) with the 
following primers: 
Forward primers: 
T7 5' AATACGACTCACTATAGGG 3' 
PLCb1_Int_5_Fw_1 5' AGCGAGATCCTCGGCTTAATG 3' 
PLCb1_Int_5_Fw_2 5' ACTGCTGGAAGTGAGGCTATG 3' 
PLCb1_Int_5_Fw_3 5' AGTGAAAGACTATGTGCCAGAC 3' 
Reverse primers: 
PLCb1_Int_5_Rv_4 5' CCTGGATATATGACCGGATC 3' 
SP6 5' ATTTAGGTGACACTATAG 3' 
 
Once the clone was checked for the correct sequence, the pCDNA3-N-PLCβ1a N-
terminal cloning vector was amplified for midiprep purification as described in 8.1.4., 
and used for cloning of PLCβ1a and HA-PLCβ1a in pCDNA3.0 plasmid. 
 
8.4. Cloning of non-tagged and HA-tagged PLCβ1a in pCDNA3.0 
8.4.1. Design 
Using the pCDNA3-N-PLCβ1a N-terminal cloning vector DNA duplexes can be 
easily inserted at the 5’ end of the sequence encoding for the human PLCB1a mRNA in 
the pCDNA3-N-PLCβ1a vector. These inserts are designed such that all contain a same 
Kozak consensus sequence GCCACCATGG (the underlined triplet is the ATG start 
codon), which plays a major role in the initiation of translation (De Angioletti et al., 
2004). The rationale of engineering all constructs with an identical Kozak sequence 
(and also removing 5’- and 3’-UTRs, see section 8.3.1.) was to obtain constructs 
exhibiting similar translation efficiencies. The DNA duplexes can be designed to 
contain the initial codons corresponding to the native PLCB1a sequence, but also to 
contain a coding sequence for a given protein tag. Obviously, the design of DNA 
duplexes must consider the reading frame is maintained after being inserted. 
 
8.4.2. DNA duplexes 
DNA duplexes containing the initial triplets coding for the human PLCB1a mRNA, 
preceded or not by a sequence coding for the human influenza hemagglutinin (HA) tag 
were obtained by annealing of synthetic oligonucleotide pairs, thus obtained two DNA 
duplexes sequences with 5’ KpnI- and 3’ AgeI-cohesive overhangs. Duplexes were 
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designed to contain one AgeI site immediately upstream of the Kozak sequence and one 
EcoRV site a few nucleotides before. Therefore, the 3’ AgeI-cohesive overhang was 
designed such that is destroyed upon ligation with the KpnI/AgeI-digested pCDNA3-N-
PLCβ1a N-terminal cloning vector (Fig. 23). 
Ss: 5' CGAGCTTCGATCCACCAGATATCCAGTACCGGTGCCACCATGGCCGGGGCTCAAC 3' 
As: 5' CCGGGTTGAGCCCCGGCCATGGTGGCACCGGTACTGGATATCTGGTGGATCGAAGCTCGGTAC 3' 
       EcoRV     AgeI  Kozak/Start 
5  CGAGCTTCGATCCACCAGATATCCAGTACCGGTGCCACCATGGCCGGGGCTCAAC 3' 
3' CATGGCTCGAAGCTAGGTGGTCTATAGGTCATGGCCACGGTGGTACCGGCCCCGAGTTGGGCC 5' 
 
Ss: 5' CAGTGATATCACCGGTGCCACCATGGCATACCCTTATGATGTGCCGGATTATGCCGCTAGCAAGGCCGGGGCTCAAC 3' 
As: 5' CCGGGTTGAGCCCCGGCCTTGCTAGCGGCATAATCCGGCACATCATAAGGGTATGCCATGGTGGCACCGGTGATATCACTGGTAC 3' 
           EcoRV  AgeI Kozak/Start          HA tag             NheI 
5'     CAGTGATATCACCGGTGCCACCATGGCATACCCTTATGATGTGCCGGATTATGCCGCTAGCAAGGCCGGGGCTCAAC     3' 
3' CATGGTCACTATAGTGGCCACGGTGGTACCGTATGGGAATACTACACGGCCTAATACGGCGATCGTTCCGGCCCCGAGTTGGGCC 5' 
Figure 23. Sequences of sense (Ss) and antisense (As) oligonucleotide pairs used to generate DNA 
duplexes for insertion in KpnI/AgeI-digested pCDNA3-N-PLCβ1a N-terminal cloning vector, thus 
generating PLCβ1a and HA- PLCβ1a constructs cloned in pCDNA3.0 vector. The pink colored 5’ and 3’ 
sticky ends of the duplexes are KpnI- and AgeI-cohesive, respectively. The AgeI-cohesive 3’ overhang 
destroys the AgeI site upon ligation with the KpnI/AgeI-digested pCDNA3-N-PLCβ1a cloning vector. 
 
8.4.3. KpnI/AgeI digestion of pCDNA3-N-PLCβ1a cloning vector, ligation and 
screening 
Digestion was performed sequentially. KpnI digestion was performed for 2 h at 
37ºC in the following reaction mixture: 
 - 67 µL ultrapure culture grade H2O (to achieve a final volume of 100 µL). 
 - 10 µL of plasmid (1 µg/µL). 
 - 10 µL NEB Buffer 1 10X. 
 - 1 µL BSA (100 X). 
 - 2 µL KpnI enzyme. 
The digestion product was purified by Nucleospin Gel and PCR Clean-Up DNA 
purification kit using the manufacturer’s instructions, eluted in 50 µL and digested with 
AgeI enzyme for 2 h at 37ºC in the following reaction mixture: 
 - 38 µL ultrapure culture grade H2O (to achieve a final volume of 100 µL). 
 - 50 µL of KpnI-digested plasmid. 
 - 10 µL NEB Buffer 3 10X. 
 - 2 µL AgeI enzyme. 
After digestion, purification of the linearized plasmid was performed by extraction 
from a preparative 1% agarose gel after being resolved by electrophoresis (see sections 
8.1.1. and 8.1.2.). 
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8.4.4. Generation of PLCβ1a and HA-PLCβ1a constructs 
Oligonucleotides shown in figure 13 were purchased from Integrated DNA 
Technologies (IDT Inc.,	   Coralville, Iowa, USA) an annealed as described in section 
8.2.4. Ligation of oligonucleotides was performed as described in section 8.4.4. 
Screening was performed as described before (section 8.2.6.) using either 
EcoRI/MluI or NheI/PmlI enzyme combinations for pCDNA3-PLCβ1a and pCDNA3-
HA-PLCβ1a constructs, respectively (Fig. 24). 
 
Figure 24. Screening of clones after ligation. The expected sizes 
of restriction fragments were 4906 and 4197 for the pCDNA3-
PLCβ1a construct, and 7315 and 1810 for the pCDNA3-HA-
PLCβ1a construct. As it can be observed, restriction maps of the 
PLCβ1a and HA-PLCβ1a clones were consistent with the 
theoretical ones. The appearance of a doublet band seen in the 
lane corresponding to HA-PLCβ1a is due to incomplete digestion 
of the plasmid. 
One positive clone of each construct was chosen for full sequencing (STAB-Vida) 
with the following primers: 
Forward primers: 
T7 5' AATACGACTCACTATAGGG 3' 
PLCb1_Int_5_Fw_1 5' AGCGAGATCCTCGGCTTAATG 3' 
PLCb1_Int_5_Fw_2 5' ACTGCTGGAAGTGAGGCTATG 3' 
PLCb1_Int_5_Fw_3 5' AGTGAAAGACTATGTGCCAGAC 3' 
Reverse primers: 
PLCb1_Int_5_Rv_4 5' CCTGGATATATGACCGGATC 3' 
SP6 5' ATTTAGGTGACACTATAG 3' 
 
Once they were checked for the correct sequence, the PLCβ1a and HA-PLCβ1a 
constructs were amplified for midiprep purification as described in 8.1.4. 
 
8.4.5. Generation of PLCβ1b and HA-PLCβ1b constructs 
The DNA sequences coding for both human PLCB1a and PLCB1b mRNAs 
encompass a unique PmlI unique site upstream of the splice variant-specific 3’-terminal 
sequence. On the other hand, the PLCB1b sequence in the pCMV6-XL6-PLCβ1b 
plasmid encompass a NotI site a few bases downstream the stop codon. Because, 
pCDNA3.0-PLCβ1a and pCDNA3.0-HA-PLCβ1a plasmids were cloned such that 
contain a unique NotI site a few bases downstream the stop codon (section 8.3.2.), it is 
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possible to generate pCDNA3.0-PLCβ1b and pCDNA3.0-HA-PLCβ1b constructs by 
PmlI/NotI digestion. Thus PmlI/NotI digestion of pCDNA3.0-PLCβ1a and pCDNA3.0-
HA-PLCβ1a results in a linearized plasmid in which the PLCB1a specific splice-variant 
3’-sequence is removed. The PLCB1b specific splice-variant 3’-sequence can be 
obtained by PmlI/NotI digestion of the pCMV6-XL6-PLCβ1b plasmid and inserted into 
the pCDNA3.0-PLCβ1a and pCDNA3.0-HA-PLCβ1a plasmids linearized by PmlI/NotI 
digestion, thus obtaining pCDNA3.0-PLCβ1b and pCDNA3.0-HA-PLCβ1b constructs. 
 
8.4.5.1.PmlI/NotI digestion 
Digestion was performed sequentially by incubation of pCDNA3-PLCβ1, 
pCDNA3-HA-PLCβ1a and pCMV6-XL6-PLCβ1b for 2 h at 37ºC in the following 
reaction mixture: 
 - 67 µL ultrapure culture grade H2O (to achieve a final volume of 100 µL). 
 - 10 µL of plasmid (1 µg/µL). 
 - 10 µL NEB Buffer 1 10X. 
 - 1 µL BSA (100X). 
 - 2 µL PmlI enzyme. 
The digestion product was purified by Nucleospin Gel and PCR Clean-Up DNA 
purification kit using the manufacturer’s instructions, eluted in 50 µL and digested with 
BglII enzyme for 2 h at 37ºC in the following reaction mixture: 
 - 50 µL of PmlI-digested plasmid. 
 - 39 µL ultrapure culture grade H2O (to achieve a final volume of 100 µL). 
 - 8 µL NEB Buffer 3 10X. 
 - 1 µL BSA (100X). 
 - 2 µL NotI enzyme. 
 
8.4.5.2. Ligation 
After being resolved by preparative agarose gel electrophoresis (see section 8.1.1.) 
the following fragments were purified  (see section 8.1.2.) and eluted in 50 µL ultrapure 
H2O: 
Pml/NotI digestion of: Fragments of interest 
pCDNA3-PLCβ1a 7225 bp 
pCDNA3-HA-PLCβ1a 7247 bp 
pCMV6-XL6-PLCβ1b 1726 bp 
 
The 1726 bp fragment was ligated with 7225 bp and 7247 bp fragments to obtain 
the pCDNA3-PLCβ1b and pCDNA3-HA-PLCβ1b plasmids coding for native human 
PLCβ1b and HA-tagged PLCβ1b. 
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For ligation the following conditions were used: 
 Ligations Control 
Ultrapure H2O 6,5 µL 10,5 µL 
Insert 4 µL - 
Linearized Vector 2 µL 2 µL 
T4 DNA ligase buffer 10X 1.5 µL 1.5 µL 
T4 DNA ligase. 1 µL 1 µL 
The mixture was mixed by vigorous shaking or vortex for ∼5 sec and incubated 
overnight at 16ºC. The ligation products were used to transform chemically competent 
E. coli cells. Bacteria were then cultured on LB agar plates containing 100 µg/mL 
ampicillin (see section 8.1.3). 
Five individual clones were chosen, inoculated in 6 mL of ampicillin-containing 
LB, grown in suspension and purified using NucleoSpin® Plasmid kit (see section 
8.1.4.) and eluted in 30 µL ultrapure H2O. 
For screening by restriction mapping, EcoRV and BamHI enzymes were used. 
Plasmids were double digested by incubation at 37ºC for 1 h in the following solution 
reaction mixture: 
Ultrapure H20 1 µL. 
Buffer 3 (10 X) 1 µL. 
BSA (10 X) 1 µL. 
Plasmid 5 µL. 
BamHI 1 µL. 
EcoRV 1 µL. 
 
The digested DNA was resolved by agarose gel electrophoresis in a minigel system 
and DNA bands were visualized as described above (see section 8.1.1.). 
 
Figure 25. Screening of clones after ligation. The expected size of restriction fragments was 
5465 and 3486 for the pCDNA3-PLCβ1b construct, and 5452 and 3521 for the pCDNA3-HA-
PLCβ1b construct. Restriction maps 3 of the 5 PLCβ1a and of all HA-PLCβ1a clones analyzed 
clones were consistent with the theoretical ones. 
As seen in figure 25, three of the five pCDNA3-PLCβ1b clones and all of the 
pCDNA3-HA-PLCβ1b clones had restriction maps coherent with the expected ones. 
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Therefore, one pCDNA3-PLCβ1b and one pCDNA3-HA-PLCβ1b was chosen for full 
sequencing (STAB-Vida) with the following primers: 
Forward primers: 
T7 5' AATACGACTCACTATAGGG 3' 
PLCb1_Int_5_Fw_1 5' AGCGAGATCCTCGGCTTAATG 3' 
PLCb1_Int_5_Fw_2 5' ACTGCTGGAAGTGAGGCTATG 3' 
PLCb1_Int_5_Fw_3 5' AGTGAAAGACTATGTGCCAGAC 3' 
Reverse primers: 
PLCb1_Int_5_Rv_4 5' CCTGGATATATGACCGGATC 3' 
SP6 5' ATTTAGGTGACACTATAG 3' 
 
Once they were checked for the correct sequence, the PLCβ1b and HA-PLCβ1b 
constructs were amplified for midiprep purification as described in 8.1.4. 
 
9. Statistical analysis 
Data were analyzed using Prism (GraphPad Software, La Jolla, CA). The number 
of samples or cells analyzed, as well as the statistical analysis performed is detailed in 
each figure legend. Results in graphs are expressed as mean ± standard error (SEM). 
Significance of differences in mean values was calculated using Student's t-test or one-
way ANOVA followed by Tukey´s post-test. For significance symbols, one symbol 
means p < 0.05, two symbols mean p < 0.01, and three symbols mean p < 0.001. 
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1. ANALYSIS OF PHOSPHOLIPASE Cβ1 EXPRESSION IN CORTICAL 
NUCLEI OF THE ADULT RAT 
As mentioned in the introduction, PLCβ1 is expressed in the nucleus of several 
non-neuronal cell lines, where it plays a pivotal role in regulation of cell proliferation 
and differentiation (Cocco et al., 2006, 2009). Therefore, before focusing on the role of 
PLCβ1 in neuronal differentiation, the expression of PLCβ1 was analyzed in isolated 
intact nuclei by Western blot, double immunofluorescence staining and confocal laser 
scanning. 
 
1.1. Expression of PLCβ1a and PLCβ1b in subcellular fractions of the rat cortex 
In view of the essential roles attributed to PLCβ1 in several cell lines (for review, 
Cocco et al., 2006, 2009), and of the lack of data about the nuclear localization of this 
protein in neurons, PLCβ1-expression was analyzed in cytosol (Cyt fraction) and crude 
membranes (P2 fraction), and in highly purified nuclei (N fraction). 
We first tested the purity of Cyt, P2 and N fractions. For that purpose, Western blot 
assays were carried out in every fraction of neocortical samples using antibodies raised 
against specific subcellular compartments. As shown in figure 26A, markers of the Cyt 
(β-tubulin), P2 (Na+/K+ ATPase, NR1 subunit of the NMDA receptor, SNAP-25 and 
58K Golgi protein) and N (nuclear pore complex, NPCx) fractions were either 
preferentially (β -tubulin) or exclusively (the rest) expressed in the expected subcellular 
compartment.  We then measured the expression levels of the splice variants PLCβ1a 
and PLCβ1b in N, P2 and Cyt fractions, using an antibody raised against a peptide 
mapping at the N-terminus of PLCβ1 (common to both PLCβ1a and PLCβ1b variants; 
Fig. 26A; Table 1). Immunoblot analysis revealed specific immunoreactivity for both 
PLCβ1a and PLCβ1b in every fraction (Fig. 26A-B). To fully investigate the subcellular 
distribution of PLCβ1a and PLCβ1b, we measured the immunoreactivity using 
increasing amounts of total protein in N, P2 and Cyt fractions (Fig. 26B). 
Regression analysis of standard curves revealed a linear relationship between the 
amount of protein and the relative optical density of PLCβ1a- and PLCβ1b-
immunoreactivity in the range of 2.5-15 µg in the Cyt and P2 fractions, and 10-25 µg in 
the N fraction. The correlation coefficients obtained using linear regression were 
between 0.89 and 0.99 (Cyt fraction PLCβ1a, r2=0.98 and PLCβ1b, r2=0.99; P2 
PLCβ1a, r2=0.99 and PLCβ1b, r2=0.98; and N PLCβ1a, r2=0.89 and PLCβ1b, r2=0.92). 
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The analysis of the slopes revealed a higher immunoreactivity of PLCβ1a than of 
PLCb1b in all subcellular fractions, although the expression of PLCβ11a was 
significantly higher only in Cyt and P2 fractions (Fig. 26C). The comparative study 
between PLCβ1a/1b ratios revealed that it was significantly higher in Cyt than in N and 
P2 fractions (inset in Fig. 26C). 
 
Figure 26. A. Western blot analysis of cytosolic (Cyt), crude membranes (P2) and “isolated 
nuclei” (N) fractions with antibodies against PLCβ1 and subcellular fraction-specific antigens. 
For each marker, equal amounts of total protein (10 µg) were loaded on the same gel. B. 
Western blot analysis of PLCβ1a and PLCβ1b in the reference control (C), and Cyt, P2 and N 
fractions. Increasing amounts of proteins were loaded (2.5, 5, 10 and 15 µg of from the Cyt and 
P2 fractions, and 10, 15, 20 and 25 µg from the N fraction) and run in parallel. C. Bar graph 
depicts the OD of PLCβ1a and PLCβ1b immunoreactivity for every fraction in lanes loaded 
with 15 µg protein, relative to the total optical density in the reference control (n = 7). Two-way 
ANOVA revealed significant differences between splice variants and subcellular fractions 
(p < 0.0001 both; p < 0.005 for splice variant-subcellular fraction interaction). Post hoc 
Bonferroni’s test revealed a significantly higher expression of PLCβ1a than PLCβ1b in Cyt and 
P2 fractions (∗∗∗p < 0.001 and ∗∗p < 0.01, respectively). PLCβ1a expression was significantly 
lower in P2 and N fractions than in Cyt (#p < 0.05 and ##p < 0.01, respectively). PLCβ1b 
expression was significantly higher in P2 than in Cyt and N fractions (+++p < 0.001). 
PLCβ1a/PLCβ1b ratios of immunoreactivity revealed significantly higher values in Cyt than in 
P2 and N fractions (inset; ∗∗p < 0.01, ∗∗∗p < 0.001) as shown by one-way ANOVA followed by 
post hoc Tukey’s test. All values shown in the bars are the mean ± SEM of four independent 
experiments. 
 
1.2. Subnuclear distribution of PLCβ1 in intact nuclei from adult rat cortex 
In order to confirm and extend results obtained by Western blot analysis, we 
isolated intact nuclei from adult rat cortex to improve antibody penetration, and 
conducted different double labeling experiments. First, double-labeling assays using the 
polyclonal anti-PLCβ1 R-233 antibody and a monoclonal antibody to the postmitotic 
neuronal marker NeuN/Fox was combined with Hoechst staining, showing that nuclei 
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Figure 27. PLCβ1-immunofluorescen-
ce combined with NeuN (A-C), 
chromatin (D-F), nuclear pore complex 
(G-I) and lamin B1 (J-L) staining in 
intact nuclei isolated from the adult rat 
brain cortex. A-C. Double PLCβ1- (A) 
and NeuN-immunofluorescence (B) 
labeling combined with Hoechst (C). 
Every NeuN-immunopositive nucleus 
exhibited strong PLCβ1-immunoreacti-
vity (filled arrowheads), whereas no 
PLCβ1-staining was observed in nuclei 
devoid of NeuN (empty arrow-heads). 
D-F. Higher magnification views of 
PLCβ1-immunollabeled nuclei (D) 
counterstained with Hoechst (E). No 
overlapping was observed between 
PLCβ1 spots and patches of intense 
Hoechst staining (F). G-I. Double 
PLCβ1- (G) and nuclear pore complex-
immunofluorescence (H) showing that 
PLCβ1 localizes internal to the nuclear 
envelope (I). J-L. Double PLCβ1- (J) 
and lamin B1-immunofluorescence (K) 
showing that PLCβ1 localizes internal 
to the nuclear lamina (L). Scale 
bars = 20 µm in C (applies to A-C); 
5 µm in L (applies to D-L). 
of neuronal origin were PLCβ1-positive (Figs. 27A-C). At high resolution, PLCβ1-
signal displayed a punctate pattern composed of bright foci distributed throughout the 
nucleoplasm in nuclear subdomains poor in Hoechst’s chromatin staining (Figs. 27D-F), 
suggesting that PLCβ1 is a component of the nuclear matrix. The distribution of PLCβ1 
within the nucleus was then analyzed in more detail by double immunofluorescence 
experiments with the R-233 antibody combined with markers of the nuclear envelope 
and lamina, and of different components of the nuclear speckles, where PLCβ1 has been 
detected in various cell types (Avazeri et al., 2000; Tabellini et al., 2003; Martelli et al., 
2005; Bavelloni et al., 2006; Miyara et al., 2008; Fiume et al., 2009). In addition, we 
observed no overlap with antibodies to nuclear pore complex or to lamin B1 (Figs. 27G-
L), indicating that PLCβ1 is internal to the nuclear envelope and lamina. Double 
immunofluorescence against PLCβ1 and the nuclear matrix component NeuN/Fox3, 
recently shown to be a marker of the nuclear speckles in neurons (Dent et al., 2010), 
revealed a similar distribution of both markers and a high overlap between PLCβ1- and 
NeuN/Fox-immunopositive puncta (Figs. 28A-C). Similar results were obtained when 
antibodies against PLCβ1 and SC-35 (a nuclear speckle marker) were combined (Figs. 
28D-F). PLCβ1 was also highly expressed in PIP2-rich regions of neuronal nuclei (Figs. 
28G-I). 
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Figure 28. Combined immunofluo-
rescence of PLCβ1 and nuclear matrix 
markers in neuronal nuclei isolated 
from the adult rat brain cortex. A-C. 
Double PLCβ1- (A) and NeuN-
immunofluorescence (B). Both 
immunostainings exhibited similar 
distribution in the nucleo-plasm (C). 
Numerous PLCβ1-immunopositive 
puncta co-localized with or were in 
close apposition to NeuN-positive 
puncta. D-F. Double PLCβ1- (D) and 
SC-35-immunofluorescence (E). 
PLCβ1-immunlolabeling partially 
overlapped with SC-35-speckles (F). 
G-I. Double PLCβ1- (G) and PIP2-
immunofluorescence (H). The bulk of 
PIP2-signal was confined to speckle-
like structures. Domains exhibiting the 
most intense PLCβ1- and PIP2-
stainings overlapped or were closely 
apposed to each other (H). Scale 
bar = 5 µm. 
 
Results described in this chapter form part of two peer-reviewed publications 
(Montaña et al., 2012; García del Caño et al., 2015) and one review article (García del 
Caño et al., 2014). 
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2. CHARACTERIZATION OF NT2-DERIVED POSTMITOTIC HUMAN 
NEURONS OBTAINED BY SHORT-TERM TREATMENT WITH THE 
NUCLEOSIDE ANALOGUE CYTOSINE Β-D-ARABINOFURANOSIDE 
As mentioned in the introduction, the use of RA/NT2N is limited by the long period 
needed for differentiation and by and the low differentiation rate. Moreover, these 
limitations make this procedure useless for transient transfection-based approaches. 
Thus, we tested the ability of the nucleoside analogues 2'-deoxy-5-azacytidine (DAC) 
and β-D-arabinofuranoside (AraC) to induce a rapid differentiation of NT2 cells and 
compared the results with those obtained by RA-treatment. 
 
2.1. Short exposure of NT2 progenitors to AraC efficiently promotes acquisition 
of neuron-like morphology 
 
Figure 29. Phase-contrast micrographs 
showing cell morphology during the 
course of RA-induced differentiation. 
A. NT2 progenitors. B-D. NT2 cells 
following treatment with 10 µM RA 
during 8 days (B), 2 weeks (C) and 4 
weeks (D). E. RA/NT2N cells isolated 
by mechanical dislodging at week 4 of 
the RA-treatment schedule and 
maintained with antimitotics for 2 
additional weeks. F. Cells remaining 
attached to the flask after mechanical 
dislodging. Arrowheads indicate 
neuron-like cells at different time 
points during RA-induced differen-
tiation. Scale bar = 50 µm. 
 
First, we sought to reproduce the RA-induced differentiation protocol published by 
Pleasure et al. (1992). Eight days after initiation of treatment, a subpopulation of the flat 
and amorphous undifferentiated NT2 precursors (Fig. 29A) began to acquire a typical 
neuronal spindle shape and to develop short neurite extensions (Fig. 29B, arrowheads). 
Neuronal morphologies stood out more clearly after 2 and, even more, after 4 weeks 
(Figs. 29C-D, arrowheads), the time at which postmitotic neurons were mechanically 
isolated. As previously described, following replating of dislodged cells and treatment 
 RESULTS 
	  
 
	  
92 
with antimitotics for 2 weeks, cells organized into aggregates and displayed large 
processes that formed bridges linking clusters of perikarya (Fig. 29E). Our results, 
showing that only 4.4 ± 0.8% (SEM) of the initial population become terminally 
differentiated RA/NT2N cells, were also in line with the observations by Pleasure et al. 
(1992). 
 
Figure 30. Phase-contrast micrographs 
comparing the effects of exposure of 
NT2 cells to equitoxic concentrations 
of RA (10 µM) (A-B), DAC (20 µM) 
(C-D) and cytosine β-D-arabino-
furanoside (AraC, 20 µM) (E-F) 
during 72 h (A, C, E) and 6 days (B, D, 
F). Arrowheads indicate cells 
displaying neurite-like processes. 
Asterisks in C and arrows in D 
indicated different non-neuronal 
morphologies identified in cultures 
treated with DAC. Scale bar = 50 µm. 
Subsequently, we tested the ability of DAC and AraC to promote short-term 
neuron-like differentiation and compared it to that of RA. After 3 days of treatment with 
RA, the vast majority of cells showed no morphological signs of differentiation, 
although a few cells displayed round phase-bright bodies and short processes (Fig. 30A, 
arrowheads). These cells developed longer neurite-like processes (Fig. 30B, arrowhead) 
6 days post-treatment, but remained a very minor component of the total cell 
population. DAC treatment for 3 days resulted in a drastic decrease in cell number, 
although the culture remained confluent due to the large size of the majority of cells, 
which consisted of flat cells with a phase-translucent cytoplasm (Fig. 30C, asterisks). 
Intermingled with them, we could observe a small population of phase-darker cells 
bearing neurite-like processes (Fig. 30C, arrowhead). Six days after DAC treatment 
these later phenotype become more evident (Fig. 30D, arrowheads), but it constituted an 
even smaller minority of cell population. Among the rest of cells, large rounded 
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morphologies were still predominant, together with a less numerous population of 
smaller irregular-shaped cells bearing filopodia-like processes (Fig. 30D, arrows). In 
turn, treatment with AraC for only 3 days resulted in a culture consisting mostly of 
profusely branched large cells of variable morphology, highly suggestive of a neuronal 
phenotype (Fig. 30E, arrowheads). At this time point, the percentage of surviving cells 
relative to the initial NT2 population was 42.18 ± 2.78%. Many surviving cells showed 
a highly polarized morphology with long processes, indicative of their neuronal identity 
(Fig. 30F, arrowheads). 
These cultures were extremely sparse and, indeed, only 10.5 ± 1.3% of the initial 
cell population survived AraC treatment. Therefore, we tested whether survival could be 
improved by increasing cell confluence. For this purpose, after 3 days of AraC 
treatment, cells were harvested, replated at higher density, and treated with AraC for 3 
additional days. In fact, this procedure resulted in a 2-fold increase of surviving cells 
(20.2 ± 3.3% vs. 9.3 ± 1.1%). Figure 29 illustrates morphological changes occurring 
during the first 72 h of AraC-induced differentiation (Figs. 31A-D) and the features of 
the culture at the end of the standard (Fig. 31E) and modified schedules (Fig. 31F). As it 
can be observed, both procedures yielded a culture highly enriched in cells with 
neuronal morphology (AraC/NT2N cells). 
 
Figure 31. Phase-contrast micrographs 
illustrating the time-course of AraC-
induced differentiation (A-E) and the 
effects of increasing cell confluence at 
72 h of AraC treatment in the state of 
cultures after 6-day period of treatment 
(F). Asterisks indicate the presence of 
a population of flat cells with phase-
translucent cytoplasm and non-
neuronal morphology at the end of 
treatment. Scale bar = 50 µm. 
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2.2. Treatment of NT2 cells with AraC for 6 days induces terminal neuron 
differentiation with high efficiency 
To ascertain whether AraC/NT2N cells expressed markers consistent with a 
neuronal phenotype, we analyzed the expression of the neuron-specific cytoskeletal 
proteins neurofilament 200 kDa (NF200), β-III tubulin and doublecortin (DCX) during 
the time-course of RA- and AraC-induced differentiation process. To this end, cell 
homogenates were subjected to SDS-PAGE, immunoblot and semiquantitative 
densitometric analysis (Fig. 32A). Both, RA and AraC led to an increase of NF200 
expression, reaching a maximum at the end of the differentiation process, showing only 
subtle differences in the relative expression level during the time-course of treatments. 
In contrast, the temporal expression profile of β-III tubulin and DCX showed marked 
differences between the RA- and AraC-induction of differentiation. Thus, upon RA 
treatment of NT2 progenitors, the expression of β-III tubulin increased rapidly and then 
decreased, whereas it increased sharply at the end of the AraC treatment. DCX, in its 
turn, increased progressively in RA-treated cells, whereas it showed an up-down 
regulation pattern in AraC-treated cells (Fig. 32A). These distinct temporal expression 
patterns in the time-course RA- and AraC-induced differentiation are discussed (see 
Discussion chapter) in relation to the cell composition of cultures and 
immunocytochemical results. 
Subsequently, we performed immunolabeling experiments for β-III tubulin, NF200 
and DCX in NT2 progenitors, RA/NT2N and AraC/NT2N cells (Figs. 32B-J). No or 
barely detectable NF200-immunolabeling was observed in NT2 cells (Fig. 32B), 
whereas a bright signal could be observed in both RA/NT2N (Fig. 32E) and 
AraC/NT2N (Fig. 32H) cells. Also in good agreement with immunoblot results (Fig. 
32A), β-III tubulin-immunolabeling was diffusely distributed in the cytoplasm of NT2 
progenitors (Fig. 32C), whereas intense immunoreactivity was found in varicosities 
within the neurites of RA/NT2N cells (Fig. 32F) and throughout the cell body and 
neurites or AraC/NT2N cells (Fig. 32I). NT2 cells resulted diffusely stained by anti-
DCX antibody, whereas it gave a strong fluorescent signal in neurites of RA/NT2N 
cells (Fig. 32G) and consistently delineated neurites of AraC/NT2N cells (Fig. 32J). 
The neuronal identity of AraC/NT2N cells was further analyzed by 
immunofluorescence labeling for NeuN/Fox-3 (a marker of adult neurons), combined 
with staining β-III tubulin, in cell cultures treated with AraC for 6 days subjected or not  
to replating on day 3. This was useful to assess the impact these two culture schedules 
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Figure 32. A. Results of immunoblots and semiquantitative densitometric analysis of 
immunoreactivity for neuronal markers NF200, β-III tubulin and DCX during RA- and AraC-
induced differentiation. Immunoblots were performed in whole homogenates of cells harvested 
at different time points of differentiation using RA- (NT2 progenitors, 48 h, 7 days, 14 days, 28 
days and terminally differentiated RA/NT2N neurons) and AraC (NT2 progenitors, 24 h, 48 h, 
72 h and terminally differentiated AraC/NT2N neurons). The amount of protein loaded per lane 
was 5 µg for immunoblots against NF200 and β-III tubulin, and 20 µg for immunoblots against 
DCX. The y-axis of graphs shows percent optical density of each band normalized to the 
highest value found during the time-course of differentiation. Error bars indicate SEM (n=4). 
(Continues in next page) 
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in neuronal enrichment and maturation. Nuclei of NT2 cells displayed a very weak 
NeuN/Fox-3 immunofluorescence signal (Figs. 33A-B), whereas dense 
immunoreactivity could be observed in nuclei of β-III tubulin-immunopositive 
AraC/NT2N neurons, irrespectively of the culture schedule used (Figs. 33C-F). 
Consistent with these results, NeuN/Fox-3 was almost undetectable by Western blot of 
NT2 cell homogenates. Immunoreactivity began to be clearly detectable after 48 h of 
AraC-treatment and reached a maximum at the end of the 6 days treatment period and 
no differences could between samples obtained from the two different treatment 
schedules (Fig. 33G).  
Because cultures of NT2 cells treated for 6 days with AraC still contained a 
population of presumably non-neuronal cells, NeuN/Fox-3 staining, together with 
morphological features, was used to evaluate the efficiency of both schedules to induce 
neuronal differentiation. For this purpose we performed cell counts on cell cultures 
doubly immunolabeled for NeuN/Fox-3 and β-III tubulin, and cells negative for 
NeuN/Fox-3 and those displaying round shapes with no or short processes were 
considered to be non-neuronal. Using these criteria, we concluded that 55.4 ± 2.4% and 
71.3 ± 3.9% of cells exposed to AraC for 6 days without replating and those subjected 
replating on day 3 fulfilled criteria to be considered as AraC/NT2N neurons, 
respectively. Using these values and the percentage of surviving cells following 6 days 
of treatment with AraC (see above) we could conclude that 5.14 ± 0.6% and 14.4 ± 
2.3% of the initial population of NT2 progenitors became terminally differentiated 
AraC/NT2N neurons (Fig. 33H). 
Finally, AraC/NT2N cells (Figs. 34B, D), but not NT2 progenitors (Figs. 34A, C), 
were strongly immunolabeled for MAP2 (Fig. 34B) and voltage-dependent sodium 
channel 1.6 (Nav 1.6) (Fig. 34D) proteins, further indicative of their adult phenotype 
and suggestive of their ability to generate action potentials, respectively. 
 
 
 
_____________ 
Figure 32. B. Micrographs of NT2 cells (B-D) and terminally differentiated RA/NT2N (E-G) 
and AraC/NT2N (H-J) neurons immunolabeled (green) for NF200 (A, E, H), DCX (C, F, I) and 
β-III-tubulin (D, G, J) combined with chromatin staining using the Hoechst’s dye 
(pseudocoloured red). Micrographs are maximum intensity projections of four consecutive 
optical sections separated by 0.24 µm, obtained using the structured illumination module 
(ApoTome) of a fluorescence microscope (Carl Zeiss Axio Observer) equipped with a XYZ 
motorized stage. Scale bar = 20 µm.  
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Figure 33. A-F. Fixed NT2 progenitors (A-
B) and NT2 cells subjected to treatment 
with AraC under two different culture 
schedules (C-F), processed for double-
immunofluores-cence against β-III-Tubulin 
(green) and NeuN/Fox-3 (red) combined 
with Hoechst’s chromatin staining (blue). 
NT2 cells in C-D were treated 
uninterruptedly with AraC. Cells in E-F 
were treated for 3 days, replated at higher 
density on day 3, and then treated for 3 
additional days. Micrographs are maximum 
intensity projections of four consecutive 
optical sections separated by 0.24 µm, 
obtained using the structured illumination 
module (ApoTome). Scale bar = 20 µm. G. 
Western blot analysis of NeuN/Fox-3 
expression in total cell lysates (30 µg) at 
different time points of standard AraC-
induced differentiation and under replating 
conditons. H. Bar graph shows the 
percentage yield of terminally differentiated 
NT2N neurons obtained by differentiation 
with RA and with AraC under the two 
culture schedules mentioned above. Data 
are mean ± SEM. One-way ANOVA 
followed by post hoc Bonferroni’s test 
(n=3; *p<0.05, **p<0.01). 
 
 
Figure 34. NT2 progenitors (A, C) and 
AraC/NT2N neurons (B, D) processed 
for double-immunofluorescence 
against MAP2 (red) and β-III-Tubulin 
(green) (A-B), or the voltage-
dependent sodium channel Nav 1.6 
(red) (C-D) and β-III-Tubulin (green), 
both combined with Hoechst’s 
chromatin staining (blue). Micrographs 
are maximum intensity projections of 
four consecutive optical sections 
separated by 0.24 µm, obtained using 
the structured illumination module 
(ApoTome). Scale bar = 20 µm. 
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Collectively, these results demonstrate the effectiveness of AraC to promote 
neuronal differentiation of NT2 cells in a short time period and highlight the importance 
of optimizing culture conditions. 
 
2.3. Cells identified as AraC/NT2N neurons are morphometrically distinguishable 
from non-neuronal cells 
To assess whether phenotypes classified as neuronal and non-neuronal after AraC-
induced differentiation were morphometrically distinguishable, we analyzed the average 
nuclear and whole cell area of both cell populations, classified on the basis of 
NeuN/Fox-3 expression and morphological features The methodology used for 
morphometric analysis is illustrated in figures 35A-F and described in detail in 
Methods. 
The average nuclear area of cells classified as non-neuronal was considerably larger 
(851.53 ± 27.63 µm2) than nuclear area of AraC/NT2N neurons (339.67 ± 11.91 µm2), 
whereas no differences in total cell area were observed (3122.36 ± 95.06 and 3326.82 ± 
177.68 µm2, respectively). Consequently, the ratio of nuclear area to total cell body area 
was about 2-fold higher in non-neuronal cells (0.280 ± 0.007) than in AraC/NT2N cells 
(0.128 ± 0.008) (Fig. 35G). These results clearly reinforce the reliability of criteria used 
to classify cell phenotypes resulting from exposure of NT2 progenitors to AraC 
treatment. 
Comparison of the nuclear area between neurons committed to differentiate with 
either RA or AraC showed that nuclei of AraC/NT2N neurons (339.78 ± 12.03 µm2) 
were 4.7-fold larger than those of RA/NT2N neurons (72.37 ± 1.85 µm2). Similarly, the 
average soma area of AraC/NT2N neurons (1103,15 ± 41.69 µm2) was about 6.8-fold 
larger compared to that of RA/NT2N neurons (162.70 ± 4.46 µm2). Consequently, the 
ratio of nuclear to body area tended to equalize in both phenotypes, although it was 
significantly lower in AraC/NT2N (0.344 ± 0.017) than in RA/NT2N (0.45 ± 0.008) 
neurons (Fig. 35H). The average value obtained here for area of nuclei of RA/NT2N 
neurons was more than double compared that obtained in a recent study (Haile et al., 
2014). This difference is discussed (see Discussion chapter) in relation to the different 
culture conditions used. Finally, neurites of AraC/NT2N neurons were 105,33 ± 3,55 
µm long in average, which represent less than half the value reported by Haile et al. 
(2014) in RA/NT2N neurons (Table 7). This, together with a lower number of neurites 
per cell (1.85 ± 0.10) found in AraC/NT2N neurons, makes total arborization 4.2-fold 
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longer in RA/NT2N neurons (Table 7). 
 
 
Figure 35. A-F. Illustration of image processing for morphometric analysis of non-neuronal and 
AraC/NT2N neuronal phenotypes. Mosaic images of cell cultures processed for double 
immunolabeling for NeuN/Fox-3 (red) and β-III-tubulin (green) combined with Hoechst’ 
staining (blue) were captured under a 20 X objective (A). The β-III-tubulin and NeuN (B) 
channels were used to identify cells of non-neuronal (arrows) and neuronal (arrowheads) 
phenotypes. Binary images Hoechst-stained nuclei (C) and inverted grayscale images of β-III-
tubulin immunostaining (D) were used to measure the nuclear and whole cell areas of non-
neuronal (E, cyan-filled cells) and neuronal cells (E, green-filled cells). Neuronal somata and 
neurites were measured on grayscale images of β-III-tubulin immunostaining (F) (see Methods 
for further details). Scale bar = 100 µm. G-H. Bar graphs show results of morphometric 
analyses to compare non-neuronal and AraC/NT2N cells grown in identical conditions (G) and 
RA/NT2N and AraC/NT2N (H). All data represent average values obtained from 99 cells in 
three independent experiments. Two-tailed unpaired t-test (***p < 0.001). 
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Table 7. Neurite length of RA/NT2N and AraC/NT2N neurons. 
 RA/NT2N1 AraC/NT2N 
Average neurite length (µm2) 
Number of neurites/cell 
Total neurite length/cell (µm2) 
239.56 ± 8.9 
3.17 ± 0.04 
759.40 
105.33 ± 3.55 
1.85 ± 0.10 
179.96 ± 9.19 
1Data of RA/NT2N cells are from Haile et al. (2014). 
2.4. AraC/NT2N co-express glutamatergic and cholinergic phenotypic markers 
To assess whether AraC/NT2N cells can be a source of specific neurotransmitter 
phenotypes, the expression of glutamatergic, cholinergic, GABAergic and dopaminergic 
specific-markers was analyzed by means of immunofluorescence microscopy and 
Western blot in cell homogenates. For this purpose, we used specific antibodies to 
vesicular glutamate transporter 1 (VGluT1), choline acetyl transferase (ChAT), 
glutamate decarboxylase 67 kDa (GAD67) and tyrosine hydroxylase (TH) enzymes. Rat 
brain homogenates and total cell lysates of the human U87 glioma cell line were used as 
positive and negative controls, respectively. In rat brain homogenates anti-VGluT1 
antibody recognized several strong bands migrating below the 75 kDa marker, which 
were within the range of molecular sizes predicted for annotated splice variants of rat 
(61.6-64.3 kDa) origin. Additionally, a minor band slightly below the 50 kDa marker 
was observed, in agreement with the supplier’s control (Fig. 36). VGluT1-
immunoreactivity in undifferentiated samples from NT2 cells was slightly above the 
threshold level, whereas two clear bands were detected in NT2 cells treated with AraC 
for 72 h and in AraC/NT2N cells: an upper minor one located between the 75 and 50 
kDa markers, probably corresponding to the human VGluT1 isoform 1 (61.6 kDa) and a 
lower major one slightly below the 50 kDa marker, close to the size predicted for the 
human VGluT1 isoform 2 (53.9 kDa). Indeed, this antibody recognizes both isoforms as 
described by supplier. VGluT1 signal was barely detectable in cell homogenates from 
NT2 cells treated with retinoic acid during 4 weeks and from RA/NT2N cells (Fig. 36). 
Remarkably, non-neuronal NT2A cells (those remaining attached to the flask after 
mechanical isolation of neuronal cells) displayed strong VGluT1-immunoreacivity. 
Only a weak signal at the level of the upper band seen in NT2A cells could be observed 
in U87 cells, along with two larger sized bands. A strong ChAT-immunoreactive band 
with an apparent molecular mass consistent with the predicted size for the ChAT 
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enzyme of rat origin (72,4 kDa) was detected in homogenates from adult brain (Fig. 36). 
A net immunoreactive band, migrating slightly below the one observed in rat brain 
homogenates, was clearly detectable in homogenates from NT2 progenitors, its apparent 
molecular mass being well consistent with the theoretical size of the human ChAT 
isoform R (70.4 kDa). ChAT-immunoreactivity increased markedly after 72 h of 
treatment with AraC and returned to levels observed in NT2 progenitors at day 6. ChAT 
protein could be detected in cell homogenates from cells treated during 4 weeks with 
RA, but not in RA/NT2N samples, and strong ChAT-immunoreactivity was found in 
homogenates from NT2A cells (Fig. 36). These data indicate that expression of ChAT 
in non-neuronal NT2A cells account for the immunoreactivity observed in samples from 
cultures at 4 weeks of RA treatment, which are composed of a mixture of neuronal and 
NT2A cells. A ChAT-positive band was also seen in immunoblots of U87 cell 
homogenates (Fig. 36). In rat brain samples, GAD67 antibody detected a strong band of 
a size consistent with the theoretical 66.6 kDa molecular mass of the rat protein. No 
detectable signal was observed in NT2 cell and AraC-treated samples. A positive band, 
consistent with the molecular mass of human GAD67 (66.9 kDA), appeared after 4 
weeks of RA-treatment (Fig. 36). This signal increased markedly in RA/NT2N cells and 
was also detectable in NT2A but not U87 samples. An additional smaller-sized band 
was detected in samples of NT2, AraC-treated, RA/NT2N and NT2A cells, being 
particularly intense in the NT2A samples (Fig. 36). Because the antibody used does not 
cross-react with GAD65, this band is presumed to be either unspecific or a degradation 
product, although the possibility of posttranslational modification cannot be ruled out. 
Finally, in rat brain homogenates, TH antibody detected a strong specific band 
migrating above the 50 kDa marker, but we found no TH-immunoreactivity in any of 
the cell samples analyzed even after overexposure of Western blots (Fig. 36). 
 
Figure 36. Western blot analysis of neurotransmitter 
phenotype markers in total cell lysates from NT2 
cells (20 µg) during the RA- and AraC-induced 
differentiation. Rat brain homogenates (4 µg) and 
human U87 glioma cell line lysates (20 µg) were 
used as positive and negative controls, respectively. 
Specific antibodies to vesicular glutamate transporter 
1 (VGluT1), choline acetyl transferase (ChAT), 
glutamate decarboxylase 67 kDa (GAD67) and 
tyrosine hydroxylase (TH) enzymes were used as 
glutamatergic, cholinergic, GABAergic and 
dopaminergic phenotype markers. 
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In agreement with the results of Western blot analysis, NT2 progenitors exhibited 
barely detectable VGlut1-immunofluorescence (Fig. 37A), whereas bright staining was 
detected throughout cells processes of cells differentiated into neurons by AraC 
treatment for 72 h and 6 days (Figs. 37B-C). In the same immunocytochemical staining 
conditions, VGluT1-signal was seen as bright foci restricted to varicosities on a small 
subset of neurites of RA/NT2N cells (Fig. 37D). ChAT-immunoreactivity was diffusely 
distributed throughout the cytoplasm of NT2 progenitors (Fig. 37E) and extended to 
neurites of AraC-differentiated cells (Figs. 37F-G), but no signal above the background 
level was detected in RA/NT2N neurons (Fig. 37H). NT2 progenitors and AraC-treated 
cells were nearly devoid of GAD67-immunofluorescence staining (Figs. 37I-K), 
whereas most neurites of RA/NT2N cell displayed bright staining (Fig. 37L). 
 
Figure 37. Immunolabeling (green) against VGlut1 (A-D), ChAT (E-H) and GAD67 (I-L) 
combined with Hoechst’s chromatin staining (pseudocoloured in red) in fixed NT2 cells, cells 
treated for 72 h with AraC, and AraC/NT2N and RA/NT2N neurons. Micrographs are 
maximum intensity projections of three consecutive optical sections separated by 0.24 µm, 
obtained by structured illumination microscopy (ApoTome). Scale bar = 20 µm. 
 
Immunofluorescence staining showed that virtually all AraC/NT2N neurons were 
both VGluT1- and ChAT-immunopositive, strongly indicating that these cells co-
express glutamatergic and cholinergic markers. Thus, we carried out double 
VGluT1/ChAT-immunofluorescence staining, showing that every VGluT1-positive 
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neuron also expressed ChAT (Fig. 38A). Although both markers were distributed in 
neurites of AraC/NT2N cells, VGluT1-immunofluorescence was highly polarized to 
neurites, whereas anti-ChAT antibody also stained flat lamellipodia (Figs. 38B-D). 
Because cells committed to differentiate into neurons by AraC treatment cannot be 
physically separated from non-neuronal cells for Western blot analysis, 
immunofluorescence analysis allowed us to compare these two cell phenotypes with 
respect to the expression of VGluT1 and ChAT. VGlut1-immunoreactivity in flat 
polygonal non-neuronal cells (Figs. 36B-D, stars) was mostly restricted to perinuclear 
locations (Fig. 38B), whereas ChAT-staining extended further to the whole cytoplasm 
(Fig. 38C), even delineating the whole cellular perimeter. 
 
Figure 38. Epifluorescence microscopy images of AraC/NT2N cells processed for double 
immunofluorescence to VGlut1 (red) and ChAT (green) combined with Hoechst’s staining 
(blue). A. Panoramic view corresponding to a mosaic from multiple images captured with a 20 
X objective. B-D. Higher magnification of the area framed in A for a better view of VGlut1- (B) 
and ChAT-immunofluorescence (C) distribution in an AraC/NT2N neuron (arrowhead) and in 
non-neuronal cells (stars). Scale bars = 100 µm in A; 50 µm in D. 
  
 RESULTS 
	  
 
	  
104 
3. THE PC12 CELL LINE AS A MODEL OF NEURONAL DIFFERENTIATION 
The PC12 cells line, derived from rat pheochromocytoma is a well-established 
model of sympathetic neuron differentiation. When exposed to NGF, PC12 cells 
undergo neuronal differentiation, acquire morphological and phenotypic features typical 
of sympathetic neurons, and synthesize and store the catecholamines dopamine and 
norepinephrine (Greene and Tischler, 1976). 
 
3.1. Morphometric analysis 
Proliferating PC12 cells, which are devoid of processes and display a rounded 
shape (Fig 39A), acquire a highly polarized morphology with long neurites and a 
triangular-shaped soma upon exposure to NGF (Fig. 39B). As described by Ignatius et 
al. (1985) cells are defined as differentiated when neurites are at least two cell body 
diameters long. Thus, we measured on phase-contrast images the diameter of cell bodies 
and neurite length (Figs. 39A-B) at 18, 24, 48, 72 and 96 h (100 cells per time point) 
after the beginning of NGF stimulation, and calculated the ratio between these two 
parameters. Then, we used this morphometric index to establish the time point at which 
differentiation is achieved after NGF treatment in our culture conditions. To this end 
mean values were fit by linear regression (Fig. 39C), and the resulting equation allowed 
us to calculate that 41 h after the beginning NGF treatment neurites reached a length of 
two body diameters (Fig. 39C, dashed line). 
 
 
Figure 39. A-B. Phase-contrast micrographs of proliferating PC12 cells (A) and differentiated 
PC12 cells by treatment with NGF (50 ng/mL) during 96 h (B). C. Graph showing the ratio 
between neurite length and diameter of cell soma during time-course of NGF-induced 
differentiation. Values were fitted by linear regression analysis. Data are mean ± SEM (n=100). 
Scale bar = 25 µm. 
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3.2. Analysis of neurofilament 200 kDa expression 
It has been described that NGF treatment leads to rapid upregulation of NF68 (68 
kDa), NF160 (160 kDa), and NF200 (200 kDa) subunits in PC12 (Xu et al., 2012). 
Therefore, expression of these proteins can be used as an additional indicator of 
neuronal differentiation. Here we analyzed the expression of the neuronal marker 
NF200 in proliferating and differentiated PC12 cells. As shown in figures 40A-B, 
NF200-immunofluorescence increased in cells treated with NGF during 96 h. 
Consistently, NF200 was barely detectable in whole cell homogenates of untreated 
PC12 cells, whereas it was clearly detectable after 96 h of NGF treatment (Fig. 40C). 
Optical density analysis of immunoreactive bands showed that NF200-
immunoreactivity increased significantly by about 3.5-fold in NGF treated PC12 cells 
with respect to proliferating cells (Fig. 40C). 
 
	  
Figure 40. A-B. NF200-immunofluorescence (green) combined with Hoechst’s chromatin 
staining (pseudocoloured in red) in fixed progenitor cells (A) and PC12 cells treated with NGF 
for 96 h (NGF/PC12 neurons). Scale bar = 50 µm. C. Results of immunoblots and 
semiquantitative densitometric analysis of immunoreactivity for the neuronal marker NF200. 
Immunoblots were performed in whole homogenates (5 µg of protein) of PC12 progenitors and 
NGF/PC12 neurons. The y-axis of the graph shows mean percent optical density normalized to 
the value in PC12 progenitor cells. Data are mean ± SEM (n=6). Two-tailed unpaired t-test 
(***p < 0.001). 
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4. PHOSPHOLIPASE Cβ1 DURING NEURONAL DIFFERENTIATION OF 
NT2 CELLS: EXPRESSION AND SUBCELLULAR LOCALIZATION 
As a first descriptive approximation previous to the study of the role of PLCβ1 in 
neuronal differentiation of NT2 cells, using Western blot and high-resolution 
fluorescence microscopy, we performed an extensive analysis of the time-course of 
PLCβ1 expression during RA- and AraC-induced differentiation of NT2 cells. 
 
4.1. PLCβ1a and PLCβ1b expression in subcellular fractions of NT2 cells 
As described in the introduction, we carried out a modification of a well described 
subfractionation protocol (Fiume et al., 2010) that enables to obtain highly purified 
nuclei from cultured cells. By this modification it was possible to separate a fraction of 
highly purified nuclei (N) along with plasma membrane fraction (P2), a fraction 
enriched in intracellular membranes (S2) and a cytosolic fraction (Cyt). 
 
Figure 41. A. Percentage of protein recovered in each subcellular fraction of NT2 progenitors. 
Data are mean ± SEM (n=4). B. Phase-contrast micrograph of intact nuclei isolated from NT2 
cells. Scale bar = 40 µm. 
As depicted in the bar graph in figure 41A, the percentage of protein recovered in 
each fraction over the total was 24.1 ±1.7%, 42.7 ±0.7%, 5.9 ±0.7% and 27.4 ±1.6% in 
Cyt, S2, P2 and N fractions, respectively. This procedure preserved morphological 
features of isolated nuclei (Fig. 41B). Indeed, about 7 x 106 nuclei were isolated from 
each 150 cm2 flask, which corresponds to an efficiency of more than 80% considering 
the amount of cells present in a 150 cm2 flask at 70-80% confluence. 
Subsequently, we analyzed by Western blot the enrichment of the Cyt, P2 and N 
fractions in specific markers of subcellular components. Specifically, antibodies against 
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to β-tubulin, α1 subunit of Na+/K+ ATPase and Histone H1 were used as specific 
markers of Cyt, P2 and N fractions. Additionally, antibodies against the endoplasmic 
reticulum (ER) chaperone binding immunoglobulin protein (BiP) and against the Golgi 
58K protein were used to assess the possible cross-contamination of subcellular 
fractions. 
As shown in figure 42, the cytoskeletal protein β-Tubulin was strongly detected in 
Cyt, whereas the α1 subunit of Na+/K+ ATPase and histone H1 were highly enriched in 
P2 and N fractions, respectively. None of the three markers was detected in 5 µg of 
whole cell homogenate. In contrast, strong immunoreactivity was observed for the 
Golgi marker Golgi 58K, indicating that Golgi membranes had been pelleted in the first 
centrifugation at low-speed and then completely solubilized and washed from intact 
nuclei by treatment with the non-ionic detergent Igepal. Indeed, no Golgi 58K-
immunoreactivity was found in N fraction. BiP signal was similar in whole homogenate 
and P2 fraction, and weaker in Cyt fraction, suggesting some contamination of P2 and, 
to a lesser extent, of Cyt by ER components. In view that BiP is not enriched in P2 and 
that this fraction constitutes only 5.9 ±0.7% of the total protein (Fig. 41), it can be 
inferred that the bulk of ER is partitioned into the first pellet and then solubilized by 
treatment with Igepal. 
Therefore, these results show that Cyt, P2 and N fractions are highly enriched in 
cytosolic, plasma membrane and nuclear proteins, respectively. 
 
 
Figure 42. Western blot analysis of Cyt, P2 
and N fractions obtained from NT2 progenitor 
cells with antibodies against subcellular 
fraction-specific antigens. For each marker, 
equal amounts of total protein (5 µg) were 
loaded on the same gel. 
 
Once the different fractions had been tested for purity, we evaluated the partitioning 
of PLCβ1a and PLCβ1b isoforms into cytosolic, plasma membrane and nuclei. To this 
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end, equivalent volumes of Cyt, P2 and N were resolved in parallel by SDS-PAGE. 
Immunoblots were performed using a mouse monoclonal antibody  raised against a 
peptide mapping at the N-terminus of PLCβ1 common to both PLCb1a and PLCb1b 
variants (PLCβ1N-ter antibody, see Table 1 in Materials). 
Western blot analysis showed that PLCβ1-immunoreactivity was highest in N, 
followed by P2 and Cyt fractions (Fig. 43), although no-significant differences were 
observed (Bar graph in Fig. 43). 
 
Figure 43. Western blot analysis of PLCβ1a 
and PLCβ1b expression in Cyt, P2 and N 
fractions obtained from NT2 progenitor cells. 
Equal volumes of each sample were loaded 
(40 µL) and run in parallel on the same gel. 
Bar graph depicts the OD of PLCβ1a and 
PLCβ1b immunoreactivity for each fraction, 
relative to total PLCβ1 (PLCβ1a and PLCβ1b) 
optical density in Cyt extract (normalized to 
1). The different shading inside bars depicts 
the relative contribution of PLCβ1a and 
PLCβ1b to the total signal. Data are mean ± 
SEM (n=4). 
Regarding the contribution of splice variants to the total signal, PLCβ1a was more 
abundant than PLCβ1b in all fractions analyzed. Thus, the PLCβ1a/PLCβ1b OD ratios 
were 1.41 ± 0.05%, 1.89 ± 0.13%, and 1.27 ± 0.07 in Cyt, P2 and N fractions, 
respectively. Statistically significant differences in PLCβ1a/b ratios were detected 
between Cyt and P2 and between P2 and N (both p < 0.01, one-way ANOVA followed 
by Tukey's test, n=4). 
 
4.2. Time-course of expression of PLCβ1a and PLCβ1b variants during RA-
induced differentiation of NT2 progenitors 
4.2.1. Western blot analysis 
Western blot analysis of whole homogenates from cells at different time points 
during RA-induced differentiation revealed a drastic increase of PLCβ1 
immunoreactivity one week after initiation of RA treatment, which remained elevated 
until day 28. In contrast, PLCβ1-immunoreactivity in isolated RA/NT2N neurons was 
equivalent to that found in NT2 cells, whereas in non-neuronal NT2A cells (remaining 
attached to the flask after mechanical dislodging of neurons at day 28, see section 2 in 
Results) was as high as that in NT2 cells between days 7 and 28 (Fig. 44). 
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Figure 44. Results of Western blot and 
semiquantitative densitometric analysis of 
PLCβ1-immunoreactivity. Immunoblots 
were performed in whole homogenates of 
NT2 progenitors, RA-treated cells (48 h, 7 
d, 14 d, 28 d), terminally differentiated 
RA/NT2N neurons and non-neuronal 
NT2A cells remaining attached to the flask 
after mechanical dislodging of neurons (see 
section 2 of Results). Equal amounts of 
total protein (12 µg) were loaded from 
each sample in the same gel (n=4). The y-
axis of the  graph  shows  relative optical 
density (OD) expressed as percent of that found in NT2 progenitor cells (normalized to 100%). 
Repeated measures one-way ANOVA followed by Tukey's post-hoc test. Significant differences 
between the different samples with respect to NT2 progenitors are shown (*p < 0.05; **p < 
0.01; ***p < 0.001). Data are mean ± SEM (n=4). 
 
The strong PLCβ1-immunoreactive signal made impossible to discern the splice-
variant specific bands between days 7 and 28. To overcome this problem, the amount of 
total protein loaded was readjusted for each condition, such that non-saturating signals 
could be obtained at all time point (details in the legend of Fig. 45). This enabled to 
resolve quantifiable signals for PLCβ1a and PLCβ1b bands in all samples. The percent 
changes in expression were corrected for amount of protein loaded. 
 
Figure 45. A. Western blot analysis of 
PLCβ1a and PLCβ1b expression during 
RA-induced differentiation. Immunoblots 
were performed in whole homogenates at 
the same time points shown in figure 44, 
but loading different amounts of total 
protein (from lane 1 to 7: 37.5, 37.5, 12.5, 
12.5, 12.5, 37.5 and 12.5 µg). Relative 
optical density (OD) is expressed as 
percent of that found for total PLCβ1 
(PLCβ1a + PLCβ1b) in NT2 progenitor 
cells (normalized to 100%). Two-way 
ANOVA with post-treatment time (NT2, 
48 h, 7 d, 14 d, 28 d, NT2N and NT2A) 
and splice variant (PLCβ1a and PLCβ1b) 
as the main factors followed by 
Bonferroni's post-hoc test. Significant 
differences between ODs for each splice 
variant in different samples with respect to 
OD found for the corresponding splice 
variant in NT2 progenitors are shown 
(***p < 0.001). B. Time-course of ratios 
between PLCβ1a and PLCβ1b 
immunoreactivity during RA-induced 
neuronal differentiation of NT2 cells. All 
data are mean ± SEM (n=2). 
 
As represented in figure 45, the expression of both splice variants increased 
significantly between days 7 and 28. However, the ratio between PLCβ1a and PLCβ1b 
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tended to equalize as differentiation progressed, and this ratio was inverted in non-
neuronal NT2A cells (Fig. 45B), although no statistically significant changes were 
detected by one-way ANOVA analysis. 
 
4.2.2. Fluoresecence microscopy analysis 
Results obtained by Western blot analysis were extended by combined PLCβ1 and 
NF200 immunofluorescence and high-resolution fluorescence microscopy. For this 
study, the monoclonal PLCβ1 (D-8) antibody raised against a synthetic peptide 
corresponding to an epitope mapping within an internal region of PLCβ1 (amino acids 
831-1063) common to PLCβ1a and PLCβ1b (see Table 1 in Materials). 
As illustrated in figure 46, PLCβ1-signal was barely detectable in NT2 progenitors, 
which were NF200-negative (Figs. 46A-B). An increase in PLCβ1-immunoreactivity 
was observed 48 h after the onset of RA-treatment. At this time point, cells began to 
express NF200, which colocalized with PLCβ1 (Fig. 46C-D). PLCβ1-immunostaining 
consisted of a dense juxtanuclear ball form which fibrilar-like processes emanated. 
PLCβ1-immunolabeling displayed a similar distribution pattern after 7 days of RA 
treatment, although immunostaining intensity increased considerably. In contrast, 
NF200-immunoreactivity increased only in a small proportion of cells, whereas it was 
undetectable in the vast majority of them (Fig. 45F). This is consistent with Western 
blot results showing a rapid increase in NF200-immunoreactivity at 48 h followed by 
progressive decrease until day 28 (Fig. 32A). The most noticeable change at day 28 was 
that NF200-immunopositive cells showed considerable less PLCβ1-immunoreactivity 
than NF200-negative cells (Fig. 46H), suggesting that PLCβ1 is downregulated as cells 
acquire neuronal fate. In agreement with this, after removal of neuronal cells by 
mechanical dislodging, NF200-immunoreactivity virtually disappeared from cultures of 
remaining non-neuronal NT2A cells, which displayed bright PLCβ1-immunostaining 
(Figs. 46K-L). RA/NT2N neurons, treated with antimitotics for 2 weeks after 
mechanical dislodging, showed intense nuclear PLCβ1-immunoreactivity. PLCβ1-
signal in the neuronal body and neurites was hardly visible when exposure settings were 
adjusted to avoid saturation of the nuclear signal (Figs. 46I-J). Notably RA/NT2N 
neurons displayed dense NF200 immunoreactivity (Fig. 46J), in agreement with 
Western blot analysis (Fig. 32A). 
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Figure 46. Double-immunofluorescence against PLCβ1 (D-8) (red) and NF200 (green) combined with Hoechst’s chromatin staining (blue) in fixed NT2 
progenitor cells (A-B), NT2 cells treated with RA 10 µM for 48 h (C-D), 8 days (E-F), 4 weeks (G-H), RA/NT2N neurons (I-J) and non-neuronal NT2A cells 
(K-L). Micrographs are maximum intensity projections of four consecutive optical sections separated by 0.24 µm, obtained using the structured illumination 
module (ApoTome). Scale bar = 20 µm. 
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4.3. Time-course of expression of PLCβ1a and PLCβ1b variants during AraC-
induced differentiation of NT2 progenitors 
4.3.1. Western blot analysis 
Treatment of NT2 cells with AraC led to an progressive increase in PLCβ1-
immunoreactivity over 72 h after the initiation of AraC treatment (Fig. 47). AraC 
appeared to have a more acute effect than RA (compare Figs. 44 and 47). Similarly to 
that observed during RA-induced differentiation, PLCβ1-immunoreactivity returned 
nearly to basal levels in terminally differentiated neurons. 
Similarly to that observed during RA-induced differentiation, strong PLCβ1-
immunoreactive signals at 48 and 72 h made impossible to discern the splice-variant 
specific bands. Therefore, the same strategy was used to overcome this inconvenience 
(see section 4.2.1.). Thus the amount of total protein loaded was readjusted for each 
condition, such that non-saturating signals could be obtained at all time point (details in 
the legend of Fig. 47) and the percent changes in expression were corrected for amount 
of protein loaded. 
 
Figure 47. Results of immunoblots and 
semiquantitative densitometric analysis of 
PLCβ1-immunoreactivity. Immunoblots 
were performed in whole homogenates of 
NT2 progenitors, AraC-treated cells (12, 
24, 48 and 72 h) and AraC/NT2N cells. 
Equal amounts of total protein (12 µg) 
were loaded from each sample in the same 
gel. The y-axis of the graph shows relative 
optical density (OD) expressed as percent 
of that found in NT2 progenitor cells 
(normalized to 100%). Repeated measures 
one-way ANOVA followed by Tukey's 
post-hoc test. Significant differences 
between the different samples with 
respect to NT2 progenitors are shown 
(***p < 0.001). Data are mean ± SEM 
(n=4). 
 
As illustrated in figure 48A, two way-ANOVA and Tukey's post-hoc test showed 
that PLCβ1a- and PLCβ1b-expression remained significantly increased at all time 
points analyzed. The expression of both splice variants increased progressively, 
reaching a maximum between 48 and 72 h post-treatment and then decreasing at the end 
of differentiation. The ratio between PLCβ1a and PLCβ1b tended to equalize during the 
first 72 h of treatment, but returned to values found in NT2 progenitors at the end of 
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AraC treatment. In any case, no statistically significant changes were detected (Fig. 
48B). 
 
Figure 48. Western blot analysis of 
PLCβ1a and PLCβ1b expression during 
AraC-induced differentiation. Immunoblots 
were performed in whole homogenates at 
the same time points shown in figure 47, 
but loading different amounts of total 
protein (from lane 1 to 6: 37.5, 25, 12,5, 
12,5, 25 and 37.5 µg). Relative optical 
density (OD) is expressed as percent of that 
found for total PLCβ1 (PLCβ1a + PLCβ1b) 
in NT2 progenitor cells (normalized to 
100%). Two-way ANOVA with post-
treatment time (NT2, 12 h, 24 h, 48 h, 72 h, 
AraC/NT2N) and splice variant (PLCβ1a 
and PLCβ1b) as the main factors followed 
by Bonferroni's post-hoc test. Significant 
differences between ODs for each splice 
variant in different samples with respect to 
OD found for the corresponding splice 
variant in NT2 progenitors are shown  
(***p < 0.001). B. Time-course of ratios 
between PLCβ1a and PLCβ1b 
immunoreactivity during RA-induced 
neuronal differeniation of NT2 cells. All 
data are mean ± SEM (n=2). 
 
Comparison of the time-course of PLCβ1-, and neuronal markers-expression 
(NF200 and β-III-tubulin) during AraC-induced differentiation (Fig. 49), showed that 
PLCβ1-upregulation preceded the increment in expression levels observed for NF200 or 
β-III-tubulin, suggesting that PLCβ1 could be involved in modulation of neuron-specific 
gene expression. 
 
 
Figure 49. Comparison of the time-
course of PLCβ1- and neuronal marker-
expression (NF200 and β-III-tubulin) 
during AraC-induced differen-tiation. 
Optical density values were normalized 
to optical density at the time point 
showing the highest expression level for 
each protein. All data are mean ± SEM 
(PLCβ1, n=4; NF200 and β-III-tub, 
n=3). 
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Figure 50. Double-immunofluorescence against PLCβ1D-8 (red) and NF200 
(green) combined with Hoechst’s chromatin staining (blue) in fixed NT2 
progenitor cells (A-B), NT2 cells treated with AraC 20 µM for 24 h (C-D), 48 
h (E-F), 72 h (G-H) and AraC/NT2N (I-J). Micrographs are maximum 
intensity projections of four consecutive optical sections separated by 0.24 
µm, obtained using the structured illumination module (ApoTome). Scale bar 
= 20 µm. 
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4.3.2. Fluorescence microscopy analysis 
Results obtained by Western blot analysis were extended by combined PLCβ1 and 
NF200 immunofluorescence and high-resolution fluorescence microscopy using the 
monoclonal PLCβ1 (PLCβ1D-8) antibody (see Table 1 in Materials). 
As illustrated in figure 50, PLCβ1-immunolabeling increased considerably in NT2 
cells treated with AraC for 24 h when compared with NT2 progenitor cells (Figs. 50 A-
D). PLCβ1-signal was intense in neurites and diffusely distributed in the cell nucleus. 
NF200 was highly upregulated in a subset of cells (Figs. 50C-D, asterisk), where it 
colocalized in growth-cone like structures (Figs. 50C-D, arrowhead). Noticeably, a 
subset of neurite-bearing cells with bright PLCβ1-immunostaining were NF200-
negative (Figs. 50C-D, star), reinforcing the notion that upregulation of PLCβ1 precedes 
the appearance of neuron-specific markers as suggested above. After 48 h and 72 h 
post-treatment, PLCβ1-immunoreactivity increased even more in neurites and continued 
to be present in the cells nucleus. The immunostaining pattern in cells displaying 
neuronal morphology did not differ between 48 h and 72 h time points (Figs. 50 E-H). 
However a major difference was that the vast majority of cells were NF200-positive at 
72 h, but not at 48 h of AraC treatment. This is in agreement with results of Western 
blot analysis, showing a sharp increase in NF200-immunoreactivity in cell whole 
homogenates between 48 and 72 h of AraC treatment (Fig. 49B). The PLCβ1- and 
NF200-immunostaining patters in AraC/NT2N neurons were similar to that observed in 
RA/NT2N neurons (compare Figs. 46I-J and 50I-J). Thus, AraC/NT2N showed intense 
nuclear PLCβ1-immunoreactivity (Figs. 50I-J), whereas a weak signal was observed in 
projections. Again, in agreement with Western blot results, AraC/NT2N neurons 
displayed dense NF200 immunoreactivity in both soma and neurites (Fig. 50J). 
Overall, the results shown in this chapter show that PLCβ1 expression and 
subcellular localization is highly regulated during the time-course of RA- and AraC-
induced differentiation suggesting a possible role of PLCβ1 in neuronal differentiation. 
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5. ROLE OF PHOSPHOLIPASE C β1 IN NEURONAL DIFFERENTIATION 
5.1. Role of PLCβ1 in AraC-induced differentiation of neuronal differentiation of 
NT2 progenitors 
To analyze whether PLCβ1 is necessary for differentiation of NT2 cells we assayed 
two different strategies for siRNA knockdown of PLCB1 gene in NT2 cells. First, we 
tested the efficiency of four shRNA constructions cloned into pSuperior.gfp/neo vector 
and compared it with that obtained using ON-TARGET plus SMART pool siRNAs (see 
Methods), which consist of four siRNAs to the same target gene mixed together. 
 
5.1.1. Silencing efficiency of PLCβ1 shRNAs 
Four different shRNAs cloned into the pSuperior.gfp/neo vector were tested for 
transfection and silencing efficiency. Because this vector contains a GFP reporter gene, 
transfection could be directly observed by fluorescence microscopy. As negative 
controls, the commercial plasmid pSuperior.gfp/neo containing no insert and a non-
targeting scramble shRNA were used. As shown in figure 51, only a proportion of NT2 
cells expressed GFP 48 h after transfections. Fluorescence intensity varied throughout 
the cell population. In any case, all plasmids, except 97 shRNA, yielded similar levels 
of transfection that was below 50% of the total population. The transfection efficiency 
was even lower for the 97 shRNA construct, which in addition appeared to compromise 
cell viability. 
Western blot analysis of PLCβ1-immunoreactivity in NT2 cell homogenates, 48 
after transfection with different shRNAs, showed that all targeting shRNAs (87, 89, 97 
and 99) caused a decrease of PLCβ1-expression in about 50%, suggesting that PLCβ1 
was efficiently knocked down. However, no statistically significant differences were 
achieved with the sample used (n=2). In any case, because transfection efficiency was 
not complete, we decided to use commercially available siRNA pools (see Methods). 
Because shRNA in the pSuperior.gfp/neo vector is under the control of an inducible H1 
promoter containing the tetracycline operator 2 (TetO2), these constructions are ideal 
for inducible knockdown of the desired gene by tetracycline treatment. Currently, we 
have designed a strategy to obtain a NT2 cell line for conditional knockdown of PLCβ1 
using shRNAs cloned in pSuperior.gfp/neo. 
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Figure 51. Evaluation of shRNA-transfection efficiency using fluorescence microscopy to 
visualize reporter protein GFP. NT2 cells were transfected with pSuperior.gfp/neo plasmid 
either with no shRNA encoding sequence (A-C) or containing non-targeting scramble RNA (D-
F) or shRNAs (87, 89, 97 and 99 shRNA) targeting human PLCB1 gene (G-R). Phase contrast 
and GFP expression were assessed under a fluorescent microscope. Scale bar = 100 µm. 
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Figure 52. Western blot and semiquantitative densito-
metric analysis of immunoreactivity for PLCβ1, GFP, 
β-actin and cyclophyllin (CyPA). Immunoblots were 
performed in whole homogenates of NT2 progenitors 
cells 48 h post transfection with pSuperior.gfp/neo 
plasmid either with no shRNA encoding sequence 
(pSup) or containing non-targeting scramble RNA 
(Scr) or shRNAs (87, 89, 97 and 99 shRNA) targeting 
human PLCB1 gene. Equal amounts of total protein 
(30 µg) were loaded on the same gel. The y-axis of the 
graph shows mean percent optical density normalized 
to the value obtained in NT2 transfected with 
pSuperior.gfp/neo plasmid. All data are mean ± SEM 
(n=2). 
 
5.1.2. Silencing efficiency of PLCβ1 siRNA pools 
In view of the not fully satisfactory results obtained with shRNA, we used 
commercially available species-specific siRNAs pools (see Materials), which consist of 
four siRNAs to the same target gene mixed together. 
First, we tested the silencing efficiency of siRNAs as well as their ability to 
produce a sustained knock of PLCβ1. For this purpose, NT2 cells were transfected with 
the siRNA pool targeting human PLCB1 gene. Transfection with a non-target pool was 
used as a negative control. Transfected cells were allowed to grow for 12, 24, 48, 72 or 
96 h and then harvested and homogenized for SDS-PAGE and immunoblot. 
 
Figure 53. PLCβ1-immunoreactivity in 
whole homogenates form control NT2 
cells or cells transfected with either non-
targeting scramble siRNA (Scr) or siRNA 
targeting human PLCB1 gene (siRNA). 
Cells were harvested at post-transfection 
times of 12, 24, 48, 72 and 96h. 30 µg 
total protein was loaded in each lane and 
resolved in parallel. Values at each time 
point represent the mean percentage of 
optical density (OD) normalized to the 
corresponding value obtained in NT2 
cells transfected with scramble siRNA. 
Repeated measures one-way ANOVA 
followed by Tukey's post-hoc test (***p 
< 0.001). Data are mean ± SEM (n=4). 
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As illustrated in Figure 53, siRNA led to a drastic decrease of PLCβ1-
immunoreactivity (∼80%) as soon as 12 h after transfection. Moreover, PLCβ1-
knockdown was sustained up to 96 h after transfection. Next, we evaluated the 
specificity of targeting by analyzing the expression of PLCβ4 and β-actin on siRNA-
transfected NT2 cells. As it can be appreciated in figure 54, neither PLCβ4 nor β-actin 
expression were affected by the siRNA pool targeting human PLCB1 transcript. 
 
 
Figure 54. PLCβ1-, PLCβ4- and β-actin-
immunoreactivity in whole homogenates of 
NT2 progenitors cells 48 h after transfection 
with either scramble siRNA or PLCβ1 siRNA. 
Equal amounts of total protein (30 µg) were 
loaded on the same gel. The experiment was 
repeated 3 times with same results. 
 
5.1.3. Effects of PLCβ1 silencing in AraC-induced differentiation 
To test whether PLCβ1 silencing affects AraC-induced differentiation, NT2 cells 
were transfected either with non-targeting or PLCB1 gene targeting siRNA and treated 
with AraC for 72 h, a time point at which neuron-specific markers are already 
expressed. As shown in figure 55, PLCβ1 siRNA prevented acquisition of the typical 
neuronal polarity induced by treatment with AraC, whereas scramble siRNA did not. 
Moreover, cells transfected with PLCβ1 siRNA continued to proliferate, preventing cell 
growth arrest induced by AraC. 
 
Figure 55. Phase-contrast micrographs of NT2 cells fixed 96 h after transfection with either 
scramble siRNA or PLCβ1 siRNA and treated with AraC for 72 h. Scale bar = 50 µm. 
 
Western blot analysis allowed us to analyze the impact of PLCβ1 silencing in 
NF200 and β-III-tubulin expression after treatment with AraC for 72 h. As expected, 
 RESULTS 
	  
 
	  
120 
scramble siRNA did not prevent upregulation of PLCβ1 expression after 72 h of AraC 
treatment, whereas targeting siRNA caused a drastic decrease of PLCβ1 expression 
(Figs. 56A-B), which was clearly below basal levels (Fig. 56 B, dashed line). In NT2 
cells transfected with scramble siRNA, the expression of the neuron-specific makers 
NF200 and β-III-tubulin increased with respect to untransfected NT2 cells as previously 
observed (see Section 1, Fig. 32A, H-I), whereas it was prevented by PLCβ1 siRNA 
(Fig. 56). 
These results, demonstrate that PLCβ1 is necessary for AraC-induced neuronal 
differentiation of NT2 cells. 
 
Figure 56. A. Western blot analysis of PLCβ1, NF200 and βIII-tubulin expression in NT2 cells 
and cells transfected either with scramble siRNA or PLCβ1 siRNA and treated with AraC for 72 
h. B. Densitometric analysis of of PLCβ1-, NF200 and βIII-tubulin-immunoreactivity. In the 
three conditions mentioned in A. Equal amounts of total protein (30 µg) were loaded on the 
same gel and run in parallel. The y-axis of the graph shows mean of optical density normalized 
to the value obtained NT2 cells. One-way followed by post hoc Tukey’s test (*p < 0.05; 
**p < 0.01; *** p < 0.001). Data are mean ± SEM (n=4). 
 
5.2. Effect of PLCβ1 overexpression on NT2 progenitor cells 
Results of siRNA knockdown shown that PLCβ1 is necessary for AraC-induced 
neuronal differentiation of NT2 progenitors prompted us to assess whether PLCβ1 
overexpression is sufficient to induce neuronal differentiation of NT2 cells in the 
absence of any added differentiating agent. To this end, we generated PLCβ1 constructs 
either untagged or HA-tagged. Thus, cDNAs encoding PLCβ1a, PLCβ1b, HA- PLCβ1a 
and HA-PLCβ1b were cloned in pCDNA3.0 vector (see Methods). 
  
5.2.1. Validation of constructs 
First, we determined by Western blot whether these constructs encoded the 
expected proteins 24 h after transfection of NT2 progenitors (Fig. 57) 
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Figure 57. Western blot analysis of PLCβ1a 
and PLCβ1b (upper blot) and HA-PLCβ1a and 
HA-PLCβ1b (lower blot) overexpression 24 h 
after transfection. Immunoblots were performed 
in whole homogenates of NT2 progenitor 
transfected with empty plasmid alone (mock) or 
pCDNA-containing the sequences encoding 
untagged or HA-tagged splice variants PLCβ1a 
and PLCβ1b. Note that PLCβ1a expression is 
not affected by transfection with either the mock 
(upper  blot,  lane  1)  of  the  pCDNA-PLCβ1b  
plasmid (upper blot, lanes 3 and 5). In conditions used for immunoblot, immunoreactivity for 
endogenous PLCβ1b was below the detection threshold in mock-transfected (upper blot, 
lane 1) as well as in PLCβ1a-transfected samples (upper blot, lanes 2 and 4). 
 
As shown in figure 57 (upper blot), overexpression of native PLCβ1a and PLCβ1b 
led to the appearance of strong immunoreactive bands at the expected positions, as 
evidenced by Western blot analysis using the monoclonal antibody PLCβ1N-ter (which 
recognizes both splice variants). Also, transfection with pCDNA-PLCβ1a and pCDNA-
PLCβ1b did not affect inmmunoreactivity of endogenous PLCβ1b and PLCβ1a, 
respectively (Fig. 57, upper blot). Immunoblots of homogenates from NT2 cells 
overexpressing either HA-PLCβ1a and PLCβ1b using a monoclonal anti-HA antibody 
yielded single strong immunoreactive bands at the expected positions (Fig. 57, lower 
blot). 
 
Figure 58. NT2 progenitors cells transfected with pcDNA-PLCβ1a (A) or HA-pcDNA-PLCβ1a 
(B), fixed 24 h after transfection and processed for double-immunofluorescence against 
PLCβ1D-8 or HA (red) and PLCβ1G-12 (green) combined with Hoechst’s chromatin staining 
(blue). Exposure was adjusted such that endogenous PLCβ1-signal could not be visualized. 
Micrographs are maximum intensity projections of four consecutive optical sections separated 
by 0.24 µm, obtained using the structured illumination module (ApoTome). Scale bar = 20 µm. 
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Next we examined overexpression of the different constructs in fixed NT2 cells 24 
h after transfections. For this purpose, different anti-PLCβ1 antibodies were used for by 
immunofluorescence and high-resolution microscopy analysis. Double-
immunofluorescence analysis of PLCβ1a-transfected cells was performed by combining 
the mouse monoclonal PLCβ1D-8 antibody (which recognized both splice variants) and 
the goat polyclonal PLCβ1G-12, raised against the splice variant-specific tail of PLCβ1a. 
As shown in figures 58A-C, under short exposure to avoid visualization of 
endogenous signal, strong signals were obtained with both PLCβ1D-8 and PLCβ1G-12 
antibodies in NT2 cells transfected with the pCDNA-PLCβ1a vector. The high 
colocalization observed using antibodies raised in different species and directed against 
distant regions of PLCβ1a amino acid sequence, demonstrate the integrity of 
recombinant PLCβ1a protein. Similarly, high colocalization was observed by combining 
the mouse monoclonal PLCβ1D-8 antibody and the rabbit polyclonal anti-HA antibody 
in NT2 cells transfected with the pCDNA-HA-PLCβ1a vector. (Figs. 58D-F). 
 
 
Figure 59. NT2 progenitors cells transfected with pcDNA-PLCβ1b (A) or HA-pcDNA-PLCβ1b 
(B), fixed 24 h after transfection and processed for immunofluorescence using the mouse 
monoclonal PLCβ1D-8 or rabbit polyclonal anti-HA antibodies (red) combined with Hoechst’s 
chromatin staining (blue). Micrographs are maximum intensity projections of four consecutive 
optical sections separated by 0.24 µm, obtained using the structured illumination module 
(ApoTome). Scale bar = 20 µm. 
 
Because there are not available antibodies against the PLCβ1b splice variant, 
immunostaining in cells transfected with the pcDNA-PLCβ1b vector was performed 
using the monoclonal PLCβ1D-8, whereas the rabbit polyclonal anti-HA antibody was 
used for assays in cells transfected with the pcDNA-HA-PLCβ1b vector. As illustrated 
in figures 59A and B, under short exposure, strong signal was observed in putatively 
PLCβ1b- and HA-PLCβ1b-transfected NT2 cells. Although immunofluorescence 
analysis was not fully conclusive to demonstrate overexpression of recombinant 
PLCβ1b, combination of immunofluorescence and Western blot results allow us to 
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conclude that PLCβ1b was actually overexpressed in NT2 cells transfected with the 
pCDNA-PLCβ1b vector. 
 
5.2.2. Effects of PLCβ1a and PLCβ1b overexpression in cell morphology and 
expression of neuron-specific markers in NT2 cells 
Once validated, constructs coding for the native amino acid sequences of human 
PLCβ1a and PLCβ1b were used to analyze the effects of their overexpression in NT2 
cell morphology. 96 h after transfection with PLCβ1a, PLCβ1b or both (Figs. 60B-D), 
cell growth was arrested and cells acquired the typical neuronal morphology, whereas 
the empty vector had no effect (Fig. 60A). PLCβ1a or PLCβ1b (Figs. 60B-C) alone 
appeared to be more potent in promoting cell growth arrest and morphological 
differentiation than in combination (Fig. 60D), as suggested by the presence of a higher 
amount of polygonal morphologies. 
 
 
Figure 60. Phase-contrast micrographs of NT2 cells fixed 96 h after transfection with pcDNA, 
pcDNA-PLCβ1a, pcDNA-PLCβ1b or co-transfection of pcDNA-PLCβ1a and pcDNA-PLCβ1b 
plasmids. Arrowheads indicate cells displaying neurite-like processes.  Scale bar = 50 µm. 
 
To assess whether PLCβ1a or PLCβ1b overexpression promotes upregulation of 
neuron-specific markers, NT2 cells transfected with PLCβ1a, PLCβ1b or both were 
homogenized after 96 h and analyzed by Western blot. As illustrated in figure 61, 
PLCβ1a or PLCβ1b alone caused a ∼3- and 2-fold increase in NF200 and βIII-tubulin 
expression, respectively, whereas co-transfection resulted in a ∼2-fold increase in 
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NF200 expression and a moderate and statistically non-significant increase of βIII-
tubulin expression. This is in agreement with the apparent higher capacity of PLCβ1a or 
PLCβ1b alone to induce morphological differentiation (Fig. 60). It must be noted that 
transfection with the mock vector also caused a moderate increase in NF200- and βIII-
tubulin-immunoreactivities (Fig. 61A), probably masking to some extent the effect of 
PLCβ1 constructs, as OD values were normalized with respect to homogenates of 
mock-transfected cells. 
Figure 61. Immunoblots (A) and semiquantitative densitometric analysis (B) of NF200 and 
βIII-tubulin. Immunoblots were performed in whole homogenates of NT2 progenitor cells, NT2 
cells treated with AraC for 96 h and NT2 cells transfected with an empty pcDNA, pcDNA-
PLCβ1a, pcDNA-PLCβ1b or a combination of pcDNA-PLCβ1a and pcDNA-PLCβ1b. Equal 
amounts of total protein (5 µg) were loaded on the same. The y-axis of the graph shows mean 
percentage of optical density normalized to the value obtained in NT2 cells transfected with the 
empty (mock) plasmid. One-way followed by post hoc Tukey’s test (*p < 0.05; 
**p < 0.01; ***p < 0.001). Data are mean ± SEM (n=4). 
 
To further demonstrate the capacity of PLCβ1a and PLCβ1b to promote neuronal 
differentiation, we carried out double PLCβ1-NF200 immunofluorescence assays in 
NT2 cells 96 h after being transfected with pcDNA-PLCβ1a and pcDNA-PLCβ1b 
plasmids, using the pcDNA empty vector as negative control. As it can be observed in 
figure 62, NF200 immunoreactivity increased considerably in cells transfected with 
pcDNA-PLCβ1a and pcDNA-PLCβ1b as compared with neighbouring untransfected 
cells (Figs. 62D-I) and mock-transfected NT2 cells (Figs. 62A-C). Moreover, these 
changes in NF200 expression levels were correlated with changes in cell morphology, 
such that the appearance of cells was similar to that observed after AraC-induced 
differentiation (Compare Figs. 62D-I with Figs. 50E-H). Of note neither PLCβ1a nor 
PLCβ1b overexpression was accompanied by a marked increase in immunoreactivity 
within the nucleus, suggesting that nuclear translocation of PLCβ1 is saturable. Changes 
in expression of βIII-tubulin followed the same pattern as described for NF200 (data not 
shown). 
Finally, assays with HA-tagged constructions confirmed the results obtained by 
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overexpression of native PLCβ1a and PLCβ1b. Thus, as shown in figure 63, 
overexpression of either HA-PLCβ1a (Figs. 63A-C) or HA-PLCβ1b (Fig. 63D) led to 
acquisition of neuronal polarity of transfected cells but not of neighboring untransfected 
cells. 
 
Figure 62. NT2 progenitor cells transfected with empty pCDNA (A-C), pcDNA-PLCβ1a (D-F) 
or pcDNA-PLCβ1b (G-I) fixed 96 h after transfection and processed for double 
immunofluorescence against PLCβ1 D-8 (red, A, D, G) and NF200 (green B, E, H), combined 
with Hoechst’s chromatin staining (blue). Micrographs are maximum intensity projections of 
four consecutive optical sections separated by 0.24 µm, obtained using the structured 
illumination module (ApoTome). Scale bar = 25 µm. 
 
 
Figure 63. A-C. NT2 cells overex-
pressing HA-PLCβ1a, fixed 96 h after 
transfection and processed for double 
immunofluorescence to HA (green) 
and PLCβ1 (red). D. NT2 cells 
overexpressing HA-PLCβ1b, fixed 96 
h after transfection and processed for 
immunofluorescence to HA (green. 
Micrographs are maximum intensity 
projections of four consecutive optical 
sections separated by 0.24 µm, 
obtained using the structured 
illumination module (ApoTome). 
Scale bar = 20 µm. 
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Taken together, these results show that PLCβ1 is necessary and sufficient for 
neuronal differentiation of NT2 cells. 
 
5.3. Effect of PLCβ1 silencing in PC12 cell differentiation 
To confirm and extend results obtained in NT2 cells we tested whether PLCβ1 
silencing impairs NGF-induced differentiation of PC12 cells. First, we analyzed 
expression of PLCβ1 by Western blot, showing that both undifferentiated and NGF-
differentiated PC12 cells express this enzyme, with no differences in OD of 
immunoreactive bands (Fig. 64). 
 
 
Figure 64. Western blot analysis of in whole 
homogenates of undifferentiated and differentitated 
PC12 cells (treated for 96 h with NGF 50 ng/mL). 20 
µg protein/lane were loaded. 
 
 
Figure 65. A-C. Phase contrast 
micrographs showing the morphology 
of PC12 cells, non-transfected (A) and 
transfected with  scramble siRNA (B) 
or PLCβ1 siRNA (C) 24 h and after 
treating them for 96 h with NGF (50 
ng/mL). Scale bar = 50 µm. (B) 
Comparison of the ratio of neurite 
length to cell body diameter in each 
condition. One-way ANOVA followed 
by post hoc Tukey’s test (***p < 
0.001). Data are mean ± SEM (n=100). 
 
 
Quantitative analysis of the ratio between neurite length and diameter of cell body 
demonstrated that PLCβ1 knockdown using ON-TARGET plus SMART pool siRNAs 
(see Methods) completely abrogated NGF-induced neurite outgrowth and neuronal 
differentitation, whereas non-targeting scramble siRNAs did not (Fig. 65). 
These results show that PLCβ1 silencing abrogates neuronal differentiation of two 
phenotypically distant cell lines and suggest that PLCβ1-mediated signaling participates 
in a universal mechanism for generic neuronal differentiation.   
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6. ROLE OF THE PHOSPHOLIPASE C β1-BINDING PARTNER TRANSLIN-
ASSOCIATED FACTOR X IN NEURONAL DIFFERENTIATION 
Recently, Scarlta and colleagues have identified the protein translin-associated 
factor X (TRAX) as a new binding partner of PLCβ1 (Aisiku et al., 2010), and showed 
that activated Gαq competes with TRAX for binding to PLCβ1, revealing a scenario in 
which PLCβ1, TRAX and Gαq levels, together with activity of Gq-coupled membrane 
receptors, would condition the location of PLCβ1 and TRAX and the possibility of 
these partners to interact. Interestingly, results of these studies showed that PLCβ1-
TRAX association plays a key role in regulating the activity of the RISC silencing 
machinery, such that PLCβ1 binding to TRAX negatively regulates maturation of 
siRNAs targeting specific genes (Philip et al., 2012). 
Based on these evidences, the expression of Gαq/11 and TRAX was analyzed 
during the time-course of AraC-induced neuronal differentiation. 
 
6.1. Expression of PLCβ1-interacting proteins Gαq/11 and TRAX during AraC-
induced differentiation of NT2 progenitors  
In agreement with findings in RA/NT2N cells (Novak et al., 2000), expression of 
Gαq/11 was strongly upregulated during AraC induced differentiation of NT2 
progenitors (Fig. 66A). Upregulation of Gαq/11 was observed as soon as 24 h after 
initiation of AraC treatment, reaching statistical significance at 48 h. 
 
Figure 66. A. Western blot analysis of Gαq/11 expression during AraC-induced differentiation. 
Immunoblots were performed in whole homogenates of NT2 progenitors, AraC-treated cells 
(12, 24, 48 or 72 h) and AraC/NT2N cells. Equal amount of total protein for each condition (10 
µg) was loaded on the same gel. The y-axis of the graph shows mean percent optical density 
(OD) normalized to the value obtained in NT2 progenitor cells. One-way ANOVA followed by 
post hoc Tukes’s test (*p < 0.05; **p < 0.01). Data are mean ± SEM (n=2). B-E. Micrographs of 
NT2 cells (A), treated with AraC for 48 h (B) or 72 h (C) and differentiated AraC/NT2N 
neurons (D) immunolabelled for αq/11 (green) combined with Hoechst´s chromatin 
immunostainning (pseudocolores in red). Scale bar = 25 µm. 
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In line with results obtained by Western blot analysis, Gαq/11-immunofluorescence 
in fixed cells showed a marked increase in Gαq/11-signal after 48 h of treatment with 
respect to NT2 progenitors (Figs. 66B-C). Immunostaining continued to increase during 
differentiation (Fig. 66D), reaching a maximum at the end of treatment and being 
particularly intense in neurites (Figs. 66E). 
Next, we analyzed TRAX expression during AraC-induced neuronal differentiation. 
Western blot analysis revealed that expression of TRAX remains close to basal levels 
during the first 48 h of treatment, and increased sharply at 72 h (Fig. 67) 
 
	  
Figure 67. Semiquantitative densitometric 
analysis of TRAX immunoreactivity during 
the time course of AraC-induced neuronal 
differentiation of NT2 cells. Immunoblots 
were performed in whole homogenates of 
NT2 progenitor cells, NT2 cells treated 
with AraC 20 µM for 24, 48 or 72 h and 
and 6 days (NT2N). 5 µg total protein  
were loaded on the same gel. The y-axis of 
the graph shows mean optical density (OD) 
normalized to the value obtained in NT2 
cells. One-way ANOVA followed by post 
hoc Tukes’s test (**p < 0.01; ***p < 
0.001). Data are mean ± SEM (n=5). 
 
Comparison of the time-course of PLCβ1-, TRAX- and Gαq/11-expression during 
AraC-induced differentiation (Fig. 68) showed that the time-course expression of the 
three partners display a markedly different profiles. Thus, there is a lag time between 
upregulation of PLCβ1 and TRAX proteins, with an inversion of the relative expression 
levels at the end of differentiation caused buy a sharp downregulation of PLCβ1. At its 
turn, Gαq/11-expresion increases steadily until the end of differentiation, which contrast 
with the up-down regulation pattern of PLCβ1 and the sharp upregulation of TRAX at 
the end of differentiation. 
 
Figure 68. Immunoreactivity for PLCβ1, Gαq/11 and TRAX during the time-course of AraC-
induced differentiation. Optical density values were normalized to optical density (OD) in NT2 
progenitors. All data are mean ± SEM (PLCβ1, n=4; Gαq/11, n=2; TRAX, n=5). 
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The lag time between upregulation of PLCβ1 and TRAX prompted us to evaluate 
whether PLCβ1 silencing and overexpression affects TRAX upregulation, as observed 
for neuron-specific markers (Figs. 56, 61 and 62). 
 
6.1.1. Effect PLCβ1 silencing on TRAX expression in AraC/NT2N neurons 
As illustrated in figure 69, AraC-treatment during 72 h caused a significant increase 
in TRAX immunoreactivity in whole homogenates of NT2 cells transfected with non-
targeting siRNA, which was reversed by siRNA targeting the human PLCB1 gene. 
 
 
Figure 69. Semiquantitative densitometric analysis of TRAX-
immunoreactivity in NT2 cells and cells transfected either 
with scramble siRNA or PLCβ1 siRNA and treated with AraC 
for 72 h. Equal amounts of total protein (5 µg) were loaded on 
the same gel and run in parallel. The y-axis of the graph shows 
mean of optical density (OD) normalized to the value obtained 
NT2 cells. One-way ANOVA followed by post hoc Tukey’s 
test (*p < 0.05; **p < 0.01). Data are mean ± SEM (n=4). 
 
6.1.2. Effect of PLCβ1 overexpression on TRAX expression in NT2 progenitors 
Constructs coding for the native amino acid sequences of human PLCβ1a and 
PLCβ1b were used to assess whether their overexpression promotes upregulation of 
TRAX. To this end, NT2 cells transfected with PLCβ1a, PLCβ1b or both were 
homogenized after 96 h and analyzed by Western blot. 
 
Figure 70. Semiquantitative densitometric analysis of TRAX expression. Immunoblots were 
performed in whole homogenates of untransfected NT2 cells, NT2 cells transfected (with 
pcDNA –mock-, pcDNA-PLCβ1a, pcDNA-PLCβ1b or a mix of pcDNA-PLCβ1a and pcDNA-
PLCβ1b) and untransfected NT2 cells treated with AraC for 96 h. Transfected cells were lysed 
96 h after transfection. 5 µg protein were loaded on the same gel. The y-axis of the graph shows 
mean of optical density (OD) normalized to the value obtained in mock-transfected cells. One-
way ANOVA followed by post hoc Tukey’s test (* p < 0.05). Data are mean ± SEM (n=4). 
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PLCβ1a or PLCβ1b alone or in combination caused an increase in TRAX 
expression (Figs. 70A-B), although only PLCβ1b led to a statistically significant 
upregulation (Fig. 70B). Because mock vector caused a moderate increase in TRAX-
immunoreactivities (Fig. 70A), probably masking to some extent the effect of PLCβ1 
constructs, optical density (OD) values were normalized with respect to homogenates of 
mock-transfected cells (Fig. 70B). 
In summary these results and those obtained after PLCβ1 silencing suggest that 
PLCβ1 regulates TRAX expression. 
 
6.2. Analysis of PLCβ1-TRAX interaction during AraC-induced differentiation of 
NT2 progenitors 
6.2.1. Double PLCβ1-TRAX immunofluorescence 
 
Figure 71. Double-immunofluorescence against PLCβ1D-8 (red) and TRAX (green) in 
fixed NT2 progenitor cells (A-C), NT2 cells treated with AraC 20 µM for 48 h (D-F), 
72 h (G-I) and AraC/NT2N (J-L). Micrographs are maximum intensity projections of 
four consecutive optical sections separated by 0.24 µm, obtained using the structured 
illumination module (ApoTome). Scale bar = 25 µm.  
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As a first approach to test whether PLCβ1 and TRAX interact during neuronal 
differentiation of NT2 cells, double immunofluorescence analysis was performed in 
fixed cells at different time points during AraC-induced differentiation. 
As shown in figure 71, TRAX was barely detectable in NT2 progenitors (Fig. 71A-
C), whereas it could be clearly observed in cell nuclei of cells treated with AraC for 48 
h, where it colocalized with PLCβ1 (Fig. 71D-F). This increase was considerably in 
cells treated with AraC during 72 h and 6 days (NT2N cells). At the end of treatment, 
immunoreactivity was also observed in the cell soma and neurites (Figs. 71I-J). 
The increase observed at 48 h of AraC treatment contrast with results of Western 
blot analysis of whole cell homogenates showing that TRAX expression is close to 
basal levels at this time point. This discrepancy could be due to a masking effect of 
nuclear upregulation caused by cytosolic and plasma membrane TRAX. Therefore, 
TRAX immunoreactivity was analyzed in purified subcellular fractions of NT2 cells, 
cells treated with AraC for 48 h and AraC/NT2N cells. As shown in figure 72, TRAX-
immunoreactivity increases selectively in the nuclear fraction N as soon as 48 h after 
initiation of AraC treatment and even more in AraC/NT2N cells, whereas it remained 
unchanged in the Cyt and P2 fractions. Of note TRAX immunoreactivity was clearly 
detectable in Cyt and P2 fractions at the three time points analyzed. This contrasts with 
the absence of immunofluorescence signal in these locations, suggesting the epitope 
recognized by anti-TRAX antibody was masked. 
 
Figure 72. Western blot analysis of TRAX in Cyt, P2 
and N fractions obtained from NT2 progenitor cells, 
NT2 cells treated for 48 h with AraC and AraC/NT2N. 
For each control point, equal amounts of total protein 
(5 µg) were loaded on the same. 
 
6.2.2. FRET analysis of PLCβ1-TRAX interaction during AraC-induced 
differentiation of NT2 progenitors 
To analyze whether PLCβ1-TRAX associate during AraC-induced differentiation 
Förster resonance energy transfer (FRET) assays were performed in NT2 cells 
cotransfected with TRAX-eCFP and PLCβ1-eYFP during the time-course of AraC-
induced differentiation. FRET efficiency was evaluated in NT2 cells and at 3 h, 24 h, 48 
h, 72 h and 96 h after initiation of AraC treatment. As seen in figure 73, FRET 
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efficiency increased with time following AraC treatment, reaching statistically 
significance as soon as 24 h after treatment. The most noticeable change was after 72-96 
h of treatment; in fact, a sharp increase could be observed between 72 and 96 h of AraC 
treatment, although methodological shortcomings could account for this apparent 
drastic change. Indeed, until 72 h FRET signal was detectable in the entire cell area, 
whereas in cells treated with AraC during 96 h, the FRET signal was confined to a 
subcellular location likely corresponding to the cell nucleus, with no detectable signal in 
the cell body and plasma membrane, making it impossible to trace manually cell 
boundaries. Therefore, in cells treated with AraC for 96 h, measurement of mean FRET 
signal was circumscribed to the FRET-positive subcellular compartment, resulting in a 
overestimation of FRET efficiency at this time point. These observations are illustrated 
in figure 74. As it could be observed, TRAX-eCFP was distributed throughout the entire 
cell area in in NT2 cells (Fig. 74A), whereas PLCβ1-eYFP was mostly cytosolic (Fig. 
74B), although a weak signal could be detected in the cell nucleus. FRET signal was 
extremely low in these cells (Fig. 74C). Consequently, no significant differences in 
FRET signal were observed in NT2 progenitors compared to the negative control (Fig. 
73). After 72 h of treatment, no noticeable changes were observed regarding the 
distribution of TRAX-eCFP (Fig. 74D). In contrast, cells exhibited a strong PLCβ1-
eYFP appeared associated to the plasma membrane (Fig. 74E). At this time point, FRET 
efficiency was significantly higher than in NT2 cells (Fig. 73). In particular, the 
strongest signal was observed in the plasma membrane and weaker in the cytoplasm and 
cell nucleus (Fig. 74F). In cells treated with AraC during 96 h, both TRAX-eCFP and 
PLCβ1-eYFP were localized to round structures resembling the cell nucleus (Figs. 74G-
H), where strong FRET signal was detected (Fig. 74I). 
 
 
Figure 73. Quantification of FRET 
efficiency between TRAX-eCFP and 
PLCβ1-eYFP during the time-course of 
AraC-induced differentiation of NT2 
progenitor cells. NT2 were co-
transfected with TRAX-eCFP and 
PLCβ1-eYFP, treated with AraC and 
analyzed at the indicated time points. 
eCFP-YFP fusion protein transfected 
cells were used as negative and positive 
controls respectively. One-way ANOVA 
followed by post hoc Tukey’s test (*p < 
0.05; ***p < 0.001). Data are mean ± 
SEM (n=45). 
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By combining fluorescence images with phase-contrast images, it could be 
confirmed that signals corresponding to TRAX-eCFP and PLCβ1-eYFP fusion proteins 
as well as FRET signal was confined to the cells nucleus (Fig. 75). 
 
Figure 74. Immunolabeling of transfected cells with TRAX-eCFP (cyan 
blue) (A, D, G) and PLCβ1a-eYFP (green) (B, E, H) and FRET signals 
(C, F, I) during the AraC-induced differentiation process. Control Points: 
NT2 progenitor cells (A-C), 72 h AraC-treated NT2 cells (D-F) and 
AraC/NT2N (G-I). Scale bar = 25 µm. 
 
Figure 75. TRAX-
eCFP (A), PLCβ1a-
eYFP (B) combined 
with phase-contrast (C) 
and FRET signals (D) 
96 h after the initiation 
of treatment with 
AraC. Scale bar = 20 
µm. 
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6.3. Involvement of TRAX in neuronal differentiation of PC12 cells 
On the basis of results described in this chapter, we hypothesized that, if PLCβ1-
TRAX interaction was involved in neuronal differentiation, TRAX silencing (similarly 
to PLCβ1-silencing) would prevent differentiation of neuronal progenitors. Thus, we 
tested this possibility using the easily measurable model of PC12 differentiation. Given 
that activation of Gq-coupled membrane receptors appears to regulate PLCβ1-TRAX 
(Aisiku et al., 2010), the effect of Gαq/11 silencing in neuronal differentiation of PC12 
cells was also analyzed. Additionally, we tested the effect of silencing of translin (the 
best characterized binding partner TRAX) in neuronal differentiation of PC12 cells. 
 
 
Figure 76. Phase contrast images showing the morphology of PC12 cells transfected with 
scramble siRNA (A), Gαq/11-siRNA (B), TRAX-siRNA (C), or translin-siRNA (D) and treated 
with 50 ng/mL NGF for 96 h. Scale bar = 50 µm. (E) Comparison of the ratio of neurite length 
to the cell body diameter in each condition. One-way ANOVA followed by post hoc Tukey’s 
test (***p < 0.001). Data are mean ± SEM (n=100). 
 
As shown in figure 76, silencing of TRAX, but not Gαq/11 or translin, completely 
abrogated NGF-induced neurite outgrowth and polarization of PC12 cells, 
demonstrating that, at least in PC12 cells, both PLCβ1 and TRAX are necessary for 
neuronal differentiation and that this requirement does not depend on Gq-signaling or 
integrity of the TRAX-Translin complex. 
 VI. DISCUSSION 
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1. PLCβ1a AND PLCβ1b SPLICE VARIANTS ARE EXPRESSED IN 
NEURONAL NUCLEI OF THE ADULT RAT CORTEX 
Most of the research on signal transduction pathways based on PLCβ1 has been 
devoted to studying phenomena that take place at the plasma membrane. However, the 
work of several independent laboratories have consistently demonstrated that the 
phosphoinositide cycle (biosynthetic and hydrolytic machinery) is present in the cell 
nucleus, and may be important for various nuclear events such as mRNA export, DNA 
repair and gene transcription (Irvine, 2003; Martelli et al., 2005). In fact, PLCβ1 was 
originally identified at the nuclear level (Martelli et al., 1992; Divecha et al., 1993), and 
now its role in the control of cell proliferation or cell cycle progression in several 
cellular models is well established (Avazeri et al., 2003; Cocco et al., 2009). The 
evidence obtained with confocal and electron microscope analysis indicates that 
enzymes required for the synthesis and hydrolysis of phosphoinositides are localized at 
nuclear membrane and ribonucleoprotein structures of the inner nuclear matrix involved 
in transcript processing within the interchromatin domains (Boronenkov et al., 1998; 
Osborne et al., 2001; Tabellini et al., 2003; Jones and Divecha, 2004). With respect to 
PLCβ1, confocal and immune-electron microscopy and classic biochemical techniques 
provide evidence that exists in the nucleus of several cellular models. In rat liver, Swiss 
3T3, MEL and PC12 cells, PLCβ1 resides in the nuclear inner matrix and lamina, and 
this intranuclear partitioning is further stressed in in situ matrix preparations which 
demonstrated that PLCβ1 is a structural insoluble component of the inner nuclear 
matrix and of the nucleolar remnant, while it is absent from the nuclear pore-lamina 
complex (Zini et al., 1993; Zini et al., 1994; Bertagnolo et al., 1995; Crljen et al., 2004; 
Fiume et al., 2009). Probably, PLCβ1 is preferentially located in subnuclear domains 
known as speckles, which are involved in splicing events and can be easily identified by 
specific markers, as the splicing factors (Bavelloni et al., 2006). Finally, it has been 
demonstrated that PLCβ1 and lamin B1 localize and physically interact in the nucleus 
of MEL cells (Fiume et al., 2009). 
With these evidences in mind, we explored whether PLCβ1 is actually present in 
the nucleus of cells of neural origin. In our study, PLCβ1 displayed a dot-like pattern 
localized to chromatin-poor compartments and colocalized to a large extent with the 
nuclear speckle marker SC-35 (Osborne et al., 2001; Tabellini et al., 2003). In contrast, 
no colocalization was found with nuclear pore complex or lamin B1. Clearly, the data 
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reported here appear to shed new light on the presence of PLCβ1 at the neuronal nuclear 
compartment. As already shown in rodent and human tissues (Bahk et al., 1994; 
Caricasole et al., 2000; Peruzzi et al., 2002), PLCβ1 exists as two alternatively spliced 
variants, 138 kDa PLCβ1a (1216 aa) and 134 kDa PLCβ1b (1141 aa). These variants 
derived from alternative splicing at the 3’ end of human PLCβ1 gene (Caricasole et al., 
2000; Peruzzi et al., 2002). The PLCβ1b variant replaces the 75 C-terminal residues of 
PLCβ1a with 32 residues unique to PLCβ1b (Bahk et al., 1994; Caricasole et al., 2000; 
Peruzzi et al., 2000). The importance of the PLCβ1 C-terminal domain may rely in two 
aspects. First of all, C-terminal region contains determinants for Gαq and phosphatidic 
acid stimulation, electrostatic dependent association with membrane lipids, nuclear 
localization, and phosphorylation/regulation by protein kinase Cα and MAP kinase 
(Bahk et al., 1994; Litosch, 2000; Martelli et al., 2000; Xu et al., 2001a,b). Although, a 
nuclear localization motif has been mapped to a cluster of lysine residues (between 
1055 and 1072) which is common to both variants (Kim et al., 1996), PLCβ1a has in its 
unique C-terminal a typical nuclear export signal which may result in this variant being 
less concentrated in the nucleus (Bahk et al., 1994). Thus, although the two splice 
variants of PLCβ1 have identical Gαq-interacting domains and are comparably 
stimulated by Gαq, have a different subcellular localization, PLCβ1a being equally 
distributed in the plasma membrane, in the cytoplasm and in the nucleus, and the 
PLCβ1b almost completely nuclear, as demonstrated by Western blot and 
inmunofluorescence in several cell lines (glioma C6Bu-1 and MEL cells) and in rat liver 
tissue (Bahk et al., 1998; Faenza et al., 2000; Crljen et al., 2004; Fiume et al., 2005). In 
the last 5 years, a critical role for the PLCβ1b-specific C-terminal tail in targeting this 
variant to the sarcolemma of cardiomyocytes has been demonstrated (Grubb et al., 
2008, 2011). Our immunoblot analysis, using an antibody targeted against the common 
N-terminal of PLCβ1, was able to detect the presence of the two variants of PLCβ1 in 
different cell compartments (plasma membrane, cytosolic and nuclear fractions) 
Clearly, PLCβ1a was predominant over PLCβ1b in all the fractions studied, although 
the relative contribution of each variant to the total signal differed between subcellular 
compartments. Thus, PLCβ1a was more abundant than PLCβ1b in all fractions, 
although analysis of the PLCβ1a/ PLCβ1a ratios revealed that relative contribution of 
PLCβ1a was significantly higher in cytosol (Cyt) than in intact nuclei (N) and 
membrane fractions (P2). 
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The deeper understanding of the subcellular location of PLCβ1 in rat cerebral 
cortex presented here represents a starting point for considering additional research 
aimed at characterizing the distribution of its splice variants, and to shed light on the 
putative role of nuclear PLCβ1 pools in the regulation of cell cycle progression and 
differentiation in cells of neural origin. However, although there is extensive evidence 
highlighting the key role of nuclear PLCβ1 and its catalytic activity in cell cycle control 
and differentiation (see Introduction, section 1.4.1.), only indirect data exist about the 
role of PLCβ1 in neuronal differentiation. In this regard, it has been shown that Plcb1- 
and mGluR5-knockout mice (Hannan et al., 2001; Böhm et al., 2002; Spires et al., 
2005) exhibit alterations in the formation of the so-called "barrels" of the somatosensory 
cortex, emphasizing the importance of this signal transduction for correct cortical 
development. Additionally, Spires et al. (2005) reported a decrease in the proportion of 
symmetrical synapses in the  "barrel” cortex of Plcb1-/- mice, suggesting a transient 
imbalance in excitatory and inhibitory circuits (Spires et al., 2005). In line with this 
idea, Plcb1-/- mice generated by Kim et al. (1997) died suddenly at early postnatal stages 
and death was preceded by status epilepticus or recurrent seizures characterized by 
tonic-clonic or tonic extension of the whole body. Moreover, a human phenotype 
described by Kurian et al. (2010), which described that an homozygous deletion, 
involving the promoter element and exons 1, 2 and 3 of human PLCB1 gene led to tonic 
seizures in early infancy and, subsequently, infantile spasms and death. Interestingly, 
missense mutations in the SH3 domain of the human SHANK3 gene (an interaction site 
for PLCβ1b, see Introduction, section 1.1.4.) produces a clinical phenotype (Gauthier et 
al., 2010) similar to that described in Plcb1-/- mice (Kurian et al. (2010). These 
evidences in animal models and humans suggest that PLCβ1 signaling, rather than 
necessary for generic neuronal differentiation, is required for synaptic activity-
dependent late maturation, a process in which membrane (but not nuclear) PLCβ1 
would be involved. However, because all isoforms of the PLCβ family are expressed in 
brain cortex (Ruiz de Azúa et al., 2006), contain a nuclear localization signal (Rebecchi 
and Pentylana, 2000) and are expressed in neuronal nuclei (García del Caño et al., 
2015), redundant PLCβs could compensate for the loss of PLCβ1 during early neuronal 
differentiation in brain of Plcb1-/- mice and patients with deletions of the PLCB1 gene 
promoter. 
Therefore, in order to clarify whether PLCβ1 is actually required for neuronal 
differentiation, we used the pluripotent NTERA2/D1 (NT2) cell line, which can be 
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induced to differentiate in vitro into postmitotic NT2N neurons by retinoic acid (RA) 
(Andrews, 1984; Pleasure et al., 1992). Yet, the major limitations of this model are the 
lengthy differentiation procedure and its low efficiency, although recent studies suggest 
that the differentiation process can be shortened to less than one week using nucleoside 
analogues. Therefore, as a first step before exploring the role of PLCβ1 in neuronal 
differentiation of NT2 progenitors, we sought to explore whether short-term exposure of 
NT2 cells to the nucleoside analogue cytosine β-D-arabinofuranoside (AraC) could be a 
suitable method to efficiently generate mature neurons for subsequent studies. 
 
2. NT2-DERIVED POSTMITOTIC HUMAN NEURONS CAN BE GENERATED 
WITH HIGH EFFICIENCY BY SHORT-TERM TREATMENT WITH THE 
NUCLEOSIDE ANALOGUE CYTOSINE β-D-ARABINOFURANOSIDE 
NT2 derived neuronal cells in vitro express a plethora of neuron-specific markers at 
both transcript and protein levels (Pleasure et al., 1992; Cheung et al., 1999; Megiorni et 
al., 2005; Couillard-Despres et al., 2008; Haile et al., 2014). Our results are roughly in 
line with previous studies showing increased expression of NF200 (Lee and Andrews, 
1986; Pleasure et al., 1992), βIII-tubulin (Megiorni et al., 2005; Couillard-Despres et al., 
2008; Popovic et al., 2014) and DCX during RA-induced differentiation (Couillard-
Despres et al., 2008). However, differences in culture conditions and the lack of data of 
the time-course expression (or election of unequal time points for analysis) make it 
difficult a reliable comparison between their and our results in these studies. An 
inherent limitation for interpretation of results arises from the heterogeneous 
composition of cultures during RA-induced differentiation. Indeed, the neuronal 
phenotype represents only a small fraction over the entire cell population before 
mechanical isolation of RA/NT2N cells. Of the three markers used, NF200 was clearly 
identified as a highly neuron-specific marker in terminal cultures, in view of the high 
enrichment in this protein in terminally differentiated RA/NT2N cells compared to cell 
samples harvested before mechanical dislodging of neuronal cells. In contrast, 
expression levels of βIII-tubulin and DCX were similar in samples from cultures after 
28 days of treatment and in those from terminally differentiated RA/NT2N cells, 
indicating that these proteins were expressed in both RA/NT2N neurons and in the 
highly adherent non-neuronal NT2A cells. Remarkably, βIII-tubulin was already 
detectable in NT2 cells, reached a maximum immunoreactivity by day 7 of RA 
treatment, and returned to basal levels at the end of the process. This is in agreement 
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with a similar time-course analysis performed by Megiorni et al. (2005), even thought 
they used a cell aggregation method that shortens the time of the RA-induced 
differentiation to 3-4 weeks. Collectively, these data support and extend previous 
findings of the expression of neuronal markers in RA/NT2N neurons, and emphasize 
the caution needed in drawing conclusions about the use of βIII-tubulin for an 
unequivocal identification of neuronal phenotypes. In line with this conclusion, βIII-
tubulin is expressed in human fetal astrocytes (Dráberová et al., 2008) as well as in 
undifferentiated mesenchymal stem cells (Foudah et al., 2014). Our findings show that 
NT2N cells derived from AraC treatment not only show neuronal morphology, but also 
express neuronal markers, albeit with remarkable differences in the expression profiles 
of βIII-tubulin and DCX during differentiation. At difference with that observed during 
RA-induced differentiation, in AraC-treated cultures, immunoreactivity for βIII-tubulin 
increased sharply at mid-treatment and reached a maximum at day 6, whereas DCX 
showed an up-down regulation pattern that peaked up at 48 h post-treatment. The 
progressive increase in expression of NeuN/Fox-3 observed during AraC-induced 
differentiation of NT2 progenitors, as analyzed by Western blot and 
immunofluorescence microscopy, further confirmed the neuronal identity of 
AraC/NT2N neurons. The sequential and non-matching upregulation of the early 
(Brown et al., 2003) and late (Mullen et al., 1992) neuronal markers DCX and 
NeuN/Fox-3 suggests that, beside differentiation, AraC/NT2N cells have begun a 
maturation process after 6 days of treatment. However, this suggestion should be 
considered with caution, as NeuN/Fox-3 expression has been found in non-neuronal 
cells, such as cultured rodent and human astrocytes and even 3T3 fibroblast cells 
(Darlington et al., 2008). Indeed, we also observed that part of the population of non-
neuronal flat polygonal cells in our AraC-treated terminal cultures displayed weak to 
moderate nuclear staining for NeuN/Fox-3, leading us to consider morphological 
features to classify cells into non-neuronal or AraC/NT2N neuronal. Less than 10% of 
the cells in culture survived the uninterrupted 6-day period of AraC treatment, and only 
about 50% of them fulfilled the double criterion to be considered as neuronal (i.e., 
NeuN/Fox-3 positive nucleus and presence of neurite extensions) leading to a 
differentiation efficiency similar to that found after RA-differentiation. Our modified 
procedure, consisting of increasing cell density at mid-treatment, doubled overall cell 
survival and increased the percentage of neuronal cells with respect the total population 
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at the end of AraC treatment to 71%, respectively. Consequently, differentiation 
efficiency was number augmented by almost 3-fold. 
The two populations identified were clearly distinguishable as demonstrated by 
morphometric measurements of cell nuclei and total cell area. When compared with 
RA/NT2N neurons, AraC/NT2N neurons displayed considerably larger nuclei and cell 
somata. However, due to the characteristic growth of RA/NT2N neurons in aggregates 
under a closed 3-D organization, measurements of nuclear and body area of these cells 
on images of virtual stacks could have exacerbated the differences with respect to the 
considerably more flattened AraC/NT2N. Indeed, the ratio of nuclear area to body area 
tended to get closer in both phenotypes, although it was significantly lower in 
AraC/NT2N neurons. An overestimation of the size of cell somata of AraC/NT2N 
neurons, due to limitations on accurately defining their boundaries of (see methods), 
could account for this difference. Morphometric analysis of neurites showed that 
AraC/NT2N neurons displayed a total neurite length per cell of about 180 µm2. In a 
recent study, Haile et al. (2014) provided a 4.2-fold greater value for the total 
arborization length of RA/NT2N neurons. The much shorter time period for neurite 
outgrowth in our study (6 days vs. 5 weeks) likely accounts for this difference. Indeed, 
AraC/NT2N neurons were enriched in lamellar extensions and filopodia-like processes, 
indicative of intensive neurite outgrowth activity. In support of this idea, neurite length 
found here was about 20% longer than that reported by Tegenge et al. (2011) in RA-
differentiated neurons using the shortened cell aggregation method described by 
Cheung et al. (1999). Testing longer time periods, growth factors, different matrices 
and/or co-culture with astrocytes will be required to determine whether AraC/NT2N 
neurons are able to develop longer neurite arborizations. In any case, the experimental 
results reported here reveal that NT2 progenitors can be committed to differentiate in a 
short time period and with high efficiency into cells that fulfill the generally accepted 
criteria for postmitotic neurons, and underline that AraC-induced differentiation of NT2 
cells represents a valuable model to study molecular mechanisms underlying neuronal 
differentiation. 
RA/NT2N neurons been shown to express a broad spectrum of neurotransmitter 
markers in vitro, including glutamatergic (Podrygajlo et al., 2009; Coyle et al., 2011), 
cholinergic (Guillemain et al., 2000; Saporta et al., 2000), GABAergic (Yoshioka et al., 
1997; Guillemain et al., 2000; Saporta et al., 2000; Podrygajlo et al., 2009; Coyle et al., 
2011), chatecolaminergic (Guillemain et al., 2000; Saporta et al., 2000) and 
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serotonergic (Podrygajlo et al., 2009) transcripts and/or proteins. The apparent absence 
of consensus on the final neurotransmitter phenotype can be attributed to differences in 
the neuronal differentiation protocol and culture conditions, although as discussed by 
Podrygajlo et al. (2009), passage number of precursors, or their genetic instability could 
also contribute to variability of results. Nevertheless, under the culture conditions 
(culture media included) described by Pleasure et al. (1992) and used here, Yoshioka et 
al. (1997) and Guillemain et al. (2000) reported that a considerable population of 
neurons possess a GABAergic phenotype, in agreement with our findings showing that 
RA/NT2 are mostly GABAergic. In their immunocytochemistry-based study, 
Guillemain et al. (2000) found that 66.5% of neurons were GABA-immunopositive, 
although they also reported that 51.8% and 49.5% of neurons were TH- and ChAT-
immunoreactive, respectively, leading to the conclusion that many neurons were 
immunopositive for at least two markers. For their part, Yoshioka et al. (1997) only 
analyzed GAD67 transcript and protein using RT-PCR and Western blot analysis. Here, 
using immunofluorescence microscopy, we observed a large amount of GAD67-
immunopositive and scarce VGluT1-immunopositive thin neurites, both likely 
corresponding to axons; hence, to the canonical distribution of these proteins. Although, 
due to this distribution pattern, we could not asses the proportion of neurons of each 
phenotype, Western blot analysis confirmed that, in our culture conditions, GABA is the 
major neurotransmitter in RA/NT2N cells, whereas only a weak VGluT1 signal could 
be observed. 
Of particular interest in the present report is the finding that cells committed to 
differentiate by short treatment with AraC displayed a completely different 
neurotransmitter phenotype when compared with RA/NT2N neurons. Western blot 
analysis showed strong immunoreactivity for VGluT1 and ChAT in samples from 
terminal cultures, starting as soon as 72 h after initiation of AraC treatment. On the 
other hand, immunofluorescence assays evidenced that virtually all terminally 
differentiated neurons co-expressed both markers, suggesting that their neurotransmitter 
phenotype was not fully defined. Noticeably, this same phenomenon has been recently 
described for hippocampal embryonic neural progenitors. Thus, Bhargava et al. (2010) 
reported that, when cultures were obtained from brain of 18-day-old embryos, most 
VGluT1-positive neurons also expressed ChAT protein. On the contrary, this ability to 
co-express both markers of neurotransmitter phenotype was not observed in cultures 
from either neonatal or adult hippocampus. Results by Bhargava et al. (2010) exemplify 
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the importance of tissue environmental signals in specification of neurotransmitter fate. 
Moreover, embryonic hippocampal neurons in culture express the late neuronal marker 
NeuN/Fox-3 (Taguchi et al., 2014), indicating that neuronal maturation and 
specification of neurotransmitter phenotype are separate developmental events. As 
discussed by Bhargava et al. (2010), a complex combinational strategy of 
electrochemical coding that involves neighboring environmental signals, as well as 
distant afferent and retrograde signals, appear to account for specification of 
neurotransmitter phenotype (Johnson, 1994; Asmus et al., 2000; Landis, 2002). As a 
result of this developmental process neurons would loss the ability to synthesize 
multiple neurotransmitters. In this regard, it is likely that AraC/NT2N cells could 
acquire a specific neurotransmitter phenotype when engrafted in brain. In support of 
this, previous studies have demonstrated that RA/NT2N neurons (Saporta et al., 2000) 
and even NT2 progenitors (Miyazono et al., 1996) transplanted in different regions of 
the rodent brain are driven to differentiate in specific neurotransmitter phenotypes 
according to local environmental cues. Although some experimental studies using 
RA/NT2N grafts in animal models of stroke (Borlongan et al., 1998a,b; Saporta et al., 
1999) and Huntington’s disease (Hurlbert et al., 1999) have yielded promising results, 
others have reported either limited improvement (Bliss et al., 2006), or no effects on 
behavior or neurological function (Baker et al., 2000; Zhang et al., 2005; Bliss et al., 
2006), which has been attributed, at least in part, to the low amount of neurons of the 
desired neurotransmitter phenotype, which is a key prerequisite for successful neuronal 
replacement. Future studies will disclose whether AraC/NT2N cells are a suitable 
source of glutamatergic and cholinergic neurons for replacement of cortical excitatory 
neurons and basal forebrain cholinergic neurons in animal models of ischemic insult 
and Alzheimer’s disease. 
More relevant to the present study, the establishment of a neuronal differentiation 
model for highly efficient generation of NT2-derived postmitotic human neurons offers 
a suitable experimental framework to approach the main aim of the present study, i.e., 
to analyze the possible role of PLCβ1 in neuronal differentiation. 
 
3. PLCβ1 IS NECESSARY AND SUFFICIENT FOR NEURONAL 
DIFFERENTIATION OF NT2 PROGENITORS 
The involvement of PLCβ1 has in cell cycle control and differentiation has been 
reported in various cell lines. For example, PLCβ1 activity correlates directly with 
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proliferation and inversely with differentiation in cultured MEL cells (Divecha et al., 
1995). The endogenous activity of PLCβ1 in MEL cells decreases upon DMSO induced 
differentiation, which is attenuated by overexpression of PLCβ1 (Matteucci et al., 
1998), which triggers cyclin D3/cdk4 activation and cell cycle progression. 
Interestingly, these effects are not observed by overexpression of the nuclear 
localization mutant PLCβ1M2b, highlighting the importance of nuclear PLCβ1-
dependent signaling in cell cycle control. In contrast, rat C2C12 myoblast 
differentiation is characterized by an increase in PLCβ1 (Faenza et al., 2003, 2007). In 
these cells, overexpression of PLCβ1 results in upregulation of the member of AP-1 
transcription complex c-jun, which binds to the cyclin D3 promoter and activates the 
cyclin D3/cdk4 pathway. Yet, at difference with that observed in MEL cells, activation 
of the cyclin D3/cdk4 pathway results in cell cycle arrest and differentiation, this 
signaling cascade being dependent on PLCβ1 catalytic activity (Ramazzotti et al., 
2008). 
These conflicting data reveal that results obtained in a given cell line or tissue 
cannot be extrapolated and, as discussed above (section 1), only indirect data exist with 
regard to the role of PLCβ1 in neuronal differentiation, stressing the need of easily 
manipulable cell culture models to clarify whether PLCβ1 is actually required for 
neuronal differentiation. In this study, we used human NT2 and rat adrenal 
pheochromocytoma PC12 cells as cell models, which have been proven to be powerful 
tools for investigating neuronal differentiation process. The NT2 cell line, which was 
derived from a human teratocarcinoma, exhibits properties that are characteristic of a 
committed neuronal precursor at an early stage of development. These embryonic 
carcinoma cells (ECCs) have long been used to study the mechanisms governing 
lineage commitment in the central nervous system. In particular, the effect of RA on 
expression of genes, enzymes and receptors has been extensively studied both in 
cultured and grafted NT2 cells (Damjanov and Andrews, 1983; Pleasure et al., 1992; 
Piontek et al., 1999; Przyborski et al., 2000). At its turn, the PC12 cell line derived from 
a pheochromocytoma of the rat adrenal medulla, also widely used as a model of 
neuronal differentiation in vitro, can be induced to differentiate by treatment with NGF, 
which causes growth arrest and morphological differentiation. Differentiated PC12 cells 
assume features typical of sympathetic neurons, including development electrical 
excitability and synthesis and storage of the catecholamines dopamine and 
norepinephrine (Greene and Tischler, 1976; Connolly et al., 1979; Fujita et al., 1989). 
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However, evidence regarding the role of PLCβ1 in neuronal differentiation of NT2 
and PC12 cell lines is currently very scarce. There is only one study in which reporting 
that RA induced differentiation is accompanied by upregulation of PLCβ1 (Novak et al., 
2000). Here we analyzed PLCβ1 expression during the time-course of RA- and AraC-
induced neuronal differentiation of NT2 progenitors. Our results showed that upon 
exposure of NT2 cells to either RA or AraC, PLCβ1 levels drastically increase, 
preceding upregulation of neuron-specific markers. Of note, PLCβ1 expression remains 
elevated during differentiation and then fall at late stages of differentiation, when the 
expression of neuron-specific markers is highest. It must be also remarked, that PLCβ1 
localization was mainly nuclear at the end of differentiation, as seen by 
immunofluorescence in fixed cells. The limitation for interpretation of results, arising 
form the heterogeneous composition of cultures during RA-induced differentiation (see 
discussion in section 2), could be circumvented by combining Western blot analysis and 
double immunofluorescence against PLCβ1 and the neuron-specific marker NF200. 
Indeed, similarly to that observed during AraC-treatment, upregulation of PLCβ1 
precedes the appearance of neuron-specific markers. The strong immunofluorescence 
signal observed in NF200-negative non-neuronal cells (which represent the most 
abundant neuronal phenotype in these cultures) would explain the unchanged drastic 
increase in PLCβ1 levels observed by Western blot until day 28 of treatment and the 
marked fall in PLCβ1-immunoreactivty in neurons isolated by mechanical dislodging. 
Our results show that PLCβ1 expression and subcellular localization is highly regulated 
during the time-course of RA- and AraC-induced differentiation, suggesting a possible 
role of PLCβ1 in neuronal differentiation. The up-down pattern of PLCβ1 expression 
also suggests that temporal and spatial regulation of PLCβ1 might be relevant for proper 
progression of the various steps that take place during the course of neuronal 
differentiation steps, i.e, growth arrest, expression of neuron-specific genes and neurite 
extension, survival and synaptogenesis. Interestingly, such a phenomenon has been 
observed in the adipocyte differentiation model of 3T3-L1 fibroblasts and in C2C12 
myoblasts (Faenza et al., 2007; O'Carroll et al., 2009). In these cells, PLCβ1 activity is 
upregulated in two phases during differentiation. The first one taking place immediately 
after induction of differentiation, is regulated by pERK and PKCα, and is not dependent 
on nuclear translocation of PLCβ1. The second one begins after 48 h, is independent of 
pERK and PKCα, and requires both upregulation and nuclear translocation of PLCβ1 
protein. 
 DISCUSSION 
	  
 
	  
147 
However, despite the promising descriptive results on PLCβ1 regulation during the 
time-course of NT2 differentiation, assessment of whether PLCβ1 affects is involved in 
neuronal differentiation requires a more conclusive experimental approach. In this 
regard, siRNA silencing and overexpression of PLCβ1 have been proven to be potent 
tools for demonstrating its biological roles. These strategies require the use of 
appropriate cell models with short lasting differentiation periods. In this regard, 
neuronal differentiation of NT2 cells by short-term treatment with AraC, characterized 
in the present study, serves as an excellent model for our purposes. On the other hand, 
the use of PC12 cells is interesting to ascertain whether observations in NT2 cells are 
exclusive of this cell line or can be extrapolated between the phenotypically distant 
neuronal progenitors. Our results clearly demonstrated that siRNA silencing of human 
PLCB1 gene in NT2 cells impaired AraC-induced morphological differentiation. 
Moreover, PLCβ1 siRNAs prevented AraC-induced cell cycle arrest, and increase in 
expression of neuron-specific markers NF200 and βIII-tubulin. On the contrary, upon 
AraC treatment, NT2 cells transfected with non-targeting siRNAs stopped to grow, 
developed neuronal processes and expressed higher levels of NF200 and βIII-tubulin 
than untreated NT2. Similarly, PLCβ1 siRNAs abrogated proliferation arrest and neurite 
outgrowth in NGF-treated PC12 cells, clearly demonstating that PLCβ1 is a necessary 
mediator for AraC- and NGF-induced neuronal differentiation of NT2 and PC12 
progenitors, respectively. To assess whether overexpression of PLCβ1 is sufficient to 
induce neuronal differentiation, NT2 progenitors were transfected with plasmid 
constructs coding for the native amino acid sequences of human PLCβ1a and PLCβ1b. 
In the absence of AraC, overexpression of both splice variants induced morphological 
differentiation of NT2 cells and increased levels of the neuron-specific markers NF200 
and βIII-tubulin, demonstrating that PLCβ1 is not only necessary but also sufficient for 
neuronal differentiation of NT2 cells. Intriguingly, despite the accumulating evidence 
showing that the splice variant-specific carboxy-terminus of PLCβ1a and PLCβ1b 
posses distinct subcellular localization domains, no remarkable differences were 
observed between the effects elicited by overexpression of either splice variant (Grubb 
et al., 2008, 2011, 2012). Because these subcellular localization domains appear to 
govern interaction with the postsynaptic cytoskeletal scaffold (see introduction) it is 
likely that these domains are only relevant in mature neurons, whereas the role of 
PLCβ1 splice variants in early differentiation events would be redundant. In line with 
this idea, both variants were expressed in plasma membrane, cytosolic and nuclear 
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fractions of NT2 progenitors, although subtle differences in the PLCβ1a/PLCβ1b ratios 
were observed between fractions. However, this assumption requires experimental 
verification. In this regard, we have recently generated PLCβ1 constructs coding for 
PLCβ1 variants truncated to varying degrees in variant-specific short carboxy-terminal 
region, which will be used to fulfill the above mentioned purpose. 
As mentioned in the introduction, molecular mechanisms responsible for the 
cellular responses mediated by PLCβ1 are poorly understood, and existing data are 
conflicting. As discussed above, PLCβ1 overexpression triggers cyclin D3/cdk4 
activation in MEL and C2C12 cells, but with a completely opposite outcome. Thus, 
PLCβ1 expression is necessary and sufficient to promote cycle progression of MEL 
cells and to induce arrest in the G0/G1 phase and differentiation of C2C12 myoblasts, 
which only can be explained by a cross-talk between signaling pathways that control the 
cell cycle and those that promote cell differentiation. Future studies will be necessary to 
determine whether these pathways are activated by PLCβ1 in NT2 cells. Another 
important question that remains to be answered is whether nuclear translocation of 
PLCβ1 is necessary for AraC-induced differentiation of NT2 cells. Therefore, it will be 
necessary to test whether the nuclear localization mutant PLCβ1M2b is unable to 
promote neuronal differentiation of NT2 progenitors and acts in a dominant negative 
fashion and suppresses neuronal differentiation as it has been described for C2C12 
myoblast differentiation. We are currently cloning of nuclear localization mutants of 
PLCβ1a and PLCβ1b, which is in an advanced stage. 
 
4. A POSSIBLE ROLE OF TRAX-PLCβ1 INTERACTION IN NEURONAL 
DIFFERENTIATION 
As mentioned in the introduction, TRAX (translin associated factor-X), and its 
binding partner protein Translin, have been implicated in a broad spectrum of biological 
activities, including cell growth regulation, mRNA processing and neuronal 
development/function (Jaendling and McFarlane, 2010), although their precise role in 
these processes remains to be elucidated. Recently, the interaction between PLCβ1 and 
TRAX has been described in cultured cells (Aisiku et al., 2010). Noticeably, it was 
demonstrated that Gαq competes with TRAX for PLCβ1 binding, revealing a scenario 
in which PLCβ1, TRAX and Gαq levels, together with activity of Gq-coupled 
membrane receptors, would condition the location of PLCβ1 and TRAX and the 
possibility of these partners to interact. A later study from the same group (Philip et al., 
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2012) elegantly demonstrated that PLCβ1-TRAX association regulates the activity of 
the RISC silencing machinery, showing that PLCβ1 binding to TRAX negatively 
regulates the maturation of siRNAs targeting specific genes (Philip et al., 2012). 
Specifically, Philip et al. (2012) reported that overexpression of PLCβ1 reverses 
exogenous siRNA-mediated knockdown of LDH or GAPDH, but	   does not affect 
silencing of other genes such as cyclophilin, Hsp90 or translin. Reversal of LDH or 
GAPDH knockdown resulted in rescue of histone H2B levels and cell survival. These 
data clearly support the idea that TRAX could be a novel mediator of PLCβ1 signaling 
in different biological processes (Aisiku et al., 2010; Philip et al., 2012, 2103). 
Interestingly, endogenous miRNAs regulate gene expression during neuronal 
differentiation (Shi et al., 2010; Coolen et al., 2012; Palm et al., 2013; Sun et al., 2013) 
and that TRAX- and translin-knockout mice display a variety of neurological deficits 
(Chennathukuzhi et al., 2003; Stein et al., 2006; Li et al., 2008). Therefore, it is 
conceivable that PLCβ1-TRAX association could play a key role in neuronal 
differentiation by regulating endogenous miRNA activity. 
Taking into consideration these evidences, we decided to characterize the 
expression and subcellular localization of the PLCβ1-binding partners TRAX and Gαq 
during neuronal differentiation of NT2 cells. Moreover, we analyzed PLCβ1-TRAX 
interaction in differentiating NT2 cells by Förster resonance energy transfer (FRET) and 
evaluated the effects of TRAX, translin and Gαq/11 silencing on differentiation of PC12 
cells. The results of these assays can be summarized as follows: 1. TRAX and Gαq/11 
levels are increased during AraC-induced neuronal differentiation of NT2 cells. 2. 
Inmunofluorescence and Western blot analysis of subcellular fractions reveal that the 
increase of TRAX expression during the time-course of neuronal differentiation of NT2 
cells preferentially involves the cell nucleus. 3. FRET assays demonstrate that the 
interaction between PLCβ1 and TRAX increases during NT2 differentiation, being 
restricted to the nucleus at the late stages of differentiation 4. TRAX, but not tranlsin or 
Gαq/11 silencing, abrogates NGF-induced neuronal differentiation of PC12 cells. 
Interestingly enough, the time-course of TRAX expression during AraC-induced 
NT2 differentiation was different from that of PLCβ1. Whereas PLCβ1 expression 
increased as soon as 24 h after the initiation of AraC treatment, TRAX levels began to 
increase significantly at 72 h, reaching a maximum at the end of the differentiation 
process. The difference in the time-course profile of both proteins could be explained 
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through a PLCβ1-mediated regulation of TRAX expression. Our results suggest that this 
could be the case. Indeed, silencing of PLCβ1 abrogated the increase of TRAX 
expression caused by AraC-treatment, whereas overexpression of PLCβ1 in absence of 
AraC resulted in a marked increase of TRAX levels. However, although PLCβ1 appears 
to regulate TRAX expression, the TRAX levels (unlike those of PLCβ1), rather than 
being decreased, were hugely increased at the end of differentiation. A deeper analysis 
of TRAX expression by Western blot analysis in subcellular fractions demonstrated that 
TRAX upregulation involved the cell nucleus but not the cytosol of the plasma 
membrane. 
Although we cannot explain the mechanisms of TRAX translocation to the nucleus 
during neuronal differentiation, in light of our data some time-related events could be 
proposed. During AraC-induced differentiation, PLCβ1-immunostaining is highly 
increased in the cytosol until 72 h. Under these conditions, the high amount of PLCβ1 
can accommodate the moderate increase of TRAX levels. It has been described that 
TRAX is able to compete and block Gαq binding and activation of PLCβ1 (Aisiku, 
2010). During NT2 differentiation the high level of PLCβ1 can attenuate the 
competition between TRAX and Gαq/11. Downregulation of PLCβ1 at the end of 
differentiation generates a new situation in which TRAX and Gαq/11 would be 
competing for the interaction with a lower population of PLCβ1. Due to the higher 
affinity of Gαq/11 for PLCβ1 association, it is conceivable that a decrease in PLCβ1-
TRAX interaction could favor the translocation of TRAX to the nucleus, as seen in 
other studies (Philip et al., 2012). Also, elevated and reduced levels of TRAX and 
PLCβ1, respectively, could be sufficient for TRAX translocation to the nucleus without 
the partnership of Gαq/11. Indeed, at the end of NT2 differentiation, semiquantitative 
Western blot analysis revealed an inversion of the relative expression levels of TRAX 
and PLCβ1 with respect to early stages of differentiation, and immunofluorescence 
assays revealed that PLCβ1-immunoreactivity was barely detectable in the cytoplasm of 
terminally differentiated AraC/NT2N neurons. In favor of this explanation is the fact 
that TRAX (but not Gαq/11) silencing did abrogate differentiation of PC12 cells. In 
spite of the differences between the two models, this would imply that Gαq/11 does not 
prevent TRAX translocation to the cell nucleus during differentitation. Further 
comparative studies in both cell models will be necessary to propose a solid hypothesis. 
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In any case, our data clearly show that TRAX is necessary for neuronal differentiation 
of PC12 cells and strongly suggest that is also the case for NT2 cell differentiation. 
However, some questions need to be answered before establishing the biological 
significance of TRAX in NT2 differentiation process. TRAX was originally described 
as a protein forming complexes with translin (Aoki et al., 1997), and both proteins have 
been implicated in the control of cell cycle (Castro et al., 2000; Ishida et al., 2002), 
although some discrepancies have been observed depending on the cell-type used for 
these studies (Yang et al., 2004; Sun et al., 2006). In this regard, our results suggest that 
TRAX, but not translin, is necessary for NGF-induced PC12 differentiation. Whether 
this occurs in the same way in NT2 differentiation process remains to be answered. The 
time-course of translin expression, and its interaction with TRAX, during NT2 
differentiation process should be performed in order to analyze whether the 
upregulation of nuclear TRAX is related to an increase of TRAX-translin complexes in 
this location. The high amount of nuclear TRAX at the end of AraC-induced NT2 
differentiation suggests that this protein could be implicated in the maintenance of 
neuronal phenotype or in differentiated neuronal survival. Answering these key 
questions will be critical to define the role of TRAX in this cellular model. 
Interestingly, recent studies have described some other TRAX interacting 
molecules, including nuclear matrix protein (CD1), an activator of DNA-dependent 
protein kinase (Erdemir et al., 2002) and an upstream activator of p53 (Rothbart et al., 
1999). Additionally, other cytosolic proteins such as snaxip1, MEA-2, Akap9 and Sun-1 
can interact with TRAX (Bray and Hecht, 2002). In this context, it will be interesting to 
evaluate in the future not only the role of TRAX in differentiation, maintenance of 
neuronal phenotype or differentiated neuronal survival, but also to analyze the signaling 
pathways involved in these processes. 
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1. The two splice variants of phospholipase C β1, PLCβ1a and PLCβ1b, are 
present in membranes, cytosolic and nuclear fractions from the adult rat 
cerebral cortex. 
1.1. Immunoblot analysis in membrane, cytosolic and nuclear fractions from the adult 
rat cortex showed that PLCβ1a is predominant over PLCβ1b in all fractions studied, 
although the relative contribution of each variant to the total signal differs between 
subcellular compartments. 
1.2. Immunofluorescence in intact nuclei isolated from the adult rat cerebral cortex, 
revealed a high overlap between PLCβ1-immunostaining and the signals provided 
by the markers of the nuclear speckles NeuN/Fox3 and SC-35. In contrast, no co-
localization of PLCβ1 with chromatin-rich domains or markers of the nuclear 
envelope and lamina was observed. 
 
2. NT2 cells induced to differentiate by short-term (6 days) treatment with the 
nucleoside analogue cytosine β-D-arabinofuranoside (AraC) (AraC/NT2N 
cells) express postmitotic neuronal markers, display significant morphometric 
differences compared with NT2-derived non-neuronal cells and differ in 
neurotransmitter phenotype from NT2N neurons induced by RA (RA/NT2N 
cells).  
2.1 Western blot and immunofluorescence analysis during the time-course of RA- and 
AraC-induced differentiation showed that immunoreactivity for NF200, βIII-
tubulin and DCX was increased in both differentiation models. 
2.2 The progressive increase in expression of NeuN/Fox-3 observed during AraC-
induced differentiation of NT2 progenitors, as analysed by Western blot and 
immunofluorescence microscopy, confirmed the neuronal identity of AraC/NT2N 
neurons. 
2.3 After an uninterrupted 6-day period of AraC treatment, increasing cell density at 
mid-treatment, about 71% of the cells in culture fulfilled the double criterion 
(NeuN/Fox-3 positive nucleus and neurite extensions) to be considered as neuronal, 
leading to a percentage of surviving terminally differentiated neurons augmented by 
almost 3-fold with respect to that found after RA-differentiation. 
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2.4 When compared with RA/NT2N neurons, AraC/NT2N neurons displayed 
considerably larger nuclei and cell somata, a 4.2-fold shorter total neurite length per 
cell and a large number of lamellar extensions and filopodia-like processes. 
2.5 Cells committed to differentiate by short treatment with AraC displayed a 
completely different neurotransmitter phenotype when compared with RA/NT2N 
neurons. Using immunofluoresecence microscopy and Western blot analysis, we 
can conclude that, in our culture conditions, GABAergic is the major 
neurotransmitter phenotype in RA/NT2N cells, whereas virtually all terminally 
differentiated AraC/NT2N neurons co-expressed both glutamatergic and 
cholinergic markers. 
 
3. Phospholipase C β1 is strongly regulated during RA- and AraC-induced 
differentiation of NT2 progenitors. 
3.1 Combination of Western blot and double immunofluorescence showed that 
exposure of NT2 cells to either RA or AraC led to a drastic increase of both 
PLCβ1a and PLCβ1b levels that preceded upregulation of the neuron-specific 
markers NF200, βIII-tubulin. 
3.2 Western blot and immunofluorescence assays showed that PLCβ1 expression fall at 
late stages of differentiation, when the expression of neuron-specific markers was 
highest. 
3.3 At the end of differentiation, PLCβ1 localization was mainly nuclear, as seen by 
immunofluorescence in fixed cells. 
 
4. Phospholipase C β1 is necessary for neuronal differentiation of NT2 and PC12 
progenitors and sufficient for differentiation of NT2 progenitors. 
4.1. Silencing of PLCβ1 expression impaired AraC-induced cell cycle arrest, 
morphological differentiation, and unpregulation of neuron-specific markers NF200 
and β-III tubulin. 
4.2. Silencing of PLCβ1 expression abrogated proliferation arrest and neurite outgrowth 
in NGF-treated PC12 cells. 
4.3. Overexpression of either PLCβ1a or PLCβ1b in the absence of AraC induced 
morphological differentiation of NT2 cells and increased levels of the neuron-
specific markers NF200 and βIII-tubulin.  
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5. Association of phospholipase C β1 with its binding partner translin-associated 
factor X (TRAX) appears to be involved in AraC-induced differentiation of 
NT2 cells in a translin- and Gαq/11-independent manner. 
5.1. TRAX and Gαq/11 levels are increased during AraC-induced neuronal 
differentiation of NT2 cells. 
5.2. Inmunofluorescence and Western blot analysis of subcellular fractions reveal that 
the increase of TRAX expression during the time-course of neuronal differentiation 
of NT2 cells preferentially involves the cell nucleus. 
5.3. FRET assays demonstrate that the interaction between PLCβ1 and TRAX increases 
during NT2 differentiation, being restricted to the nucleus at the late stages of 
differentiation. 
5.4. TRAX, but not tranlsin or Gαq/11 silencing, abrogates NGF-induced neuronal 
differentiation of PC12 cells. 
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